<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse - Salang, L - 2022 | Cochrane Library</title> <meta content="Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse - Salang, L - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012396.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse - Salang, L - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012396.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012396.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse" name="citation_title"/> <meta content="Lingling Salang" name="citation_author"/> <meta content="Faculty of Medicine, Khon Kaen University" name="citation_author_institution"/> <meta content="slingling@kku.ac.th" name="citation_author_email"/> <meta content="Danielle M Teixeira" name="citation_author"/> <meta content="Federal University of Paraná" name="citation_author_institution"/> <meta content="Ivan Solà" name="citation_author"/> <meta content="CIBER Epidemiología y Salud Pública (CIBERESP)" name="citation_author_institution"/> <meta content="Jen Sothornwit" name="citation_author"/> <meta content="Faculty of Medicine, Khon Kaen University" name="citation_author_institution"/> <meta content="Wellington P Martins" name="citation_author"/> <meta content="SEMEAR Fertilidade, Reproductive Medicine" name="citation_author_institution"/> <meta content="Magdalena Bofill Rodriguez" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Pisake Lumbiganon" name="citation_author"/> <meta content="Khon Kaen University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD012396.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/08/24" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012396.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012396.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012396.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Abortion, Spontaneous [epidemiology]; Chorionic Gonadotropin [therapeutic use]; Clomiphene [therapeutic use]; Coitus; Gonadotropin-Releasing Hormone; Insemination; Letrozole [pharmacology]; Lipopolysaccharides [pharmacology]; Live Birth [epidemiology]; *Luteal Phase; Pregnancy Rate; Progesterone [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012396.pub2&amp;doi=10.1002/14651858.CD012396.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="9nGOjNGw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012396\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012396\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012396\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012396\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012396.pub2",title:"Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse",firstPublishedDate:"Aug 24, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012396.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012396.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012396.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012396.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012396.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012396.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012396.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012396.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012396.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012396.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4973 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012396.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-sec-0148"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-sec-0045"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-sec-0142"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/appendices#CD012396-sec-0153"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/supinfo/CD012396StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/supinfo/CD012396StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/information#CD012396-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Lingling Salang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/information#CD012396-cr-0005">Danielle M Teixeira</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/information#CD012396-cr-0006">Ivan Solà</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/information#CD012396-cr-0007">Jen Sothornwit</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/information#CD012396-cr-0008">Wellington P Martins</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/information#CD012396-cr-0009">Magdalena Bofill Rodriguez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012396.pub2/information#CD012396-cr-0010">Pisake Lumbiganon</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/information/en#CD012396-sec-0170">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 24 August 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012396.pub2">https://doi.org/10.1002/14651858.CD012396.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012396-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012396-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012396-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012396-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012396-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012396-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012396-abs-0001" lang="en"> <section id="CD012396-sec-0001"> <h3 class="title" id="CD012396-sec-0001">Background</h3> <p>Ovulation induction may impact endometrial receptivity due to insufficient progesterone secretion. Low progesterone is associated with poor pregnancy outcomes. </p> </section> <section id="CD012396-sec-0002"> <h3 class="title" id="CD012396-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of luteal phase support (LPS) in infertile women trying to conceive by intrauterine insemination or by sexual intercourse. </p> </section> <section id="CD012396-sec-0003"> <h3 class="title" id="CD012396-sec-0003">Search methods</h3> <p>We searched the Cochrane Gynaecology and Fertility Group Specialised Register, CENTRAL, MEDLINE, Embase, PsycINFO, LILACS, trial registries for ongoing trials, and reference lists of articles (from inception to 25 August 2021). </p> </section> <section id="CD012396-sec-0004"> <h3 class="title" id="CD012396-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) of LPS using progestogen, human chorionic gonadotropin (hCG), or gonadotropin‐releasing hormone (GnRH) agonist supplementation in IUI or natural cycle. </p> </section> <section id="CD012396-sec-0005"> <h3 class="title" id="CD012396-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. Our primary outcomes were live birth rate/ongoing pregnancy rate (LBR/OPR) and miscarriage.  </p> </section> <section id="CD012396-sec-0006"> <h3 class="title" id="CD012396-sec-0006">Main results</h3> <p>We included 25 RCTs (5111 participants). Most studies were at unclear or high risk of bias. We graded the certainty of evidence as very low to low. The main limitations of the evidence were poor reporting and imprecision. </p> <p><i>1. Progesterone supplement versus placebo or no treatment </i> </p> <p>We are uncertain if vaginal progesterone increases LBR/OPR (risk ratio (RR) 1.10, 95% confidence interval (CI) 0.81 to 1.48; 7 RCTs; 1792 participants; low‐certainty evidence) or decreases miscarriage per pregnancy compared to placebo or no treatment (RR 0.70, 95% CI 0.40 to 1.25; 5 RCTs; 261 participants). There were no data on LBR or miscarriage with oral stimulation. We are uncertain if progesterone increases LBR/OPR in women with gonadotropin stimulation (RR 1.24, 95% CI 0.80 to 1.92; 4 RCTs; 1054 participants; low‐certainty evidence) and oral stimulation (clomiphene citrate or letrozole) (RR 0.97, 95% CI 0.58 to 1.64; 2 RCTs; 485 participants; low‐certainty evidence). One study reported on OPR in women with gonadotropin plus oral stimulation; the evidence from this study was uncertain (RR 0.73, 95% CI 0.37 to 1.42; 1 RCT; 253 participants; low‐certainty evidence). Given the low certainty of the evidence, it is unclear if progesterone reduces miscarriage per clinical pregnancy in any stimulation protocol (RR 0.68, 95% CI 0.24 to 1.91; 2 RCTs; 102 participants, with gonadotropin; RR 0.67, 95% CI 0.30 to 1.50; 2 RCTs; 123 participants, with gonadotropin plus oral stimulation; and RR 0.53, 95% CI 0.25 to 1.14; 2 RCTs; 119 participants, with oral stimulation). Low‐certainty evidence suggests that progesterone in all types of ovarian stimulation may increase clinical pregnancy compared to placebo (RR 1.38, 95% CI 1.10 to 1.74; 7 RCTs; 1437 participants, with gonadotropin; RR 1.40, 95% CI 1.03 to 1.90; 4 RCTs; 733 participants, with gonadotropin plus oral stimulation (clomiphene citrate or letrozole); and RR 1.44, 95% CI 1.04 to 1.98; 6 RCTs; 1073 participants, with oral stimulation). </p> <p><i>2. Progesterone supplementation regimen </i> </p> <p>We are uncertain if there is any difference between 300 mg and 600 mg of vaginal progesterone for OPR and multiple pregnancy (RR 1.58, 95% CI 0.81 to 3.09; 1 RCT; 200 participants; very low‐certainty evidence; and RR 0.50, 95% CI 0.05 to 5.43; 1 RCT; 200 participants, very low‐certainty evidence, respectively). No other outcomes were reported for this comparison. </p> <p>There were three different comparisons between progesterone regimens. For OPR, the evidence is very uncertain for intramuscular (IM) versus vaginal progesterone (RR 0.59, 95% CI 0.34 to 1.02; 1 RCT; 225 participants; very low‐certainty evidence); we are uncertain if there is any difference between oral and vaginal progesterone (RR 1.25, 95% CI 0.70 to 2.22; 1 RCT; 150 participants; very low‐certainty evidence) or between subcutaneous and vaginal progesterone (RR 1.05, 95% CI 0.54 to 2.05; 1 RCT; 246 participants; very low‐certainty evidence). We are uncertain if IM or oral progesterone reduces miscarriage per clinical pregnancy compared to vaginal progesterone (RR 0.75, 95% CI 0.43 to 1.32; 1 RCT; 81 participants and RR 0.58, 95% CI 0.11 to 3.09; 1 RCT; 41 participants, respectively). Clinical pregnancy and multiple pregnancy were reported for all comparisons; the evidence for these outcomes was very uncertain. Only one RCT reported adverse effects. We are uncertain if IM route increases the risk of adverse effects when compared with the vaginal route (RR 9.25, 95% CI 2.21 to 38.78; 1 RCT; 225 participants; very low‐certainty evidence). </p> <p><i>3. GnRH agonist versus placebo or no treatment </i> </p> <p>No trials reported live birth. The evidence is very uncertain about the effect of GnRH agonist in ongoing pregnancy (RR 1.10, 95% CI 0.70 to 1.74; 1 RCT; 291 participants, very low‐certainty evidence), miscarriage per clinical pregnancy (RR 0.73, 95% CI 0.26 to 2.10; 2 RCTs; 79 participants, very low‐certainty evidence) and clinical pregnancy (RR 1.00, 95% CI 0.68 to 1.47; 2 RCTs; 340 participants; very low‐certainty evidence), and multiple pregnancy (RR 0.28, 95% CI 0.11 to 0.70; 2 RCTs; 126 participants). </p> <p><i>4. GnRH agonist versus vaginal progesterone </i> </p> <p>The evidence for the effect of GnRH agonist injection on clinical pregnancy is very uncertain (RR 1.00, 95% CI 0.51 to 1.95; 1 RCT; 242 participants). </p> <p><i>5. HCG injection versus no treatment </i> </p> <p>The evidence for the effect of hCG injection on clinical pregnancy (RR 0.93, 95% CI 0.40 to 2.13; 1 RCT; 130 participants) and multiple pregnancy rates (RR 1.03, 95% CI 0.22 to 4.92; 1 RCT; 130 participants) is very uncertain. </p> <p><i>6. Luteal support in natural cycle</i> </p> <p>No study evaluated the effect of LPS in natural cycle.</p> <p>We could not perform sensitivity analyses, as there were no studies at low risk of selection bias and not at high risk in other domains. </p> </section> <section id="CD012396-sec-0007"> <h3 class="title" id="CD012396-sec-0007">Authors' conclusions</h3> <p>We are uncertain if vaginal progesterone supplementation during luteal phase is associated with a higher live birth/ongoing pregnancy rate. Vaginal progesterone may increase clinical pregnancy rate; however, its effect on miscarriage rate and multiple pregnancy rate is uncertain. We are uncertain if IM progesterone improves ongoing pregnancy rates or decreases miscarriage rate when compared to vaginal progesterone. Regarding the other reported comparisons, neither oral progesterone nor any other medication appears to be associated with an improvement in pregnancy outcomes (very low‐certainty evidence). </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012396-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012396-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012396-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012396-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012396-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012396-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012396-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012396-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012396-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012396-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012396-abs-0002" lang="en"> <h3>What is the effectiveness and safety of luteal support in infertile women trying to conceive by intrauterine insemination (IUI) or by sexual intercourse? </h3> <p><b>Background</b> </p> <p>Luteal phase is part of the menstrual cycle. It is the time between the release of an egg (ovulation) and before the start of menstruation, and when the body produces progesterone (a hormone released by the ovaries) and prepares for a possible pregnancy. Ovarian stimulation (use of fertility medicines) might affect progesterone production during the luteal phase. Low levels of progesterone in the luteal phase are associated with decreased rates of pregnancy outcomes such as ongoing pregnancy (pregnancy after 12 weeks) and live birth. Luteal phase support including progesterone and/or other medical agents including pregnancy hormone (human chorionic gonadotropin (hCG), which stimulates progesterone production) or gonadotropin‐releasing hormone (GnRH) agonist, which increases progesterone level after ovulation, may improve pregnancy outcomes. </p> <p><b>Study characteristics</b> </p> <p>We included 25 randomised controlled trials (a type of study where participants are randomly assigned to one of two or more treatment groups) involving a total of 5111 participants. We identified nine comparisons, including progesterone compared with placebo (dummy treatment) or no treatment, different dosages of vaginal progesterone supplement, different routes of progesterone supplement, GnRH agonist compared with placebo or no treatment, vaginal progesterone compared with GnRH agonist, and hCG compared with no treatment. All studies reported pregnancy outcomes, but only one study reported adverse events. All included studies reported on intrauterine insemination, a procedure where sperm is placed directly into the uterus (womb) using a thin, flexible plastic tube inserted through the vagina and cervix. No trial evaluated the effect of luteal support when trying to get pregnant naturally. </p> <p><b>Key results</b> </p> <p><i>Progesterone supplementation versus placebo or no treatment</i> </p> <p>We are uncertain if vaginal progesterone increases live birth/ongoing pregnancy rate when compared to placebo or no treatment in any of the types of ovarian stimulation cycle evaluated (gonadotropin (injectable hormones), gonadotropin plus oral stimulation, and oral stimulation alone). We are uncertain if progesterone reduces miscarriage rates. Vaginal progesterone may slightly increase clinical pregnancy (when the pregnancy is confirmed through ultrasound and a heartbeat is be detected). Progesterone supplementation may increase clinical pregnancy slightly in all types of ovarian stimulation cycle (gonadotropin (injectable hormones), gonadotropin plus oral stimulation, and oral stimulation alone). However, given the low certainty of the evidence, it is unclear whether the treatment makes a difference for the other prespecified outcomes (adverse events or multiple pregnancy rate (having twins/triplets)). </p> <p><i>300 mg versus 600 mg vaginal progesterone</i> </p> <p>It is unclear if 300 mg vaginal progesterone has an effect on live birth, ongoing pregnancy, miscarriage, or adverse events when compared to 600 mg vaginal progesterone.  </p> <p><i>Different routes of progesterone administration versus vaginal route</i> </p> <p>We do not know if other routes of progesterone (intramuscular, oral, or subcutaneous) have an effect on live birth, ongoing pregnancy, and miscarriage when compared to vaginal progesterone. Intramuscular progesterone may result in a large increase in adverse events (pain at site of injection), although the certainty of the evidence was very low. </p> <p><i>Other interventions versus placebo or no treatment </i> </p> <p>We do not know if other interventions (GnRH agonist or hCG injection) have an effect on our prespecified outcomes. </p> <p><b>Certainty of the evidence</b> </p> <p>The evidence for most comparisons was of very low to low certainty. The main limitations of the evidence were poor reporting of study methods and imprecision due to low numbers of women in the studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012396-sec-0148" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012396-sec-0148"></div> <h3 class="title" id="CD012396-sec-0149">Implications for practice</h3> <section id="CD012396-sec-0149"> <p>We are uncertain if vaginal progesterone supplementation during luteal phase is associated with higher live birth/ongoing pregnancy rate. Vaginal progesterone may increase clinical pregnancy rate. However, we are uncertain about its effect on miscarriage rate and multiple pregnancy rate. There was insufficient evidence to determine whether another route of progesterone supplementation influences pregnancy outcomes when compared to vaginal progesterone. In addition, we found no evidence suggesting that progesterone supplementation plus other interventions offer any benefit on pregnancy outcomes. We are uncertain if intramuscular progesterone improves ongoing pregnancy rate or decreases miscarriage rate when compared to vaginal progesterone. Regarding the other reported comparisons, neither oral progesterone nor any other medication appears to be associated with an improvement in pregnancy outcomes (very low‐certainty evidence). </p> </section> <h3 class="title" id="CD012396-sec-0150">Implications for research</h3> <section id="CD012396-sec-0150"> <p>Future high‐quality, adequately powered randomised controlled trials utilising blinding where possible are needed to evaluate the effectiveness and safety of progesterone and other interventions including human chorionic gonadotropin (hCG) and gonadotropin‐releasing hormone (GnRH) agonist during luteal phase support in intrauterine insemination or natural conception. In addition, these future randomised controlled trials should include live birth rate, miscarriage rate, and adverse events as primary outcomes. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012396-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012396-sec-0008"></div> <div class="table" id="CD012396-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Progesterone compared to no treatment or placebo (route of progesterone administration) for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Progesterone compared to no treatment or placebo (route of progesterone administration) for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women trying to conceive by intrauterine insemination<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> progesterone<br/><b>Comparison:</b> no treatment or placebo (route of progesterone administration) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes*</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects** (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no treatment or placebo (route of progesterone administration)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with progesterone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth/ongoing pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000<br/>(102 to 187) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.10<br/>(0.81 to 1.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1792<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage per clinical pregnancy</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>183 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 per 1000<br/>(73 to 228) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70<br/>(0.40 to 1.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy per woman</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>134 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>181 per 1000<br/>(153 to 216) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.35<br/>(1.14 to 1.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2794<br/>(13 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy per woman ‐ oral route</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>449 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>301 per 1000<br/>(180 to 507) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.67<br/>(0.40 to 1.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple pregnancy per woman</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/>(5 to 40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.84<br/>(0.30 to 2.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>956<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events, OHSS, preterm delivery, congenital anomaly</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*All studies reporting vaginal route unless otherwise indicated.<br/>**<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>  </p> <p><b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection and reporting bias.<br/><sup>b</sup>Evidence downgraded by one level due to imprecision (small study size).<br/><sup>c</sup>Evidence downgraded by two levels due to serious imprecision; single study with low event rate. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012396-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Progesterone compared to placebo/no treatment for gonadotropin stimulation for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Progesterone compared to placebo/no treatment for gonadotropin stimulation for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with gonadotropin stimulation<br/><b>Setting: </b> clinic<br/><b>Intervention:</b> progesterone<br/><b>Comparison:</b> placebo/no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with progesterone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth rate/ongoing pregnancy rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>132 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>164 per 1000<br/>(106 to 254) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.24<br/>(0.80 to 1.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1054<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate per clinical pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1000<br/>(40 to 318) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.68<br/>(0.24 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>142 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>196 per 1000<br/>(156 to 247) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.38<br/>(1.10 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1437<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple pregnancy rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000<br/>(6 to 120) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.72<br/>(0.17 to 3.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events, OHSS, preterm delivery, congenital anomaly</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection and reporting bias.<br/><sup>b</sup>Evidence downgraded by one level due to imprecision (low event rate). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012396-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Progesterone compared to placebo/no treatment for gonadotropin plus oral (clomiphene citrate/letrozole) stimulation for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Progesterone compared to placebo/no treatment for gonadotropin plus oral (clomiphene citrate/letrozole) stimulation for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with gonadotropin plus oral (clomiphene citrate or letrozole) stimulation<br/><b>Setting: </b> clinic<br/><b>Intervention:</b> progesterone<br/><b>Comparison:</b> placebo/no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with progesterone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing pregnancy rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>142 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>103 per 1000<br/>(52 to 201) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.73<br/>(0.37 to 1.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate per clinical pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>188 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000<br/>(56 to 281) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.67<br/>(0.30 to 1.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>157 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>219 per 1000<br/>(161 to 298) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.40<br/>(1.03 to 1.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>733<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup>  </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple pregnancy rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(3 to 120) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.44<br/>(0.24 to 8.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>290<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events, OHSS, preterm delivery, congenital anomaly</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection and reporting bias.<br/><sup>b</sup>Evidence downgraded by one level due to imprecision (small study size). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012396-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Progesterone compared to placebo/no treatment for oral (clomiphene citrate or letrozole) stimulation for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Progesterone compared to placebo/no treatment for oral (clomiphene citrate or letrozole) stimulation for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with oral (clomiphene citrate or letrozole) stimulation<br/><b>Setting: </b> clinic<br/><b>Intervention:</b> progesterone<br/><b>Comparison:</b> placebo/no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with progesterone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth rate/ongoing pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1000<br/>(61 to 172) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.97<br/>(0.58 to 1.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate per clinical pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>256 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000<br/>(64 to 292) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.53<br/>(0.25 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>131 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 per 1000<br/>(136 to 259) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.44<br/>(1.04 to 1.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1073<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(1 to 26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.58<br/>(0.10 to 3.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>586<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events, OHSS, preterm delivery, congenital anomaly</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection and reporting bias.<br/><sup>b</sup>Evidence downgraded by one level due to imprecision (small study size). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012396-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">300 mg vaginal progesterone compared to 600 mg vaginal progesterone for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>300 mg vaginal progesterone compared to 600 mg vaginal progesterone for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women trying to conceive by intrauterine insemination<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> 300 mg vaginal progesterone<br/><b>Comparison:</b> 600 mg vaginal progesterone </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with 600 mg vaginal progesterone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with 300 mg vaginal progesterone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing pregnancy rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000<br/>(97 to 371) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.58<br/>(0.81 to 3.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple pregnancy rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/>(1 to 109) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.50<br/>(0.05 to 5.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>None of the other main outcomes were reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection and reporting bias.<br/><sup>b</sup>Evidence downgraded by two levels due to very serious imprecision (small study size). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012396-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Intramuscular (IM) progesterone compared to vaginal progesterone for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intramuscular (IM) progesterone compared to vaginal progesterone for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women trying to conceive by intrauterine insemination<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> IM progesterone<br/><b>Comparison:</b> vaginal progesterone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with vaginal progesterone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with IM progesterone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth rate</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>252 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>149 per 1000<br/>(86 to 257) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.59<br/>(0.34 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333 per 1000<br/>(191 to 587) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.75<br/>(0.43 to 1.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>405 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>316 per 1000<br/>(223 to 450) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.78<br/>(0.55 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000<br/>(40 to 699) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 9.25<br/>(2.21 to 38.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OHSS, preterm delivery, congenital anomaly</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection, performance, detection, and reporting bias.<br/><sup>b</sup>Evidence downgraded by two levels due to imprecision (small study size). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012396-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Oral progesterone compared to vaginal progesterone for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Oral progesterone compared to vaginal progesterone for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women trying to conceive by intrauterine insemination<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> oral progesterone<br/><b>Comparison:</b> vaginal progesterone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with vaginal progesterone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with oral progesterone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth rate</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>213 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>267 per 1000<br/>(149 to 474) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.25<br/>(0.70 to 2.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate per clinical pregnancy</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1000<br/>(17 to 488) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.58<br/>(0.11 to 3.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>253 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>294 per 1000<br/>(175 to 497) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.16<br/>(0.69 to 1.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events, OHSS, preterm delivery, congenital anomaly</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection and reporting bias.<br/><sup>b</sup>Evidence downgraded by two levels due to imprecision (small study size). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012396-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Aqueous subcutaneous (Sc) progesterone compared to vaginal progesterone gel for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Aqueous subcutaneous (Sc) progesterone compared to vaginal progesterone gel for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women trying to conceive by intrauterine insemination<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> aqueous Sc progesterone<br/><b>Comparison:</b> vaginal progesterone gel </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with vaginal progesterone gel</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with aqueous Sc progesterone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>119 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>125 per 1000<br/>(64 to 244) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.05<br/>(0.54 to 2.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>246<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>127 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>142 per 1000<br/>(75 to 268) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.12<br/>(0.59 to 2.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>246<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>None of the other main outcomes were reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection bias and high risk of other bias.<br/><sup>c</sup>Evidence downgraded by two levels due to imprecision (small study size). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012396-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Subcutaneous (Sc) gonadotropin‐releasing hormone (GnRH) agonist compared to placebo/no treatment for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Subcutaneous (Sc) gonadotropin‐releasing hormone (GnRH) agonist compared to placebo/no treatment for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women trying to conceive by intrauterine insemination<br/><b>Setting: </b> clinic<br/><b>Intervention:</b> Sc GnRH agonist<br/><b>Comparison:</b> placebo/no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Sc GnRH agonist</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>193 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>213 per 1000<br/>(135 to 336) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.10<br/>(0.70 to 1.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>291<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17.1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>125 per 1000<br/>(44 to 359) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.73<br/>(0.26 to 2.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>233 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>233 per 1000<br/>(158 to 342) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/>(0.68 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>281 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000<br/>(31 to 197) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.28<br/>(0.11 to 0.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events, OHSS, preterm delivery, congenital anomaly</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection and reporting bias.<br/><sup>b</sup>Evidence downgraded by two levels due to imprecision (small study size and wide CIs). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012396-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Vaginal progesterone compared to gonadotropin‐releasing hormone (GnRH) agonist for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Vaginal progesterone compared to gonadotropin‐releasing hormone (GnRH) agonist for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women trying to conceive by intrauterine insemination<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> vaginal progesterone<br/><b>Comparison:</b> GnRH agonist </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with GnRH agonist</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with vaginal progesterone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>124 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>124 per 1000<br/>(63 to 242) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/>(0.51 to 1.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>None of the other main outcomes were reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection and reporting bias.<br/><sup>b</sup>Evidence downgraded by two levels due to imprecision (small study size). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012396-tbl-0011"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Human chorionic gonadotropin (hCG) injection compared to no treatment for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Human chorionic gonadotropin (hCG) injection compared to no treatment for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women trying to conceive by intrauterine insemination<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> hCG injection<br/><b>Comparison:</b> no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with hCG injection</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>152 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>141 per 1000<br/>(61 to 323) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.93<br/>(0.40 to 2.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b,</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000<br/>(10 to 224) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/>(0.22 to 4.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b,</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>None of the other main outcomes were reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection and reporting bias and high risk of other bias.<br/><sup>b</sup>Evidence downgraded by two levels due to imprecision as small study size. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012396-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012396-sec-0009"></div> <section id="CD012396-sec-0010"> <h3 class="title" id="CD012396-sec-0010">Description of the condition</h3> <p>Up to 10% to 15% of individuals wanting a baby encounter difficulty trying to conceive (<a href="./references#CD012396-bbs2-0087" title="BoivinJ , BuntingL , CollinsJA , NygrenKG . International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Human Reproduction2007;22(6):1506-12. [DOI: 10.1093/humrep/dem046] [PMID: 17376819]">Boivin 2007</a>). This condition, which is known as infertility (<a href="./references#CD012396-bbs2-0097" title="GnothC , GodehardtE , Frank-HerrmannP , FriolK , TiggesJ , FreundlG . Definition and prevalence of subfertility and infertility. Human Reproduction2005;20(5):1144-7. [DOI: 10.1093/humrep/deh870] [PMID: 15802321]">Gnoth 2005</a>), has several known causes, such as ovulatory disorders, no or infrequent coitus during the fertile period, advanced female age, sperm disorder, tubal disease, peritoneal adhesions, endometriosis and uterine abnormalities. However, even after investigation, a reasonable proportion of couples may have no problem that can be detected. Ovulation induction (OI), timed intercourse (TI), and intrauterine insemination/ovulation induction (IUI/OI) are medical treatments that can be used for infertile people before in vitro fertilisation (IVF) is considered (<a href="./references#CD012396-bbs2-0080" title="AdamsonGD , BakerVL . Subfertility: causes, treatment and outcome. Best Practice &amp; Research. Clinical Obstetrics &amp; Gynaecology2003;17(2):169-85. [PMID: 12758094]">Adamson 2003</a>). </p> <p>Ovulation induction consists of using oral agents, mainly clomiphene citrate or letrozole, or low‐dose follicle‐stimulating hormone (FSH) injections to induce follicular growth and ovulation in women with ovulatory dysfunction, thereby improving their chance of achieving pregnancy (<a href="./references#CD012396-bbs2-0085" title="Birch PetersenK , PedersenNG , PedersenAT , LauritsenMP , la Cour FreieslebenN . Mono-ovulation in women with polycystic ovary syndrome: a clinical review on ovulation induction. Reproductive Biomedicine Online2016;32(6):563-83. [DOI: 10.1016/j.rbmo.2016.03.006] [PMID: 27151490]">Birch Petersen 2016</a>; <a href="./references#CD012396-bbs2-0096" title="FranikS , EltropSM , KremerJAM , KieselL , FarquharC . Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2018, Issue 5. Art. No: CD010287. [DOI: 10.1002/14651858.CD010287.pub3]">Franik 2018</a>; <a href="./references#CD012396-bbs2-0117" title="WeissNS , KostovaE , NahuisM , MolBWJ , van derVeenF , vanWelyM . Gonadotrophins for ovulation induction in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2019, Issue 1. Art. No: CD010290. [DOI: 10.1002/14651858.CD010290.pub3]">Weiss 2019</a>). Timed intercourse is based on identification of the ovulation period by any available method, such as urinary luteinising hormone (LH) measurement, basal body temperature recording, changes in cervical mucus, or ultrasonography. As conception is more likely to happen when intercourse or IUI takes place one or two days before ovulation (<a href="https://archie.cochrane.org/sections/documents/view?version=z1511191536298323124512953290616&amp;format=REVMAN#REF-Stanford-2002" target="_blank">Stanford 2002</a>), couples are encouraged to intensify sexual intercourse frequency during this time window. The monitored cycle can be a natural or stimulated one; the latter is particularly useful for women with ovulatory dysfunction (<a href="./references#CD012396-bbs2-0085" title="Birch PetersenK , PedersenNG , PedersenAT , LauritsenMP , la Cour FreieslebenN . Mono-ovulation in women with polycystic ovary syndrome: a clinical review on ovulation induction. Reproductive Biomedicine Online2016;32(6):563-83. [DOI: 10.1016/j.rbmo.2016.03.006] [PMID: 27151490]">Birch Petersen 2016</a>). Intrauterine insemination is a procedure whereby sperm are injected into the uterine cavity just before ovulation during a natural cycle or after ovarian stimulation (<a href="./references#CD012396-bbs2-0102" title="KimD , ChildT , FarquharC . Intrauterine insemination: a UK survey on the adherence to NICE clinical guidelines by fertility clinics. BMJ2015;5(5):e007588. [PMID: 25979869]">Kim 2015</a>). </p> </section> <section id="CD012396-sec-0011"> <h3 class="title" id="CD012396-sec-0011">Description of the intervention</h3> <p>Luteal phase support (LPS) aims to increase progesterone levels during the luteal phase of the menstrual cycle, which is the phase following ovulation. This can be achieved by administration of progesterone, dydrogesterone, human chorionic gonadotropin (hCG), or gonadotropin‐releasing hormone (GnRH) agonist. </p> <p> <ul id="CD012396-list-0001"> <li> <p>Progesterone supplementation can be administered vaginally with a progesterone gel or in capsules of natural micronised progesterone, orally in capsules of natural micronised progesterone, by intramuscular injections of progesterone in oil, or by subcutaneous injections of progesterone. With regard to natural progesterone, oral preparations are of limited use in reproduction because they have poor bioavailability (<a href="./references#CD012396-bbs2-0115" title="SimonJA , RobinsonDE , AndrewsMC , Hildebrand JR 3rd, Rocci ML Jr, BlakeRE , et al. The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertility and Sterility1993;60(1):26-33. [PMID: 8513955]">Simon 1993</a>). Vaginal preparations are associated with vaginal discomfort and discharge, but they yield high serum concentrations by bypassing the first‐pass effect through the liver, achieving adequate endometrial transformation and sustained circulating levels across 24 hours (<a href="./references#CD012396-bbs2-0086" title="BlakeEJ , NorrisPM , DorfmanSF , LongstrethJ , YankovVI . Single and multidose pharmacokinetic study of a vaginal micronized progesterone insert (Endometrin) compared with vaginal gel in healthy reproductive-aged female subjects. Fertility and Sterility2010;94(4):1296-301. [DOI: 10.1016/j.fertnstert.2009.06.014] [PMID: 19608168]">Blake 2010</a>; <a href="./references#CD012396-bbs2-0104" title="LevyT , YairiY , Bar-HavaI , ShalevJ , OrvietoR , Ben-RafaelZ . Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction. Steroids2000;65(10-1):645-9.">Levy 2000</a>). Intramuscular oil‐based progesterone achieves good levels of circulating progesterone, but the injections cause discomfort and pain (<a href="./references#CD012396-bbs2-0110" title="NilliusSJ , JohanssonED . Plasma levels of progesterone after vaginal, rectal, or intramuscular administration of progesterone. American Journal of Obstetrics and Gynecology1971;110(4):470-7. [PMID: 5582003]">Nillius 1971</a>). A novel aqueous progesterone preparation is administered subcutaneously that might result in similar progesterone levels with less pain than can be achieved with intramuscular preparations (<a href="./references#CD012396-bbs2-0112" title="SatorM , RadicioniM , ComettiB , LopreteL , LeurattiC , SchmidlD , et al. Pharmacokinetics and safety profile of a novel progesterone aqueous formulation administered by the subcutaneous route. Gynecological Endocrinology2013;29(3):205-8.">Sator 2013</a>). </p> </li> <li> <p>Dydrogesterone (6‐dehydro‐retroprogesterone) is structurally and pharmacologically similar to natural progesterone, and has good oral bioavailability and better tolerability than vaginal progesterone (<a href="./references#CD012396-bbs2-0084" title="BarbosaMW , SilvaLR , NavarroPA , FerrianiRA , NastriCO , MartinsWP . Dydrogesterone vs progesterone for luteal-phase support: systematic review and meta-analysis of randomised controlled trials. Ultrasound in Obstetrics and Gynecology2016;48(2):161-70. [DOI: 10.1002/uog.15814] [PMID: 26577241]">Barbosa 2016</a>). </p> </li> <li> <p>Human chorionic gonadotropin is similar to LH in its molecular structure but has greater potency and a longer serum half‐life, working as LPS by stimulating the corpus luteum to produce progesterone (<a href="./references#CD012396-bbs2-0081" title="AndersenCY , ElbaekHO , AlsbjergB , LaursenRJ , PovlsenBB , ThomsenL , et al. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial. Human Reproduction2015;30(10):2387-95. [DOI: 10.1093/humrep/dev184] [PMID: 26209535]">Andersen 2015</a>; <a href="./references#CD012396-bbs2-0105" title="MartinsWP , VieiraAD , FigueiredoJB , NastriCO . FSH replaced by low-dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques. Cochrane Database of Systematic Reviews2013, Issue 3. Art. No: CD010042. [DOI: 10.1002/14651858.CD010042.pub2] [PMID: 23543584]">Martins 2013</a>; <a href="./references#CD012396-bbs2-0108" title="NastriCO , TeixeiraDM , MoroniRM , LeitãoVM , MartinsWP . Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention. Ultrasound in Obstetrics and Gynecology2015;45(4):377-93.">Nastri 2015</a>). It is administrated by subcutaneous or intramuscular injections. </p> </li> <li> <p>Gonadotropin‐releasing hormone agonist increases LH secretion by the pituitary, resulting in increased progesterone production by the corpus luteum (<a href="./references#CD012396-bbs2-0079" title="AboulgharMA , MarieH , AminYM , AboulgharMM , NasrA , SerourGI , et al. GnRH agonist plus vaginal progesterone for luteal phase support in ICSI cycles: a randomised study. Reproductive Biomedicine Online2015;30(1):52-6. [DOI: 10.1016/j.rbmo.2014.09.017] [PMID: 2545166]">Aboulghar 2015</a>; <a href="./references#CD012396-bbs2-0106" title="MartinsWP , FerrianiRA , NavarroPA , NastriCO . GnRH agonist during luteal phase for women undergoing assisted reproductive techniques: systematic review and meta-analysis of randomised controlled trials. Ultrasound in Obstetrics and Gynecology2015;47(2):144-51. [DOI: 10.1002/uog.14874] [PMID: 25854891]">Martins 2015</a>). It is frequently administered by subcutaneous daily injections or by nasal spray. </p> </li> </ul> </p> </section> <section id="CD012396-sec-0012"> <h3 class="title" id="CD012396-sec-0012">How the intervention might work</h3> <p>The process of implantation and maintenance of pregnancy during early stages depends on both embryo and endometrial receptivity (<a href="./references#CD012396-bbs2-0103" title="LensenSF , ArmstrongS , GibreelA , NastriCO , Raine-FenningN , MartinsWP . Endometrial injury in women undergoing in vitro fertilisation (IVF). Cochrane Database of Systematic Reviews2021, Issue 6. Art. No: CD009517. [DOI: 10.1002/14651858.CD009517.pub4]">Lensen 2021</a>). Endometrial receptivity relies on several factors, but is strongly dependent on the production of progesterone, primarily by the corpus luteum. Progesterone plays an essential role in embryo implantation, inducing secretory transformation and improved endometrial receptivity. Its actions include changes in the immune system that promote an endometrial gene expression profile shift, <a href="./references#CD012396-bbs2-0100" title="HaouziD , BissonnetteL , GalaA , AssouS , EntezamiF , PerrochiaH , et al. Endometrial receptivity profile in patients with premature progesterone elevation on the day of HCG administration. BioMed Research International2014;2014:951937. [PMID: 24877150]">Haouzi 2014</a>, and production of non‐inflammatory T‐helper‐2 cytokines (<a href="./references#CD012396-bbs2-0094" title="DruckmannR , DruckmannMA . Progesterone and the immunology of pregnancy. Journal of Steroid Biochemistry and Molecular Biology2005;97(5):389-96. [PMID: 16198558]">Druckmann 2005</a>); improve local blood flow and oxygen by increasing nitric oxide production (<a href="./references#CD012396-bbs2-0091" title="ChwaliszK , GarfieldRE . Role of nitric oxide in implantation and menstruation. Human Reproduction2000;15(Suppl 3):96-111. [PMID: 11041226]">Chwalisz 2000</a>); and reduce myometrial contractility around the time of implantation (<a href="./references#CD012396-bbs2-0095" title="FanchinR , RighiniC , OlivennesF , TaylorS , deZieglerD , FrydmanR . Uterine contractions at the time of embryo transfer alter pregnancy rates after in-vitro fertilization. Human Reproduction1998;13(7):1968-74. [PMID: 9740459]">Fanchin 1998</a>). The role of progesterone in the maintenance of early pregnancy is widely known, and luteal phase deficiency has for decades been recognised as a cause of recurrent miscarriage (<a href="./references#CD012396-bbs2-0113" title="ShahD , NagarajanN . Luteal insufficiency in first trimester. Indian Journal of Endocrinology and Metabolism2013;17(1):44-9. [PMID: 23776852]">Shah 2013</a>). Certain conditions are associated with both ovulatory dysfunction and low progesterone levels during the luteal phase, such as hyperandrogenism, endometriosis, hyperprolactinaemia, thyroid disorders, intense physical activity, and dietary factors (<a href="./references#CD012396-bbs2-0082" title="AndrewsMA , SchliepKC , Wactawski-WendeJ , StanfordJB , ZarekSM , RadinRG , et al. Dietary factors and luteal phase deficiency in healthy eumenorrhoea women. Human Reproduction2015;30(8):1942-51. [PMID: 26082480]">Andrews 2015</a>; <a href="./references#CD012396-bbs2-0083" title="ArredondoF , NobleLS . Endocrinology of recurrent pregnancy loss. Seminars in Reproductive Medicine2006;24(1):33-9. [PMID: 16418976]">Arredondo 2006</a>; <a href="./references#CD012396-bbs2-0088" title="BoutziosG , KaralakiM , ZapantiE . Common pathophysiological mechanisms involved in luteal phase deficiency and polycystic ovary syndrome. Impact on fertility. Endocrinology2013;43(2):314-7. [DOI: 10.1007/s12020-012-9778-9] [PMID: 22930247]">Boutzios 2013</a>; <a href="./references#CD012396-bbs2-0090" title="BulunSE , ChengYH , PavoneME , XueQ , AttarE , TrukhachevaE , et al. Estrogen receptor-beta, oestrogen receptor-alpha, and progesterone resistance in endometriosis. Seminars in Reproductive Medicine2010;28(1):36-43. [PMID: 20104427]">Bulun 2010</a>). </p> <p>High oestradiol levels due to ovarian stimulation exert direct negative feedback at the pituitary gland, reducing LH secretion and thereby impairing the ability of the corpus luteum to produce sufficient levels of progesterone to maintain pregnancy (<a href="./references#CD012396-bbs2-0084" title="BarbosaMW , SilvaLR , NavarroPA , FerrianiRA , NastriCO , MartinsWP . Dydrogesterone vs progesterone for luteal-phase support: systematic review and meta-analysis of randomised controlled trials. Ultrasound in Obstetrics and Gynecology2016;48(2):161-70. [DOI: 10.1002/uog.15814] [PMID: 26577241]">Barbosa 2016</a>; <a href="./references#CD012396-bbs2-0114" title="ShawND , HistedSN , SroujiSS , YangJ , LeeH , HallJE . Estrogen negative feedback on gonadotropin secretion: evidence for a direct pituitary effect in women. Journal of Clinical Endocrinology and Metabolism2010;95(4):1955-61. [PMID: 20133465]">Shaw 2010</a>). Additionally, some women have underlying conditions that have been associated with progesterone deficiency, which might impair the implantation process and reduce pregnancy rates amongst these women; LPS may also be effective for improving anovulatory or ovulatory cycle of progesterone deficiency. </p> </section> <section id="CD012396-sec-0013"> <h3 class="title" id="CD012396-sec-0013">Why it is important to do this review</h3> <p>Luteal support has been shown to benefit women undergoing in vitro fertilisation (IVF), with increased clinical pregnancy and live birth rates (<a href="./references#CD012396-bbs2-0116" title="van derLindenM , BuckinghamK , FarquharC , KremerJA , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD009154. [DOI: 10.1002/14651858.CD009154.pub3] [PMID: 26148507]">van der Linden 2015</a>). However, the role of luteal support is unclear amongst women trying to conceive by IUI or by sexual intercourse (<a href="./references#CD012396-bbs2-0092" title="CohlenBJ . Should luteal phase support be introduced in ovarian stimulation/IUI programmes? An evidence-based review. Reproductive Biomedicine Online2009;19(Suppl 4):4239-46. [PMID: 20034415]">Cohlen 2009b</a>; <a href="./references#CD012396-bbs2-0107" title="MiralpeixE , Gonzalez-ComadranM , SolaI , ManauD , CarrerasR , ChecaMA . Efficacy of luteal phase support with vaginal progesterone in intrauterine insemination: a systematic review and meta-analysis. Journal of Assisted Reproduction and Genetics2014;31(1):89-100. [PMID: 24189966]">Miralpeix 2014b</a>). Although the mechanism behind LPS is not well established, this review may still provide evidence for its effect on clinical outcomes.  </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012396-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012396-sec-0014"></div> <p>To assess the effectiveness and safety of luteal phase support in infertile women trying to conceive by intrauterine insemination or by sexual intercourse. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012396-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012396-sec-0015"></div> <section id="CD012396-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012396-sec-0017"> <h4 class="title">Types of studies</h4> <p>Published and unpublished randomised controlled trials (RCTs) were eligible for inclusion. We did not include studies with inadequate randomisation, such as randomisation based on alternate days or patient numbers/initials, as this is associated with high risk of bias. We included cross‐over trials, but only pooled data from the first phase for meta‐analyses, as cross‐over was not a valid design in this context. There were no limitations on language, publication date, or status.  </p> </section> <section id="CD012396-sec-0018"> <h4 class="title">Types of participants</h4> <p>Infertile women trying to conceive by IUI or sexual intercourse, with or without ovarian stimulation. </p> </section> <section id="CD012396-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Luteal phase support using any dose or route of administration, administered after the day of ovulation. </p> <p>Eligible interventions included progesterone, dydrogesterone, hCG, and GnRH agonist (e.g. leuprolide, nafarelin, triptorelin). </p> <p>Eligible comparators were placebo, no treatment, and other treatments.</p> <p>We planned to exclude studies that started LPS before or more than one week after the expected day of ovulation, as well as studies that discontinued LPS before a negative pregnancy test or six weeks of gestational age in women with a positive pregnancy test. We would not consider hCG injections given to trigger ovulation as LPS. </p> </section> <section id="CD012396-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD012396-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012396-list-0002"> <li> <p>Live birth and ongoing pregnancy per woman</p> <ul id="CD012396-list-0003"> <li> <p>Live birth was defined as delivery of a live foetus after 20 completed weeks of gestational age; ongoing pregnancy was defined as evidence of a gestational sac with foetal heart motion at 12 weeks, confirmed by ultrasonography. We used ongoing pregnancy as a surrogate for live birth in cases where studies did not report live birth but reported ongoing pregnancy. </p> </li> </ul> </li> <li> <p>Miscarriage per clinical pregnancy/per woman</p> <ul id="CD012396-list-0004"> <li> <p>Defined as the spontaneous loss of a clinical pregnancy before 20 completed weeks of gestational age (18 weeks after fertilisation), or, if gestational age was unknown, the loss of an embryo/foetus weighing less than 400 grams. </p> </li> </ul> </li> </ul> </p> </section> <section id="CD012396-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012396-list-0005"> <li> <p>Clinical pregnancy per woman</p> <ul id="CD012396-list-0006"> <li> <p>Defined as evidence of a gestational sac, confirmed by ultrasonography. Multiple gestational sacs were counted as a single clinical pregnancy. </p> </li> </ul> </li> <li> <p>Adverse events</p> <ul id="CD012396-list-0007"> <li> <p>Multiple pregnancy per woman, defined as the presence of two or more gestational sacs in the uterine cavity detected by ultrasonography, or the presence of one or more gestational sacs in the uterine cavity plus an ectopic pregnancy. </p> </li> <li> <p>Ovarian hyperstimulation syndrome (OHSS) rate per woman, defined as the presence of ascites and/or hydrothorax plus haemoconcentration (haematocrit &gt; 45%) (<a href="./references#CD012396-bbs2-0108" title="NastriCO , TeixeiraDM , MoroniRM , LeitãoVM , MartinsWP . Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention. Ultrasound in Obstetrics and Gynecology2015;45(4):377-93.">Nastri 2015</a>; <a href="./references#CD012396-bbs2-0109" title="NavotD , BerghPA , LauferN . Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility and Sterility1992;58(2):249-61. [PMID: 1633889]">Navot 1992</a>). </p> </li> <li> <p>Preterm birth (&lt; 37 weeks) per woman.</p> </li> <li> <p>Congenital anomaly per woman/per clinical pregnancy.</p> </li> <li> <p>Any other adverse events per woman.</p> </li> </ul> </li> </ul> </p> </section> </section> </section> <section id="CD012396-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all published and unpublished RCTs evaluating LPS for women who were trying to conceive by IUI or sexual intercourse, without language or date restriction and in consultation with the Cochrane Gynaecology and Fertility Group Information Specialist. </p> <section id="CD012396-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases for appropriate RCTs, from their inception to 25 August 2021: </p> <p> <ul id="CD012396-list-0008"> <li> <p>the Cochrane Gynaecology and Fertility Specialised Register of Controlled Trials, ProCite platform, searched 25 August 2021 (<a href="./appendices#CD012396-sec-0154">Appendix 1</a>); </p> </li> <li> <p>CENTRAL via the Cochrane Register of Studies Online (CRSO), Web platform, searched 25 August 2021 (<a href="./appendices#CD012396-sec-0155">Appendix 2</a>); </p> </li> <li> <p>MEDLINE, Ovid platform, searched from 1946 to 25 August 2021 (<a href="./appendices#CD012396-sec-0156">Appendix 3</a>); </p> </li> <li> <p>Embase, Ovid platform, searched from 1980 to 25 August 2021 (<a href="./appendices#CD012396-sec-0157">Appendix 4</a>); </p> </li> <li> <p>PsycINFO, Ovid platform, searched from 1806 to 25 August 2021 (<a href="./appendices#CD012396-sec-0158">Appendix 5</a>); </p> </li> <li> <p>CINAHL (Cumulative Index to Nursing and Allied Health Literature), EBSCO platform, searched from 1961 to 13 February 2020 (<a href="./appendices#CD012396-sec-0159">Appendix 6</a>) (CINAHL output from the 25 August 2021 search is contained in the CENTRAL search output); </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Sciences database), Web platform, searched 25 August 2021 (<a href="./appendices#CD012396-sec-0160">Appendix 7</a>); </p> </li> <li> <p>SCOPUS, Web platform, searched 25 August 2021(<a href="./appendices#CD012396-sec-0161">Appendix 8</a>); </p> </li> <li> <p>PubMed, Web platform, searched 25 August 2021 (<a href="./appendices#CD012396-sec-0162">Appendix 9</a>); </p> </li> <li> <p>Google Scholar, Web platform, searched 25 August 2021 (<a href="./appendices#CD012396-sec-0163">Appendix 10</a>). </p> </li> </ul> </p> <p>We also searched for studies in the following trial registers:</p> <p> <ul id="CD012396-list-0009"> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>) (<a href="./appendices#CD012396-sec-0164">Appendix 11</a>); </p> </li> <li> <p>ISRCTN registry (<a href="https://www.isrctn.com/" target="_blank">www.isrctn.com/</a>) (<a href="./appendices#CD012396-sec-0165">Appendix 12</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="https://trialsearch.who.int/" target="_blank">trialsearch.who.int/</a>) (<a href="./appendices#CD012396-sec-0166">Appendix 13</a>). </p> </li> </ul> </p> <p>We searched the grey literature using OpenGrey (<a href="https://opengrey.eu/" target="_blank">opengrey.eu/</a>) (<a href="./appendices#CD012396-sec-0167">Appendix 14</a>). </p> </section> <section id="CD012396-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We handsearched the reference lists of relevant trials and systematic reviews retrieved by the electronic searches and contacted experts in the field to obtain additional trial data. We also handsearched relevant journals and conference abstracts that were not covered in the Cochrane Gynaecology and Fertility Specialised Register. </p> </section> </section> <section id="CD012396-sec-0026"> <h3 class="title" id="CD012396-sec-0026">Data collection and analysis</h3> <section id="CD012396-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (LS and MBR) independently screened the titles and abstracts of studies retrieved by the literature search using the pre‐established inclusion criteria. We retrieved the full texts of all studies deemed potentially eligible, and the same two review authors independently evaluated the full texts for inclusion in the review using Covidence (<a href="./references#CD012396-bbs2-0093" title="Covidence. Version accessed 7 November 2019. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a>). Any disagreements were resolved by consensus or by involving a third review author (JS). One review author (LS) transferred data into the Review Manager 5 files (<a href="./references#CD012396-bbs2-0111" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We double‐checked that data were entered correctly by comparing the data presented in the systematic review with the study reports. A second review author (PL) spot‐checked study characteristics for accuracy against the trial report. </p> </section> <section id="CD012396-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>One review author (LS) independently extracted data from the included studies. Two other review authors (MBR and JS) performed a second data extraction from the included studies, with both steps conducted using a data extraction form designed and pilot‐tested by the review authors. We noted in the 'Characteristics of included studies' table if outcome data were not reported in a usable way. Any disagreements were resolved by discussion (LS and JS) or by consultation with another review author (PL). We extracted data on study characteristics as well as outcome data. When studies had multiple publications, we used the main trial report as the reference and derived additional details from secondary papers. We corresponded with study investigators to request further data on methods and results, as required. </p> </section> <section id="CD012396-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (LS and DMT) independently assessed risk of bias using the Cochrane risk of bias assessment tool for the following domains: selection, performance, detection, attrition, reporting, and other bias. Any disagreements were resolved by discussion or by consultation with two other review authors (JS and PL). We described all judgements fully and presented our conclusions in the risk of bias tables, which we incorporated into our interpretation of review findings by performing sensitivity analyses. </p> <section id="CD012396-sec-0030"> <h5 class="title">Selection bias</h5> <p>We considered the following methods of random sequence generation to be adequate: referring to a random number table; using a computer random number generator; tossing a coin; shuffling cards or envelopes; throwing dice; drawing lots. </p> <p>We considered the following methods of allocation concealment to be adequate: central allocation (including telephone, internet‐based, or pharmacy‐controlled randomisation); sequentially numbered, opaque, sealed envelopes; coin tossing; shuffling of cards/envelopes; throwing dice; and drawing lots only after the participant had been included. </p> <p>Any other methods of random sequence generation and allocation concealment used in the included studies were evaluated and potential risk of bias assessed. </p> </section> <section id="CD012396-sec-0031"> <h5 class="title">Performance bias</h5> <p>We subjectively evaluated whether participants received similar treatment. We did not consider lack of blinding of participants or personnel, or both, as a relevant source of bias. </p> </section> <section id="CD012396-sec-0032"> <h5 class="title">Detection bias</h5> <p>We did not consider lack of blinding of outcome assessors as a relevant source of bias. If the outcome was not defined by the study or was assessed differently from the way it was defined in the review, we considered the study as having a high risk of detection bias. </p> </section> <section id="CD012396-sec-0033"> <h5 class="title">Attrition bias</h5> <p>We considered studies with losses over 15% or lack of balance between groups as at high risk of attrition bias; balanced losses between 5% and 15% as unclear risk of attrition bias; and balanced losses less than 5% as low risk of attrition bias. </p> </section> <section id="CD012396-sec-0034"> <h5 class="title">Reporting bias</h5> <p>We considered studies reporting outcomes in the final report that differed from those specified in the protocol as at high risk of reporting bias. We also considered studies that did not report clinical pregnancy as at high risk of reporting bias. </p> <p>When studies failed to report our primary outcome of live birth or ongoing pregnancy but reported interim outcomes such as clinical pregnancy, we assessed whether the interim values were similar to those reported in studies that also reported live birth. </p> </section> <section id="CD012396-sec-0035"> <h5 class="title">Other bias</h5> <p>We subjectively assessed other important aspects that could have influenced the results (e.g. significantly or clinically relevant differences in age, body mass index (BMI) between intervention and control groups). </p> </section> </section> <section id="CD012396-sec-0036"> <h4 class="title">Measures of treatment effect</h4> <p>All of our prespecified outcomes were dichotomous. We calculated risk ratios (RRs) and corresponding 95% confidence intervals (95% CIs) to express effects of the intervention. We considered the clinical relevance of any statistically significant findings, and translated effect estimates for primary outcomes (and any other highly important clinical outcomes) into language that used natural frequencies to express differences in absolute risk. </p> </section> <section id="CD012396-sec-0037"> <h4 class="title">Unit of analysis issues</h4> <p>We randomised the primary analysis per woman, and planned to conducted additional analysis to examine whether the effect estimate would be different if miscarriage and congenital abnormalities were analysed per clinical pregnancy. We briefly summarised data that did not allow valid analysis (e.g. 'per‐cycle' data) in an Additional table, and did not include them in the meta‐analysis. We counted multiple live births (e.g. twins, triplets) as a single live birth event, and included only first‐phase data from cross‐over trials in the analysis. </p> </section> <section id="CD012396-sec-0038"> <h4 class="title">Dealing with missing data</h4> <p>We analysed data on an intention‐to‐treat basis to the greatest degree possible (i.e. we included all randomised women in the analysis in the groups to which they had been randomised). We attempted to obtain missing data from authors of the original trials. We did not perform imputations, and considered losses as a source of attrition bias. </p> </section> <section id="CD012396-sec-0039"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered whether clinical and methodological characteristics of the included studies were sufficiently similar in terms of participant characteristics, intervention protocols, and indications for meta‐analysis to provide a clinically meaningful summary. As we anticipated some degree of heterogeneity resulting from the pooled analyses, we assessed the impact of such inconsistency over effect estimated by measuring I<sup>2</sup>. We interpreted I<sup>2</sup> &gt; 50% as indicative of substantial heterogeneity (<a href="./references#CD012396-bbs2-0101" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2021</a>). </p> </section> <section id="CD012396-sec-0040"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by staying alert for duplication of data. If in the future update we include 10 or more studies in the analysis, we will use a funnel plot to explore the possibility of small‐study effects (i.e. the tendency for estimates of the intervention effect to be more beneficial in smaller studies). </p> </section> <section id="CD012396-sec-0041"> <h4 class="title">Data synthesis</h4> <p>If we considered that studies were sufficiently similar, in terms of participant characteristics, intervention protocols, and indications, we combined data for meta‐analysis using RRs and a random‐effects model for all included comparisons. We preferred to use a random‐effects model because the estimated 95% CI was more conservative in the presence of heterogeneity and was similar to that estimated by a fixed‐effect model when heterogeneity was minimal or absent. We combined data from primary studies comparing the intervention versus no intervention or placebo, or, when appropriate, comparing interventions versus other active interventions. </p> <p>We planned the following comparisons.</p> <p> <ul id="CD012396-list-0010"> <li> <p>Any type of LPS versus placebo or no treatment, stratified by type of LPS (pooling both subtotals and totals). For example: </p> <ul id="CD012396-list-0011"> <li> <p>progesterone versus control (placebo or no treatment);</p> </li> <li> <p>dydrogesterone versus control (placebo or no treatment);</p> </li> <li> <p>hCG versus control (placebo or no treatment);</p> </li> <li> <p>GnRH agonist versus control (placebo or no treatment).</p> </li> </ul> </li> <li> <p>Head‐to‐head comparisons, for example progesterone versus dydrogesterone. We considered each different head‐to‐head comparison separately and reported all outcomes together. </p> </li> </ul> </p> <p>We displayed graphically in the meta‐analyses to the right of the centre‐line any increase in the risk of a particular outcome that may be beneficial (e.g. live birth) or detrimental (e.g. adverse effects), and to the left of the centre‐line any decrease in the risk of an outcome. </p> </section> <section id="CD012396-sec-0042"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In the case of substantial heterogeneity (I<sup>2</sup> &gt; 50%), we addressed this by (1) checking that the data were correct; and (2) exploring possible explanations in sensitivity analyses. We took any statistical heterogeneity into account when interpreting the results, especially if we noted any variation in the direction of effect. </p> <p>We planned to perform the following subgroup analyses regardless of observed heterogeneity.</p> <p> <ul id="CD012396-list-0012"> <li> <p>Intervention: sexual intercourse or IUI.</p> </li> <li> <p>Ovarian stimulation: subcutaneous FSH, oral agents (clomiphene citrate or letrozole), or natural cycle. </p> </li> <li> <p>Ovulation: final triggering with hCG or natural ovulation.</p> </li> </ul> </p> <p>Additionally, we planned to perform a subgroup analysis for the primary outcome of effectiveness, to evaluate whether the estimate based only on studies reporting live birth differs from the estimate based only on studies reporting ongoing pregnancy. </p> <p>After we extracted the results from the included studies, we found that the studies only investigated luteal support in IUI cycle, and that they preferred using only hCG for final ovarian triggering, therefore we only performed subgroup analysis according to ovarian stimulation. </p> </section> <section id="CD012396-sec-0043"> <h4 class="title">Sensitivity analysis</h4> <p>We considered sensitivity analyses for the primary outcomes to determine whether the conclusions were robust to arbitrary decisions made regarding eligibility and analysis. These analyses included consideration of whether review conclusions would have differed if eligibility were restricted to studies at low risk of selection bias and not at high risk for the other domains. </p> </section> <section id="CD012396-sec-0044"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We prepared summary of findings tables using GRADEpro GDT and Cochrane methods (<a href="./references#CD012396-bbs2-0098" title="GRADEpro GDT. Version accessed 11 May 2020. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). These tables evaluate the overall quality of the body of evidence for the main review outcomes (live birth/ongoing pregnancy, miscarriage per clinical pregnancy, clinical pregnancy, other adverse events (multiple pregnancy, OHSS, preterm birth, congenital anomalies)). Two review authors (LS and JS) independently made judgements about evidence certainty (high, moderate, low, or very low) using the five GRADE criteria (study limitations, consistency of effect, imprecision, indirectness, and publication bias), resolving any disagreements by discussion. We justified, documented, and incorporated judgements into the reporting of results for each outcome. We extracted study data, formatted our comparisons in data tables, and prepared a summary of findings table before writing the results and conclusions of our review. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012396-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012396-sec-0045"></div> <section id="CD012396-sec-0046"> <h3 class="title">Description of studies</h3> <p>We included 25 RCTs (5111 participants) comparing any type of LPS versus placebo or no treatment or other treatment in participants who were trying to conceive by IUI. See <a href="./references#CD012396-sec-0176" title="">Characteristics of included studies</a> and <a href="./references#CD012396-sec-0177" title="">Characteristics of excluded studies</a>. </p> <section id="CD012396-sec-0047"> <h4 class="title">Results of the search</h4> <p>We searched for references up to 25 August 2021. We found 1206 references that met our search criteria, of which 270 were duplicates. Two review authors (LS and MBR) independently screened the titles and abstracts of records identified by the search; the majority of references identified were either not RCTs, or the objective of study was to investigate the effect of luteal support on IVF cycle. We reviewed 78 full‐text references, excluding 49 references that did not meet the inclusion criteria. Three studies are ongoing and one study is awaiting classification. We identified 25 RCTs for inclusion in the review. A PRISMA flow diagram is presented in <a href="#CD012396-fig-0001">Figure 1</a><i>.</i> </p> <div class="figure" id="CD012396-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012396-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012396-sec-0048"> <h4 class="title">Included studies</h4> <section id="CD012396-sec-0049"> <h5 class="title">Study design</h5> <p>We included 25 RCTs in the review. Information on study methods, participants, interventions, outcomes, funding, and other details such as whether the study was published is presented in <a href="./references#CD012396-sec-0176" title="">Characteristics of included studies</a>. Seventeen RCTs reported our primary outcomes of live birth, ongoing pregnancy, and miscarriage rates. In addition, 23 RCTs reported our secondary outcomes of clinical pregnancy and multiple pregnancy rates. Only one RCT reported on adverse effects. No RCTs evaluated the effect of LPS in natural cycle. </p> <p>All trials were parallel‐group RCTs.</p> <p> <ul id="CD012396-list-0013"> <li> <p>Twenty‐three RCTs were two‐arm studies (<a href="./references#CD012396-bbs2-0001" title="AaliBS , EbrahimipourS , MedhdizadehS . The effectiveness of luteal phase support with Cyclogest in ovarian stimulated intra uterine insemination cycles: a randomised controlled trial. Iranian Journal of Reproductive Medicine2013;11(4):309-14. ">Aali 2013</a>; <a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0004" title="AnSJ , JungJY , KwonHC , KimHM , HanJH , LeeSJ . Effect of luteal phase support in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2010;94 Suppl 1(4):S176-7. ">An 2010</a>; <a href="./references#CD012396-bbs2-0005" title="AzmoodehA , MohamadpoorJ , AsbaghFA , GhaseminezhadA , LorzadehN , ForghaniF . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Medicine and Health Research2016;2(9):84-8. MohamadpoorJ . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Fertility and Sterility2013;7:112. ">Azmoodeh 2016</a>; <a href="./references#CD012396-bbs2-0006" title="BekuretsionM , LundkvistO , KarlstromPO . A randomised study comparing low and high dose of HMG/FSH with and without luteal phase support in intrauterine insemination cycles. Human Reproduction1998;13:199. ">Bekuretsion 1998</a>; <a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>; <a href="./references#CD012396-bbs2-0008" title="BiberogluEH , TanrikuluF , ErdemM , ErdemA , BiberogluKO . Luteal phase support in intrauterine insemination cycles: a prospective randomised study of 300 mg versus 600 mg intravaginal progesterone tablet. Gynecological Endocrinology2016;32(1):55-7. ">Biberoglu 2016</a>; <a href="./references#CD012396-bbs2-0009" title="BussoC , LabartaE , MeloMAB , NavarroC , VidalC , RemohiJ , et al. Effect of a single dose of a GnRH agonist in the luteal phase of intrauterine insemination cycles: a randomised study. Interim analysis. Human Reproduction2006;21(Suppl 1):i116. ">Busso 2006</a>; <a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0014" title="KeskinM , AytaçR . Does luteal phase support effect pregnancy rates in intrauterine insemination cycles? A prospective randomised controlled study in a tertiary center. Obstetrics and Gynecology International2020:1-5. [DOI: 10.1155/2022/6234070]">Keskin 2020</a>; <a href="./references#CD012396-bbs2-0015" title="KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. ">Khadem 2011</a>; <a href="./references#CD012396-bbs2-0016" title="KhosraviD , TaheripanahR , KhosraviR , Taheri PanahA , Tarighat MonfaredV , DefaeeS , et al. Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial (RCT). Iranian Journal of Obstetrics, Gynecology and Infertility2015;13:433-8. KhosraviD , TaheripanahR , TaheripanahA , MonfaredV , Hosseini-ZijoudSM . Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial. Iranian Journal of Obstetrics, Gynecology and Infertility2015;13(7):433-8. ">Khosravi 2015</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0018" title="PakrashiT , BaydounH , BoccaS , OehningerS , StadtmauerL . Luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome and ovulatory dysfunction undergoing ovulation induction with letrozole: a randomised controlled trial. Fertility and Sterility2014;102 Suppl(3):e237. ">Pakrashi 2014</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>; <a href="./references#CD012396-bbs2-0024" title="VenturellaR , MocciaroR , LicoD , RoccaM , Di CelloA , PiccioneF , et al. Subcutaneous aqueous versus vaginal progesterone gel for luteal phase support in intrauterine insemination cycles: a pilot randomised, controlled trial. Human Reproduction2016;31 Suppl 1:i304-5. ">Venturella 2016</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>). </p> </li> <li> <p>Two RCTs included four study arms (<a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>; <a href="./references#CD012396-bbs2-0013" title="KaradagB , DilbazB , KarcaaltincabaD , SahinEG , ErcanF , KarasuY , et al. The effect of luteal-phase support with vaginal progesterone on pregnancy rates in gonadotropin and clomiphene citrate/intra-uterine insemination cycles in unexplained infertility: a prospective randomised study. Journal of Obstetrics and Gynaecology2016;36:794-9. ">Karadag 2016</a>). </p> </li> </ul> </p> </section> <section id="CD012396-sec-0050"> <h5 class="title">Sample size</h5> <p>The sample size of most RCTs was more than 100 participants. Of the 26 included RCTs, only four RCTs had a sample size of fewer than 100 participants (<a href="./references#CD012396-bbs2-0009" title="BussoC , LabartaE , MeloMAB , NavarroC , VidalC , RemohiJ , et al. Effect of a single dose of a GnRH agonist in the luteal phase of intrauterine insemination cycles: a randomised study. Interim analysis. Human Reproduction2006;21(Suppl 1):i116. ">Busso 2006</a>; <a href="./references#CD012396-bbs2-0014" title="KeskinM , AytaçR . Does luteal phase support effect pregnancy rates in intrauterine insemination cycles? A prospective randomised controlled study in a tertiary center. Obstetrics and Gynecology International2020:1-5. [DOI: 10.1155/2022/6234070]">Keskin 2020</a>; <a href="./references#CD012396-bbs2-0018" title="PakrashiT , BaydounH , BoccaS , OehningerS , StadtmauerL . Luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome and ovulatory dysfunction undergoing ovulation induction with letrozole: a randomised controlled trial. Fertility and Sterility2014;102 Suppl(3):e237. ">Pakrashi 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>). </p> </section> <section id="CD012396-sec-0051"> <h5 class="title">Participants</h5> <p>We included various types of participants.</p> <p> <ul id="CD012396-list-0014"> <li> <p>Sixteen RCTs included women aged between 18 and 40 years (<a href="./references#CD012396-bbs2-0001" title="AaliBS , EbrahimipourS , MedhdizadehS . The effectiveness of luteal phase support with Cyclogest in ovarian stimulated intra uterine insemination cycles: a randomised controlled trial. Iranian Journal of Reproductive Medicine2013;11(4):309-14. ">Aali 2013</a>; <a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>; <a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>; <a href="./references#CD012396-bbs2-0008" title="BiberogluEH , TanrikuluF , ErdemM , ErdemA , BiberogluKO . Luteal phase support in intrauterine insemination cycles: a prospective randomised study of 300 mg versus 600 mg intravaginal progesterone tablet. Gynecological Endocrinology2016;32(1):55-7. ">Biberoglu 2016</a>; <a href="./references#CD012396-bbs2-0009" title="BussoC , LabartaE , MeloMAB , NavarroC , VidalC , RemohiJ , et al. Effect of a single dose of a GnRH agonist in the luteal phase of intrauterine insemination cycles: a randomised study. Interim analysis. Human Reproduction2006;21(Suppl 1):i116. ">Busso 2006</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0013" title="KaradagB , DilbazB , KarcaaltincabaD , SahinEG , ErcanF , KarasuY , et al. The effect of luteal-phase support with vaginal progesterone on pregnancy rates in gonadotropin and clomiphene citrate/intra-uterine insemination cycles in unexplained infertility: a prospective randomised study. Journal of Obstetrics and Gynaecology2016;36:794-9. ">Karadag 2016</a>; <a href="./references#CD012396-bbs2-0014" title="KeskinM , AytaçR . Does luteal phase support effect pregnancy rates in intrauterine insemination cycles? A prospective randomised controlled study in a tertiary center. Obstetrics and Gynecology International2020:1-5. [DOI: 10.1155/2022/6234070]">Keskin 2020</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0018" title="PakrashiT , BaydounH , BoccaS , OehningerS , StadtmauerL . Luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome and ovulatory dysfunction undergoing ovulation induction with letrozole: a randomised controlled trial. Fertility and Sterility2014;102 Suppl(3):e237. ">Pakrashi 2014</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0024" title="VenturellaR , MocciaroR , LicoD , RoccaM , Di CelloA , PiccioneF , et al. Subcutaneous aqueous versus vaginal progesterone gel for luteal phase support in intrauterine insemination cycles: a pilot randomised, controlled trial. Human Reproduction2016;31 Suppl 1:i304-5. ">Venturella 2016</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>). </p> </li> <li> <p>One RCT included women aged between 20 and 43 years (<a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>) </p> </li> <li> <p>Eight RCTs did not specify the age of participants (<a href="./references#CD012396-bbs2-0004" title="AnSJ , JungJY , KwonHC , KimHM , HanJH , LeeSJ . Effect of luteal phase support in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2010;94 Suppl 1(4):S176-7. ">An 2010</a>; <a href="./references#CD012396-bbs2-0005" title="AzmoodehA , MohamadpoorJ , AsbaghFA , GhaseminezhadA , LorzadehN , ForghaniF . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Medicine and Health Research2016;2(9):84-8. MohamadpoorJ . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Fertility and Sterility2013;7:112. ">Azmoodeh 2016</a>; <a href="./references#CD012396-bbs2-0006" title="BekuretsionM , LundkvistO , KarlstromPO . A randomised study comparing low and high dose of HMG/FSH with and without luteal phase support in intrauterine insemination cycles. Human Reproduction1998;13:199. ">Bekuretsion 1998</a>; <a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0015" title="KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. ">Khadem 2011</a>; <a href="./references#CD012396-bbs2-0016" title="KhosraviD , TaheripanahR , KhosraviR , Taheri PanahA , Tarighat MonfaredV , DefaeeS , et al. Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial (RCT). Iranian Journal of Obstetrics, Gynecology and Infertility2015;13:433-8. KhosraviD , TaheripanahR , TaheripanahA , MonfaredV , Hosseini-ZijoudSM . Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial. Iranian Journal of Obstetrics, Gynecology and Infertility2015;13(7):433-8. ">Khosravi 2015</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>). </p> </li> </ul> </p> </section> <section id="CD012396-sec-0052"> <h5 class="title">Setting</h5> <p>The 25 RCTs took place in infertility clinics in various countries, including:</p> <p> <ul id="CD012396-list-0015"> <li> <p>19 RCTs in middle‐income countries (<a href="./references#CD012396-bbs2-0001" title="AaliBS , EbrahimipourS , MedhdizadehS . The effectiveness of luteal phase support with Cyclogest in ovarian stimulated intra uterine insemination cycles: a randomised controlled trial. Iranian Journal of Reproductive Medicine2013;11(4):309-14. ">Aali 2013</a>; <a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>; <a href="./references#CD012396-bbs2-0004" title="AnSJ , JungJY , KwonHC , KimHM , HanJH , LeeSJ . Effect of luteal phase support in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2010;94 Suppl 1(4):S176-7. ">An 2010</a>; <a href="./references#CD012396-bbs2-0005" title="AzmoodehA , MohamadpoorJ , AsbaghFA , GhaseminezhadA , LorzadehN , ForghaniF . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Medicine and Health Research2016;2(9):84-8. MohamadpoorJ . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Fertility and Sterility2013;7:112. ">Azmoodeh 2016</a>; <a href="./references#CD012396-bbs2-0006" title="BekuretsionM , LundkvistO , KarlstromPO . A randomised study comparing low and high dose of HMG/FSH with and without luteal phase support in intrauterine insemination cycles. Human Reproduction1998;13:199. ">Bekuretsion 1998</a>; <a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>; <a href="./references#CD012396-bbs2-0008" title="BiberogluEH , TanrikuluF , ErdemM , ErdemA , BiberogluKO . Luteal phase support in intrauterine insemination cycles: a prospective randomised study of 300 mg versus 600 mg intravaginal progesterone tablet. Gynecological Endocrinology2016;32(1):55-7. ">Biberoglu 2016</a>; <a href="./references#CD012396-bbs2-0009" title="BussoC , LabartaE , MeloMAB , NavarroC , VidalC , RemohiJ , et al. Effect of a single dose of a GnRH agonist in the luteal phase of intrauterine insemination cycles: a randomised study. Interim analysis. Human Reproduction2006;21(Suppl 1):i116. ">Busso 2006</a>; <a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0013" title="KaradagB , DilbazB , KarcaaltincabaD , SahinEG , ErcanF , KarasuY , et al. The effect of luteal-phase support with vaginal progesterone on pregnancy rates in gonadotropin and clomiphene citrate/intra-uterine insemination cycles in unexplained infertility: a prospective randomised study. Journal of Obstetrics and Gynaecology2016;36:794-9. ">Karadag 2016</a>; <a href="./references#CD012396-bbs2-0014" title="KeskinM , AytaçR . Does luteal phase support effect pregnancy rates in intrauterine insemination cycles? A prospective randomised controlled study in a tertiary center. Obstetrics and Gynecology International2020:1-5. [DOI: 10.1155/2022/6234070]">Keskin 2020</a>; <a href="./references#CD012396-bbs2-0015" title="KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. ">Khadem 2011</a>; <a href="./references#CD012396-bbs2-0016" title="KhosraviD , TaheripanahR , KhosraviR , Taheri PanahA , Tarighat MonfaredV , DefaeeS , et al. Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial (RCT). Iranian Journal of Obstetrics, Gynecology and Infertility2015;13:433-8. KhosraviD , TaheripanahR , TaheripanahA , MonfaredV , Hosseini-ZijoudSM . Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial. Iranian Journal of Obstetrics, Gynecology and Infertility2015;13(7):433-8. ">Khosravi 2015</a>; <a href="./references#CD012396-bbs2-0018" title="PakrashiT , BaydounH , BoccaS , OehningerS , StadtmauerL . Luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome and ovulatory dysfunction undergoing ovulation induction with letrozole: a randomised controlled trial. Fertility and Sterility2014;102 Suppl(3):e237. ">Pakrashi 2014</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>); and </p> </li> <li> <p>seven RCTs in high‐income countries (<a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0018" title="PakrashiT , BaydounH , BoccaS , OehningerS , StadtmauerL . Luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome and ovulatory dysfunction undergoing ovulation induction with letrozole: a randomised controlled trial. Fertility and Sterility2014;102 Suppl(3):e237. ">Pakrashi 2014</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>; <a href="./references#CD012396-bbs2-0024" title="VenturellaR , MocciaroR , LicoD , RoccaM , Di CelloA , PiccioneF , et al. Subcutaneous aqueous versus vaginal progesterone gel for luteal phase support in intrauterine insemination cycles: a pilot randomised, controlled trial. Human Reproduction2016;31 Suppl 1:i304-5. ">Venturella 2016</a>). </p> </li> </ul> </p> </section> <section id="CD012396-sec-0053"> <h5 class="title">Interventions</h5> <p>The following interventions and comparisons were undertaken.</p> <section id="CD012396-sec-0054"> <h6 class="title">Comparisons between progesterone and placebo or no treatment (17 RCTs)</h6> <p> <ul id="CD012396-list-0016"> <li> <p>Six RCTs compared vaginal progesterone with no treatment on live birth rate (<a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>). </p> </li> <li> <p>Four RCTs compared vaginal progesterone with no treatment on ongoing pregnancy (<a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>). </p> </li> <li> <p>Nine RCTs compared vaginal progesterone with no treatment on miscarriage rate (<a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>). </p> </li> <li> <p>Fifteen RCTs compared vaginal progesterone with no treatment on clinical pregnancy rate (<a href="./references#CD012396-bbs2-0001" title="AaliBS , EbrahimipourS , MedhdizadehS . The effectiveness of luteal phase support with Cyclogest in ovarian stimulated intra uterine insemination cycles: a randomised controlled trial. Iranian Journal of Reproductive Medicine2013;11(4):309-14. ">Aali 2013</a>; <a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0004" title="AnSJ , JungJY , KwonHC , KimHM , HanJH , LeeSJ . Effect of luteal phase support in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2010;94 Suppl 1(4):S176-7. ">An 2010</a>; <a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0013" title="KaradagB , DilbazB , KarcaaltincabaD , SahinEG , ErcanF , KarasuY , et al. The effect of luteal-phase support with vaginal progesterone on pregnancy rates in gonadotropin and clomiphene citrate/intra-uterine insemination cycles in unexplained infertility: a prospective randomised study. Journal of Obstetrics and Gynaecology2016;36:794-9. ">Karadag 2016</a>; <a href="./references#CD012396-bbs2-0014" title="KeskinM , AytaçR . Does luteal phase support effect pregnancy rates in intrauterine insemination cycles? A prospective randomised controlled study in a tertiary center. Obstetrics and Gynecology International2020:1-5. [DOI: 10.1155/2022/6234070]">Keskin 2020</a>; <a href="./references#CD012396-bbs2-0018" title="PakrashiT , BaydounH , BoccaS , OehningerS , StadtmauerL . Luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome and ovulatory dysfunction undergoing ovulation induction with letrozole: a randomised controlled trial. Fertility and Sterility2014;102 Suppl(3):e237. ">Pakrashi 2014</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>) </p> </li> <li> <p>One RCT compared oral progesterone with no treatment on clinical pregnancy rate (<a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>). </p> </li> <li> <p>Five RCTs compared vaginal progesterone with no treatment on multiple pregnancy rate (<a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>). </p> </li> </ul> </p> </section> <section id="CD012396-sec-0055"> <h6 class="title">Comparisons of difference dosages of vaginal progesterone (1 RCT)</h6> <p>One RCT compared 300 mg vaginal progesterone with 600 mg vaginal progesterone on ongoing pregnancy and multiple pregnancy rates (<a href="./references#CD012396-bbs2-0008" title="BiberogluEH , TanrikuluF , ErdemM , ErdemA , BiberogluKO . Luteal phase support in intrauterine insemination cycles: a prospective randomised study of 300 mg versus 600 mg intravaginal progesterone tablet. Gynecological Endocrinology2016;32(1):55-7. ">Biberoglu 2016</a>). </p> </section> <section id="CD012396-sec-0056"> <h6 class="title">Comparisons between intramuscular (IM) progesterone and vaginal progesterone (1 RCT)</h6> <p>One RCT compared IM progesterone with vaginal progesterone on ongoing pregnancy, miscarriage, and clinical pregnancy rates and adverse effects (<a href="./references#CD012396-bbs2-0015" title="KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. ">Khadem 2011</a>). </p> </section> <section id="CD012396-sec-0057"> <h6 class="title">Comparisons between oral progesterone and vaginal progesterone (1 RCT)</h6> <p>One RCT compared oral progesterone with vaginal progesterone on ongoing pregnancy rate, miscarriage rate, and clinical pregnancy rate (<a href="./references#CD012396-bbs2-0016" title="KhosraviD , TaheripanahR , KhosraviR , Taheri PanahA , Tarighat MonfaredV , DefaeeS , et al. Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial (RCT). Iranian Journal of Obstetrics, Gynecology and Infertility2015;13:433-8. KhosraviD , TaheripanahR , TaheripanahA , MonfaredV , Hosseini-ZijoudSM . Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial. Iranian Journal of Obstetrics, Gynecology and Infertility2015;13(7):433-8. ">Khosravi 2015</a>). </p> </section> <section id="CD012396-sec-0058"> <h6 class="title">Comparisons between subcutaneous (Sc) progesterone and vaginal progesterone (1 RCT)</h6> <p>One RCT compared Sc injection progesterone with vaginal progesterone on ongoing pregnancy rate and clinical pregnancy rate (<a href="./references#CD012396-bbs2-0024" title="VenturellaR , MocciaroR , LicoD , RoccaM , Di CelloA , PiccioneF , et al. Subcutaneous aqueous versus vaginal progesterone gel for luteal phase support in intrauterine insemination cycles: a pilot randomised, controlled trial. Human Reproduction2016;31 Suppl 1:i304-5. ">Venturella 2016</a>). </p> </section> <section id="CD012396-sec-0059"> <h6 class="title">Comparisons between GnRH agonist plus progesterone and vaginal progesterone plus placebo (0 RCTs) </h6> <p>No study compared GnRH agonist plus progesterone with vaginal progesterone plus placebo.</p> </section> <section id="CD012396-sec-0060"> <h6 class="title">Comparisons between Sc GnRH agonist and no treatment (2 RCTs)</h6> <p> <ul id="CD012396-list-0017"> <li> <p>One RCT compared Sc GnRH agonist with no treatment on ongoing pregnancy rate (<a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>). </p> </li> <li> <p>Two RCTs compared Sc GnRH agonist with no treatment on miscarriage, clinical pregnancy, and multiple pregnancy rates (<a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>; <a href="./references#CD012396-bbs2-0009" title="BussoC , LabartaE , MeloMAB , NavarroC , VidalC , RemohiJ , et al. Effect of a single dose of a GnRH agonist in the luteal phase of intrauterine insemination cycles: a randomised study. Interim analysis. Human Reproduction2006;21(Suppl 1):i116. ">Busso 2006</a>). </p> </li> </ul> </p> </section> <section id="CD012396-sec-0061"> <h6 class="title">Comparisons between Sc GnRH agonist and vaginal progesterone (1 RCT)</h6> <p>One RCT compared Sc GnRH agonist with vaginal progesterone on clinical pregnancy rate (<a href="./references#CD012396-bbs2-0005" title="AzmoodehA , MohamadpoorJ , AsbaghFA , GhaseminezhadA , LorzadehN , ForghaniF . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Medicine and Health Research2016;2(9):84-8. MohamadpoorJ . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Fertility and Sterility2013;7:112. ">Azmoodeh 2016</a>). </p> </section> <section id="CD012396-sec-0062"> <h6 class="title">Comparisons between hCG injection and no treatment (1 RCT)</h6> <p>One RCT compared hCG injection with vaginal progesterone on clinical pregnancy and multiple pregnancy rates (<a href="./references#CD012396-bbs2-0006" title="BekuretsionM , LundkvistO , KarlstromPO . A randomised study comparing low and high dose of HMG/FSH with and without luteal phase support in intrauterine insemination cycles. Human Reproduction1998;13:199. ">Bekuretsion 1998</a>). </p> </section> </section> <section id="CD012396-sec-0063"> <h5 class="title">Outcomes</h5> <section id="CD012396-sec-0064"> <h6 class="title">Primary outcomes</h6> <p>Seventeen RCTs reported our primary outcomes of live birth, ongoing pregnancy, and miscarriage rates. </p> <p><b>Live birth rate:</b> six RCTs compared vaginal progesterone with placebo or no treatment (<a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>). </p> <p><b>Ongoing pregnancy rate:</b> nine RCTs reported ongoing pregnancy rate that allowed the following comparisons. </p> <p> <ul id="CD012396-list-0018"> <li> <p>Three RCTs compared vaginal progesterone with no treatment (<a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>) </p> </li> <li> <p>One RCT compared different dosages of vaginal progesterone (<a href="./references#CD012396-bbs2-0008" title="BiberogluEH , TanrikuluF , ErdemM , ErdemA , BiberogluKO . Luteal phase support in intrauterine insemination cycles: a prospective randomised study of 300 mg versus 600 mg intravaginal progesterone tablet. Gynecological Endocrinology2016;32(1):55-7. ">Biberoglu 2016</a>). </p> </li> <li> <p>One RCT compared oral progesterone with vaginal progesterone (<a href="./references#CD012396-bbs2-0016" title="KhosraviD , TaheripanahR , KhosraviR , Taheri PanahA , Tarighat MonfaredV , DefaeeS , et al. Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial (RCT). Iranian Journal of Obstetrics, Gynecology and Infertility2015;13:433-8. KhosraviD , TaheripanahR , TaheripanahA , MonfaredV , Hosseini-ZijoudSM . Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial. Iranian Journal of Obstetrics, Gynecology and Infertility2015;13(7):433-8. ">Khosravi 2015</a>). </p> </li> <li> <p>One RCT compared IM progesterone with vaginal progesterone (<a href="./references#CD012396-bbs2-0015" title="KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. ">Khadem 2011</a>). </p> </li> <li> <p>One RCT compared Sc progesterone with vaginal progesterone (<a href="./references#CD012396-bbs2-0024" title="VenturellaR , MocciaroR , LicoD , RoccaM , Di CelloA , PiccioneF , et al. Subcutaneous aqueous versus vaginal progesterone gel for luteal phase support in intrauterine insemination cycles: a pilot randomised, controlled trial. Human Reproduction2016;31 Suppl 1:i304-5. ">Venturella 2016</a>). </p> </li> <li> <p>One RCT compared Sc GnRH agonist with no treatment (<a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>). </p> </li> </ul> </p> <p><b>Miscarriage rate:</b> 13 RCTs reported miscarriage rate that allowed the following comparisons. </p> <p> <ul id="CD012396-list-0019"> <li> <p>Nine RCTs compared vaginal progesterone with placebo or no treatment (<a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>). </p> </li> <li> <p>One RCT compared IM progesterone with vaginal progesterone (<a href="./references#CD012396-bbs2-0015" title="KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. ">Khadem 2011</a>). </p> </li> <li> <p>One RCT compared oral progesterone with vaginal progesterone (<a href="./references#CD012396-bbs2-0016" title="KhosraviD , TaheripanahR , KhosraviR , Taheri PanahA , Tarighat MonfaredV , DefaeeS , et al. Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial (RCT). Iranian Journal of Obstetrics, Gynecology and Infertility2015;13:433-8. KhosraviD , TaheripanahR , TaheripanahA , MonfaredV , Hosseini-ZijoudSM . Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial. Iranian Journal of Obstetrics, Gynecology and Infertility2015;13(7):433-8. ">Khosravi 2015</a>). </p> </li> <li> <p>Two RCTs compared Sc GnRH agonist with no treatment (<a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>; <a href="./references#CD012396-bbs2-0009" title="BussoC , LabartaE , MeloMAB , NavarroC , VidalC , RemohiJ , et al. Effect of a single dose of a GnRH agonist in the luteal phase of intrauterine insemination cycles: a randomised study. Interim analysis. Human Reproduction2006;21(Suppl 1):i116. ">Busso 2006</a>). </p> </li> </ul> </p> </section> <section id="CD012396-sec-0065"> <h6 class="title">Secondary outcomes</h6> <p>Twenty‐three RCTs reported clinical pregnancy rate, whilst multiple pregnancy rate was reported in nine RCTs. Only one RCT reported on adverse effects of medication (<a href="./references#CD012396-bbs2-0015" title="KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. ">Khadem 2011</a>). </p> <p><b>Clinical pregnancy rate:</b> 23 RCTs reported clinical pregnancy rate that allowed the following comparisons. </p> <p> <ul id="CD012396-list-0020"> <li> <p>Fifteen RCTs compared vaginal progesterone with placebo or no treatment (<a href="./references#CD012396-bbs2-0001" title="AaliBS , EbrahimipourS , MedhdizadehS . The effectiveness of luteal phase support with Cyclogest in ovarian stimulated intra uterine insemination cycles: a randomised controlled trial. Iranian Journal of Reproductive Medicine2013;11(4):309-14. ">Aali 2013</a>; <a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0004" title="AnSJ , JungJY , KwonHC , KimHM , HanJH , LeeSJ . Effect of luteal phase support in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2010;94 Suppl 1(4):S176-7. ">An 2010</a>; <a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0013" title="KaradagB , DilbazB , KarcaaltincabaD , SahinEG , ErcanF , KarasuY , et al. The effect of luteal-phase support with vaginal progesterone on pregnancy rates in gonadotropin and clomiphene citrate/intra-uterine insemination cycles in unexplained infertility: a prospective randomised study. Journal of Obstetrics and Gynaecology2016;36:794-9. ">Karadag 2016</a>; <a href="./references#CD012396-bbs2-0014" title="KeskinM , AytaçR . Does luteal phase support effect pregnancy rates in intrauterine insemination cycles? A prospective randomised controlled study in a tertiary center. Obstetrics and Gynecology International2020:1-5. [DOI: 10.1155/2022/6234070]">Keskin 2020</a>; <a href="./references#CD012396-bbs2-0018" title="PakrashiT , BaydounH , BoccaS , OehningerS , StadtmauerL . Luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome and ovulatory dysfunction undergoing ovulation induction with letrozole: a randomised controlled trial. Fertility and Sterility2014;102 Suppl(3):e237. ">Pakrashi 2014</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>). </p> </li> <li> <p>One RCT compared oral progesterone with placebo or no treatment (<a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>). </p> </li> <li> <p>One RCT compared IM progesterone with vaginal progesterone (<a href="./references#CD012396-bbs2-0015" title="KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. ">Khadem 2011</a>). </p> </li> <li> <p>One RCT compared oral progesterone with vaginal progesterone (<a href="./references#CD012396-bbs2-0016" title="KhosraviD , TaheripanahR , KhosraviR , Taheri PanahA , Tarighat MonfaredV , DefaeeS , et al. Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial (RCT). Iranian Journal of Obstetrics, Gynecology and Infertility2015;13:433-8. KhosraviD , TaheripanahR , TaheripanahA , MonfaredV , Hosseini-ZijoudSM . Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial. Iranian Journal of Obstetrics, Gynecology and Infertility2015;13(7):433-8. ">Khosravi 2015</a>). </p> </li> <li> <p>One RCT compared Sc progesterone with vaginal progesterone (<a href="./references#CD012396-bbs2-0024" title="VenturellaR , MocciaroR , LicoD , RoccaM , Di CelloA , PiccioneF , et al. Subcutaneous aqueous versus vaginal progesterone gel for luteal phase support in intrauterine insemination cycles: a pilot randomised, controlled trial. Human Reproduction2016;31 Suppl 1:i304-5. ">Venturella 2016</a>). </p> </li> <li> <p>Two RCTs compared Sc GnRH agonist with no treatment (<a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>; <a href="./references#CD012396-bbs2-0009" title="BussoC , LabartaE , MeloMAB , NavarroC , VidalC , RemohiJ , et al. Effect of a single dose of a GnRH agonist in the luteal phase of intrauterine insemination cycles: a randomised study. Interim analysis. Human Reproduction2006;21(Suppl 1):i116. ">Busso 2006</a>). </p> </li> <li> <p>One RCT compared Sc GnRH agonist with vaginal progesterone (<a href="./references#CD012396-bbs2-0005" title="AzmoodehA , MohamadpoorJ , AsbaghFA , GhaseminezhadA , LorzadehN , ForghaniF . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Medicine and Health Research2016;2(9):84-8. MohamadpoorJ . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Fertility and Sterility2013;7:112. ">Azmoodeh 2016</a>). </p> </li> <li> <p>One RCT compared hCG injection with vaginal progesterone (<a href="./references#CD012396-bbs2-0006" title="BekuretsionM , LundkvistO , KarlstromPO . A randomised study comparing low and high dose of HMG/FSH with and without luteal phase support in intrauterine insemination cycles. Human Reproduction1998;13:199. ">Bekuretsion 1998</a>). </p> </li> </ul> </p> <p><b>Multiple pregnancy rate:</b> nine RCTs reported multiple pregnancy rate that allowed the following comparisons. </p> <p> <ul id="CD012396-list-0021"> <li> <p>Five RCTs compared vaginal progesterone with no treatment (<a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>). </p> </li> <li> <p>One RCT compared 300 mg with 600 mg vaginal progesterone (<a href="./references#CD012396-bbs2-0008" title="BiberogluEH , TanrikuluF , ErdemM , ErdemA , BiberogluKO . Luteal phase support in intrauterine insemination cycles: a prospective randomised study of 300 mg versus 600 mg intravaginal progesterone tablet. Gynecological Endocrinology2016;32(1):55-7. ">Biberoglu 2016</a>). </p> </li> <li> <p>Two RCTs compared Sc GnRH agonist with no treatment (<a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>; <a href="./references#CD012396-bbs2-0009" title="BussoC , LabartaE , MeloMAB , NavarroC , VidalC , RemohiJ , et al. Effect of a single dose of a GnRH agonist in the luteal phase of intrauterine insemination cycles: a randomised study. Interim analysis. Human Reproduction2006;21(Suppl 1):i116. ">Busso 2006</a>). </p> </li> <li> <p>One RCT compared hCG injection with vaginal progesterone (<a href="./references#CD012396-bbs2-0006" title="BekuretsionM , LundkvistO , KarlstromPO . A randomised study comparing low and high dose of HMG/FSH with and without luteal phase support in intrauterine insemination cycles. Human Reproduction1998;13:199. ">Bekuretsion 1998</a>). </p> </li> </ul> </p> <p><b>Adverse effects:</b> one RCT compared IM progesterone with vaginal progesterone (<a href="./references#CD012396-bbs2-0015" title="KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. ">Khadem 2011</a>). </p> <p>None of the included studies reported on OHSS, preterm birth, or congenital anomalies.</p> </section> </section> </section> <section id="CD012396-sec-0066"> <h4 class="title">Excluded studies</h4> <p>We excluded 49 RCTs from the review. We excluded 14 studies that were prospective cohort studies or reviews (<a href="./references#CD012396-bbs2-0026" title="AboulgharM . Luteal support in reproduction: when, what and how?Current Opinion in Obstetrics and Gynecology2009;21(3):279-84. ">Aboulghar 2009</a>; <a href="./references#CD012396-bbs2-0027" title="Arango MartÃ­nezA , Betancourt MarÃ­nJ . Utilidad del soporte en fase lutea con Ã³vulos de progesterone in artificial intrauterine insemination. Profamilia-in ser. 1996-1997. CES Medicina1997;11(1):1-25. ">Arango 1997</a>; <a href="./references#CD012396-bbs2-0030" title="BakayK , AytekinF , CelikNY . Progesterone supplement and luteal phase deficiency in uni-follicular intrauterine insemination cycles. Journal of Clinical and Analytical Medicine2015;6:691-3. ">Bakay 2015</a>; <a href="./references#CD012396-bbs2-0035" title="CohlenBJ . Should luteal phase support be introduced in ovarian stimulation/IUI programmes? An evidence-based review. Reproductive Biomedicine Online2009;19(Suppl 4):31-8. ">Cohlen 2009a</a>; <a href="./references#CD012396-bbs2-0039" title="ErgurAR , YergokY , ErtekinA , MungenE , TutuncuL . Efficacy of luteal phase supplementation with human chorionic gonadotropin (HCG) in gonadotropin induced cycles. Human Reproduction1997;12(Suppl 2):322-3. ">Ergur 1998</a>; <a href="./references#CD012396-bbs2-0042" title="GagliardiCL . Utility of gonadotropin-releasing hormone agonists in programs of ovarian hyperstimulation with intrauterine insemination. Clinical Obstetrics &amp; Gynecology1993;36(3):711-8. ">Gagliardi 1993</a>; <a href="./references#CD012396-bbs2-0045" title="GünI , Özdamar Ö, YılmazA . Luteal phase support in intrauterine insemination cycles. Turkish Journal of Obstetrics and Gynecology2016;13(2):90-4. ">Gun 2016</a>; <a href="./references#CD012396-bbs2-0057" title="MiralpeixE , González-ComadranM , SolàI , ManauD , CarrerasR , ChecaMA . Efficacy of luteal phase support with vaginal progesterone in intrauterine insemination: a systematic review and meta-analysis. Journal of Assisted Reproduction and Genetics2014;31(1):89-100. ">Miralpeix 2014a</a>; <a href="./references#CD012396-bbs2-0058" title="MiralpeixE , González-ComadranM , SolàI , ManauD , CarrerasR , ChecaMA . Efficacy of luteal phase support with vaginal progesterone in intrauterine insemination: a systematic review and meta-analysis. Journal of Assisted Reproduction and Genetics2014;31:89-100. ">Miralpeix 2016</a>; <a href="./references#CD012396-bbs2-0059" title="MukherjeeG , KonarH , MandveP , SharmaS , GhoshS , ChakrabortyP , et al. Progesterone supplementation in PCOS women undergoing clomiphene citrate stimulated IUI may improve pregnancy by increasing uterine blood. Fertility and Sterility2016;106:e260. ">Mukherjee 2016</a>; <a href="./references#CD012396-bbs2-0066" title="PeñarrubiaJ , BalaschJ , FábreguesF , CreusM , CasamitjanaR , BallescáJL , et al. Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles. Human Reproduction1998;13(12):3315-8. ">Penarrubia 1998</a>; <a href="./references#CD012396-bbs2-0069" title="SchwarzeJE , VillaS , ManzurA , MagendzoA , PommerR . Progesterone-releasing vaginal ring for luteal phase support after superovulation and intrauterine insemination cycles, a pilot study. JBRA Assisted Reproduction2013;17:313-5. ">Schwarze 2013</a>; <a href="./references#CD012396-bbs2-0070" title="TaşM , UludagSZ , AygenME , SahinY . Comparison of oral dydrogesterone and vaginal micronized progesterone for luteal phase support in intrauterine insemination. Gynecology Endocrinology2020;36(1):77-80. TaşM , UludagSZ , AygenME , SahinY . Comparison of oral dydrogesterone and vaginal micronized progesterone for luteal phase support in intrauterine insemination. Gynecology Endocrinology2020;36(1):77-80. ">Tas 2020</a>; <a href="./references#CD012396-bbs2-0071" title="YilmazB , KelekciS , SavanK , OralH , MollamahmutogluL . Addition of human chorionic gonadotropin to clomiphene citrate ovulation induction therapy does not improve pregnancy outcomes and luteal function. Fertility and Sterility2006;85(3):783-6. ">Yilmaz 2006</a>). We excluded 31 studies because they did not include a comparison of interest in this review (<a href="./references#CD012396-bbs2-0028" title="AtmacaS , ErdemM , ErdemA , GulerI . The impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2007;88 Suppl 1:163. ">Atmaca 2007</a>; <a href="./references#CD012396-bbs2-0029" title="BachusKE , Hughes CL Jr, HaneyAF , DodsonWC . The luteal phase in polycystic ovary syndrome during ovulation induction with human menopausal gonadotropin with human menopausal gonadotropin with and without leuprolide acetate. Fertility and Sterility1990;54(1):27-31. ">Bachus 1990</a>; <a href="./references#CD012396-bbs2-0031" title="BalaschJ , VanrellJA , MÃ¡rquezM , GonzÃ¡lez-MerloJ . Dehydrogesterone treatment of endometrial luteal phase deficiency after ovulation induced by clomiphene citrate and human chorionic gonadotropin. Fertility and Sterility1983;40(4):469-71. ">Balasch 1983</a>; <a href="./references#CD012396-bbs2-0032" title="BeltsosAN , SanchezMD , DoodyKJ , BushMR , DomarAD , CollinsMG . Patients' administration preferences: progesterone vaginal insert (Endometrin®) compared to intramuscular progesterone for luteal phase support. Reproductive Health2014;11(1):78-85. ">Beltsos 2014</a>; <a href="./references#CD012396-bbs2-0033" title="BlumenfeldZ , NahhasF . Luteal dysfunction in ovulation induction: the role of repetitive human chorionic gonadotropin supplementation during the luteal phase. Fertility and Sterility1988;50(3):403-7. ">Blumenfeld 1988</a>; <a href="./references#CD012396-bbs2-0034" title="CheckJH , WuCH , AdelsonHG . Bromocriptine versus progesterone therapy for infertility related to luteal phase defects in hyperprolactinaemia patients. International Journal of Fertility1989;34(3):209-14. ">Check 1989</a>; <a href="./references#CD012396-bbs2-0036" title="CorsonSL , BatzerFR , GocialB , MaislinG . The luteal phase after ovulation induction with human menopausal gonadotropin and one versus two doses of a gonadotropin-releasing hormone agonist. Fertility and Sterility1993;59(6):1251-6. ">Corson 1993</a>; <a href="./references#CD012396-bbs2-0037" title="DuffyDA , ManziD , BenadivaC , MaierD , SaundersM , NulsenJ . Impact of leuprolide acetate on luteal phase function in women undergoing controlled ovarian hyperstimulation and intrauterine insemination. Fertility and Sterility2006;85(2):407-11. ">Duffy 2006</a>; <a href="./references#CD012396-bbs2-0038" title="Elkind HirschK , PhillipsK , KellerMG , BelloS , McNicholM . Hormone supplementation (vaginal oestradiol and Crinone 8%) corrects delayed endometrial development during the late luteal phase. Human Reproduction2000;15:174. ">Elkind 2000</a>; <a href="./references#CD012396-bbs2-0040" title="ForoozanfardF , SaberiH , MoravvegiA , KazemiM . Vaginal progesterone effect on pregnancy rate in polycystic ovary syndrome patients. Iranian Journal of Reproductive Medicine2012;10:10. ">Foroozanfard 2012</a>; <a href="./references#CD012396-bbs2-0041" title="ForoozanfardF , SaberiH , MoravejiSA , BazarganipourF . Pregnancy rate following luteal phase support in Iranian women with polycystic ovarian syndrome. International Journal of Fertility and Sterility2014;8(3):235-42. ForoozanfardF , SaberiH , MoravvegiA , KazemiM . Pregnancy rate following luteal phase support in polycystic ovarian syndrome using combination therapies for ovulation induction: a randomised clinical trial. Human Reproduction2013;28:i311-56 P. ForoozanfardF , SaberiH , MoravvegiA , KazemiM . Pregnancy rate following luteal phase support in polycystic ovarian syndrome using combination therapies for ovulation induction: a randomised clinical trial. Human Reproduction2013;28 Suppl 1:i311-56 P. ">Foroozanfard 2013</a>; <a href="./references#CD012396-bbs2-0043" title="GleicherN , BrownT , DudkiewiczA , KarandeV , RaoR , BalinM , et al. Estradiol/progesterone substitution in the luteal phase improves pregnancy rates in stimulated cycles - but only in younger women. Early Pregnancy: Biology and Medicine2000;4(1):64-73. ">Gleicher 2000</a>; <a href="./references#CD012396-bbs2-0044" title="GreenKA , ZoltonJR , SchermerhornSM , DeCherneyAH , HillMJ . An updated meta-analysis evaluating the effect of progesterone (P) luteal support on live birth after ovulation induction (OI) and intrauterine insemination (IUI). Reproductive Sciences2017;1(Suppl 1):166A. ">Green 2017a</a>; <a href="./references#CD012396-bbs2-0046" title="HansenKR , EisenbergE , BakerV , HillMJ , ChenS , TalkenS , et al. Midluteal progesterone: a marker of treatment outcomes in couples with unexplained infertility. Journal of Clinical Endocrinology and Metabolism2018;103(7):2743-51. ">Hansen 2018</a>; <a href="./references#CD012396-bbs2-0047" title="IRCT201202078948N1. The effect of progesterone in intrauterine insemination [Comparison the efficacy of using intravaginal progesterone in pregnancy rate in intrauterine insemination]. www.irct.ir/trial/9407 (first received 17 August 2012). ">IRCT201202078948N1</a>; <a href="./references#CD012396-bbs2-0048" title="IRCT2015030521344N1. Comparing intramuscular (25 and 50 milligram) and vaginal suppository (400 and 800 milligram) progesterone for luteal phase support in IUI cycle in infertile women with age of 20 to 38 years, who were candidate for IUI cycles due to male factor and unexplained infertility [Comparison of intramuscular progesterone and suppository progesterone for luteal phase support in IUI cycles]. www.irct.ir/trial/18732 (first received 1 May 2015). ">IRCT2015030521344N1</a>; <a href="./references#CD012396-bbs2-0049" title="KeenanJA , MoghissiKS . Luteal phase support with hCG does not improve fecundity rate in human menopausal gonadotropin-stimulated cycles. Obstetrics and Gynecology1992;79(6):983-7. ">Keenan 1992</a>; <a href="./references#CD012396-bbs2-0050" title="LebrocquyC , GeriilA , JanssenJ , EvenepoelJ , BrandenK . Results of an artificial insemination programme with cryopreserved donor spermatozoa with or without luteal supplementation in cycles with clomiphene citrate. Human Reproduction1998;13(1):19. ">Lebrocquy 1998</a>; <a href="./references#CD012396-bbs2-0051" title="LudwigM , FinasA , KatalinicA , StrikD , KowalcekI , SchwartzP , et al. Prospective, randomised study to evaluate the pregnancy rate using HCG, vaginal progesterone (Utrogest), or a combination of both for luteal-phase support: preliminary results. Acta Obstetricia et Gynecologica Scandinavica2001;80(1):574-82. ">Ludwig 2001</a>; <a href="./references#CD012396-bbs2-0052" title="MadkourWA , NoahB , ArmMS , HamidA , ZeheerH , Al-BahrA , et al. Luteal phase support with progesterone versus estrogen and progesterone on pregnancy rates. Human Fertility2016;19:142-9. ">Madkour 2016</a>; <a href="./references#CD012396-bbs2-0053" title="MaherMA . Luteal phase support may improve pregnancy outcomes during intrauterine insemination cycles. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2011;157:57-62. ">Maher 2011</a>; <a href="./references#CD012396-bbs2-0054" title="MalhotraJ , KrishnaprasadK . Open-label, prospective, investigator initiated study to assess the clinical role of oral natural or synthetic progesterone during stimulated IUI cycles for unexplained infertility. Journal of Clinical and Diagnostic Research2016;10(1):8-10. ">Malhotra 2016</a>; <a href="./references#CD012396-bbs2-0055" title="MalikS , KrishnaprasadK . Natural micronized progesterone sustained release (SR) and luteal phase: role redefined!!Journal of Clinical and Diagnostic Research2016;10(2):QE01-4. ">Malik 2016</a>; <a href="./references#CD012396-bbs2-0056" title="MartinsWP . Suporte da fase lútea. Femina2010;38(5):271-6. ">Martins 2010</a>; <a href="./references#CD012396-bbs2-0064" title="NilesAM , FrickeHP , CarvalhoPD , WiltbankMC , HernandezLL , FrickePM . Effect of treatment with human chorionic gonadotropin 7 days after artificial insemination or at the time of embryo transfer on reproductive outcomes in nulliparous Holstein heifers. Journal of Dairy Science2019;102(3):2593-606. ">Niles 2019</a>; <a href="./references#CD012396-bbs2-0065" title="OzcimenE , UgurM , OzcimenN , YilmazZ . Is luteal phase support with hCG or vaginal micronized progesterone beneficial in non-IVF gonadotropin induction of ovulation?Fertility and Sterility2004;82(Suppl 2):S142. ">Ozcimen 2004</a>; <a href="./references#CD012396-bbs2-0067" title="PirardC , DonnezJ , LoumayeE . GnRH agonist as novel luteal support: results of a randomised, parallel group, feasibility study using intranasal administration of buserelin. Human Reproduction2005;20(7):1798-804. ">Pirard 2005</a>; <a href="./references#CD012396-bbs2-0068" title="PomettiniA , CapalbiA , MellusoJ , RealeMG , AgostiniR . Progesterone supplementation for induction of ovulation. Giomale Italiano di Ostetrica e Gonecologia2001;23(6):285-9. ">Pomettini 2001</a>; <a href="./references#CD012396-bbs2-0072" title="YoussefG , MaguidA , El-InanyH . Progesterone supplementation in clomiphene citrate treated anovulatory patients with menstrual irregularities: a randomised controlled trial. Middle East Fertility Society Journal2000;5(3):209-12. ">Youssef 2000</a>; <a href="./references#CD012396-bbs2-0073" title="ZaffaroniL , CostaP , VinciG . Topical progesterone as support for the luteal phase in induced cycles. Minerva Gynaecology1997;49:361-4. ">Zaffaroni 1997</a>; <a href="./references#CD012396-bbs2-0074" title="ZayedFF , El-JalladMF , Al-ChalabiHA . Luteal phase support in ovarian induction cycles using human chorionic gonadotropin or oral progestogens. Saudi Medical Journal2003;24(1):34-6. ">Zayed 2003</a>). We excluded four studies that had been terminated (<a href="./references#CD012396-bbs2-0060" title="NCT00700492. Does hormonal luteal support after intra-uterine insemination (IUI) increase the pregnancy rate?www.clinicaltrials.gov/ct2/show/NCT00700492 (first received 18 June 2008). ">NCT00700492 (a)</a>; <a href="./references#CD012396-bbs2-0061" title="NCT00700492. Does hormonal luteal support after intra-uterine insemination (IUI) increase the pregnancy rate?clinicaltrials.gov/ct2/show/NCT00700492 (first received 18 June 2008). ">NCT00700492 (b)</a>; <a href="./references#CD012396-bbs2-0062" title="NCT02510534. Effect of luteal progesterone support on pregnancy rates with combined clomid/ gonadotropin &amp; IUI. clinicaltrials.gov/ct2/show/NCT02510534 (first received 23 September 2016). ">NCT02510534 (a)</a>; <a href="./references#CD012396-bbs2-0063" title="NCT02510534. Effect of luteal progesterone support on pregnancy rates with combined clomid/gonadotropin &amp; IUI. clinicaltrials.gov/ct2/show/NCT02510534 (first received 29 July 2015). ">NCT02510534 (b)</a>). See <a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001838.pub6/references#CD001838-sec-0149" target="_blank">Characteristics of excluded studies</a>. </p> </section> <section id="CD012396-sec-0067"> <h4 class="title">Studies awaiting classification</h4> <p>One study is awaiting classification (<a href="./references#CD012396-bbs2-0075" title="EbrahimiM , AsbaghFA , DarvishS . The effect of luteal phase support on pregnancy rates of the stimulated intrauterine insemination cycles in couples with unexplained infertility. International Journal of Fertility and Sterility2010;4:51-6. ">Ebrahimi 2010</a>). </p> </section> <section id="CD012396-sec-0068"> <h4 class="title">Ongoing studies</h4> <p>We identified three ongoing studies (<a href="./references#CD012396-bbs2-0076" title="IRCT2017041233379N. The effect of progesterone on pregnancy rates in the intrauterine insemination cycles [The effect of progesterone on pregnancy rates in the intrauterine insemination cycles]. apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2017041233379N1 (first received 22 February 2018). IRCT2017041233379N1. The effect of progesterone on pregnancy rates in the intrauterine insemination cycles [The effect of progesterone suppository to luteal phase support on pregnancy rates in the intrauterine insemination cycles]. apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2017041233379N1 (first received 22 February 2018). ">Maryam 2017</a>; <a href="./references#CD012396-bbs2-0077" title="NCT03115307. Luteal phase support in insemination cycles [A protocol for a randomized, controlled study to compare the use of gonodotropin-releasing hormone agonist triptoreline (Gonapeptyl®) for luteal phase support versus natural luteal phase in the insemination cycles]. clinicaltrials.gov/ct2/show/NCT03115307 (first received 14 April 2017). ">NCT03115307</a>; <a href="./references#CD012396-bbs2-0078" title="NCT03440359. Vaginal progesterone supplementation in women with PCOS undergoing ovulation induction with letrozole [Supplementation of the luteal phase with vaginal progesterone (Crinone 8%) in women with polycystic ovary syndrome undergoing ovulation induction with letrozole: a prospective and randomized controlled trial]. clinicaltrials.gov/ct2/show/NCT03440359 (first received 22 Febuary 2018). ">NCT03440359</a>). </p> </section> </section> <section id="CD012396-sec-0069"> <h3 class="title">Risk of bias in included studies</h3> <p>See the risk of bias graph (<a href="#CD012396-fig-0002">Figure 2</a>) and risk of bias summary (<a href="#CD012396-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD012396-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012396-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD012396-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012396-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012396-sec-0070"> <h4 class="title">Allocation</h4> <section id="CD012396-sec-0071"> <h5 class="title">Random sequence generation</h5> <p>Sixteen RCTs reported acceptable methods of sequence generation and were judged as being at low risk of bias for this domain (<a href="./references#CD012396-bbs2-0001" title="AaliBS , EbrahimipourS , MedhdizadehS . The effectiveness of luteal phase support with Cyclogest in ovarian stimulated intra uterine insemination cycles: a randomised controlled trial. Iranian Journal of Reproductive Medicine2013;11(4):309-14. ">Aali 2013</a>; <a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>; <a href="./references#CD012396-bbs2-0008" title="BiberogluEH , TanrikuluF , ErdemM , ErdemA , BiberogluKO . Luteal phase support in intrauterine insemination cycles: a prospective randomised study of 300 mg versus 600 mg intravaginal progesterone tablet. Gynecological Endocrinology2016;32(1):55-7. ">Biberoglu 2016</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0013" title="KaradagB , DilbazB , KarcaaltincabaD , SahinEG , ErcanF , KarasuY , et al. The effect of luteal-phase support with vaginal progesterone on pregnancy rates in gonadotropin and clomiphene citrate/intra-uterine insemination cycles in unexplained infertility: a prospective randomised study. Journal of Obstetrics and Gynaecology2016;36:794-9. ">Karadag 2016</a>; <a href="./references#CD012396-bbs2-0014" title="KeskinM , AytaçR . Does luteal phase support effect pregnancy rates in intrauterine insemination cycles? A prospective randomised controlled study in a tertiary center. Obstetrics and Gynecology International2020:1-5. [DOI: 10.1155/2022/6234070]">Keskin 2020</a>; <a href="./references#CD012396-bbs2-0016" title="KhosraviD , TaheripanahR , KhosraviR , Taheri PanahA , Tarighat MonfaredV , DefaeeS , et al. Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial (RCT). Iranian Journal of Obstetrics, Gynecology and Infertility2015;13:433-8. KhosraviD , TaheripanahR , TaheripanahA , MonfaredV , Hosseini-ZijoudSM . Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial. Iranian Journal of Obstetrics, Gynecology and Infertility2015;13(7):433-8. ">Khosravi 2015</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0018" title="PakrashiT , BaydounH , BoccaS , OehningerS , StadtmauerL . Luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome and ovulatory dysfunction undergoing ovulation induction with letrozole: a randomised controlled trial. Fertility and Sterility2014;102 Suppl(3):e237. ">Pakrashi 2014</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>). </p> <p>Nine RCTs did not report what method was used for sequence generation and were assessed as at unclear risk of bias (<a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>; <a href="./references#CD012396-bbs2-0004" title="AnSJ , JungJY , KwonHC , KimHM , HanJH , LeeSJ . Effect of luteal phase support in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2010;94 Suppl 1(4):S176-7. ">An 2010</a>; <a href="./references#CD012396-bbs2-0006" title="BekuretsionM , LundkvistO , KarlstromPO . A randomised study comparing low and high dose of HMG/FSH with and without luteal phase support in intrauterine insemination cycles. Human Reproduction1998;13:199. ">Bekuretsion 1998</a>; <a href="./references#CD012396-bbs2-0009" title="BussoC , LabartaE , MeloMAB , NavarroC , VidalC , RemohiJ , et al. Effect of a single dose of a GnRH agonist in the luteal phase of intrauterine insemination cycles: a randomised study. Interim analysis. Human Reproduction2006;21(Suppl 1):i116. ">Busso 2006</a>; <a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0015" title="KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. ">Khadem 2011</a>; <a href="./references#CD012396-bbs2-0005" title="AzmoodehA , MohamadpoorJ , AsbaghFA , GhaseminezhadA , LorzadehN , ForghaniF . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Medicine and Health Research2016;2(9):84-8. MohamadpoorJ . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Fertility and Sterility2013;7:112. ">Azmoodeh 2016</a>; <a href="./references#CD012396-bbs2-0024" title="VenturellaR , MocciaroR , LicoD , RoccaM , Di CelloA , PiccioneF , et al. Subcutaneous aqueous versus vaginal progesterone gel for luteal phase support in intrauterine insemination cycles: a pilot randomised, controlled trial. Human Reproduction2016;31 Suppl 1:i304-5. ">Venturella 2016</a>). </p> </section> <section id="CD012396-sec-0072"> <h5 class="title">Allocation concealment</h5> <p>Four RCTs provided sufficient details on the allocation concealment method and were assessed as at low risk of selection bias (<a href="./references#CD012396-bbs2-0001" title="AaliBS , EbrahimipourS , MedhdizadehS . The effectiveness of luteal phase support with Cyclogest in ovarian stimulated intra uterine insemination cycles: a randomised controlled trial. Iranian Journal of Reproductive Medicine2013;11(4):309-14. ">Aali 2013</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>). The other 21 RCTs did not describe how allocation concealment was undertaken and were assessed as at unclear risk of bias (<a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>; <a href="./references#CD012396-bbs2-0004" title="AnSJ , JungJY , KwonHC , KimHM , HanJH , LeeSJ . Effect of luteal phase support in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2010;94 Suppl 1(4):S176-7. ">An 2010</a>; <a href="./references#CD012396-bbs2-0005" title="AzmoodehA , MohamadpoorJ , AsbaghFA , GhaseminezhadA , LorzadehN , ForghaniF . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Medicine and Health Research2016;2(9):84-8. MohamadpoorJ . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Fertility and Sterility2013;7:112. ">Azmoodeh 2016</a>; <a href="./references#CD012396-bbs2-0006" title="BekuretsionM , LundkvistO , KarlstromPO . A randomised study comparing low and high dose of HMG/FSH with and without luteal phase support in intrauterine insemination cycles. Human Reproduction1998;13:199. ">Bekuretsion 1998</a>; <a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>; <a href="./references#CD012396-bbs2-0008" title="BiberogluEH , TanrikuluF , ErdemM , ErdemA , BiberogluKO . Luteal phase support in intrauterine insemination cycles: a prospective randomised study of 300 mg versus 600 mg intravaginal progesterone tablet. Gynecological Endocrinology2016;32(1):55-7. ">Biberoglu 2016</a>; <a href="./references#CD012396-bbs2-0009" title="BussoC , LabartaE , MeloMAB , NavarroC , VidalC , RemohiJ , et al. Effect of a single dose of a GnRH agonist in the luteal phase of intrauterine insemination cycles: a randomised study. Interim analysis. Human Reproduction2006;21(Suppl 1):i116. ">Busso 2006</a>; <a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0013" title="KaradagB , DilbazB , KarcaaltincabaD , SahinEG , ErcanF , KarasuY , et al. The effect of luteal-phase support with vaginal progesterone on pregnancy rates in gonadotropin and clomiphene citrate/intra-uterine insemination cycles in unexplained infertility: a prospective randomised study. Journal of Obstetrics and Gynaecology2016;36:794-9. ">Karadag 2016</a>; <a href="./references#CD012396-bbs2-0014" title="KeskinM , AytaçR . Does luteal phase support effect pregnancy rates in intrauterine insemination cycles? A prospective randomised controlled study in a tertiary center. Obstetrics and Gynecology International2020:1-5. [DOI: 10.1155/2022/6234070]">Keskin 2020</a>; <a href="./references#CD012396-bbs2-0015" title="KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. ">Khadem 2011</a>; <a href="./references#CD012396-bbs2-0016" title="KhosraviD , TaheripanahR , KhosraviR , Taheri PanahA , Tarighat MonfaredV , DefaeeS , et al. Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial (RCT). Iranian Journal of Obstetrics, Gynecology and Infertility2015;13:433-8. KhosraviD , TaheripanahR , TaheripanahA , MonfaredV , Hosseini-ZijoudSM . Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial. Iranian Journal of Obstetrics, Gynecology and Infertility2015;13(7):433-8. ">Khosravi 2015</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0018" title="PakrashiT , BaydounH , BoccaS , OehningerS , StadtmauerL . Luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome and ovulatory dysfunction undergoing ovulation induction with letrozole: a randomised controlled trial. Fertility and Sterility2014;102 Suppl(3):e237. ">Pakrashi 2014</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>; <a href="./references#CD012396-bbs2-0024" title="VenturellaR , MocciaroR , LicoD , RoccaM , Di CelloA , PiccioneF , et al. Subcutaneous aqueous versus vaginal progesterone gel for luteal phase support in intrauterine insemination cycles: a pilot randomised, controlled trial. Human Reproduction2016;31 Suppl 1:i304-5. ">Venturella 2016</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>). </p> </section> </section> <section id="CD012396-sec-0073"> <h4 class="title">Blinding</h4> <p>We did not consider that blinding was likely to influence findings for the main clinical outcomes (live birth, ongoing pregnancy, miscarriage, clinical pregnancy, and multiple pregnancy rates), therefore we assessed 23 RCTs as at low risk of bias (<a href="./references#CD012396-bbs2-0001" title="AaliBS , EbrahimipourS , MedhdizadehS . The effectiveness of luteal phase support with Cyclogest in ovarian stimulated intra uterine insemination cycles: a randomised controlled trial. Iranian Journal of Reproductive Medicine2013;11(4):309-14. ">Aali 2013</a>; <a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>; <a href="./references#CD012396-bbs2-0004" title="AnSJ , JungJY , KwonHC , KimHM , HanJH , LeeSJ . Effect of luteal phase support in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2010;94 Suppl 1(4):S176-7. ">An 2010</a>; <a href="./references#CD012396-bbs2-0005" title="AzmoodehA , MohamadpoorJ , AsbaghFA , GhaseminezhadA , LorzadehN , ForghaniF . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Medicine and Health Research2016;2(9):84-8. MohamadpoorJ . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Fertility and Sterility2013;7:112. ">Azmoodeh 2016</a>; <a href="./references#CD012396-bbs2-0006" title="BekuretsionM , LundkvistO , KarlstromPO . A randomised study comparing low and high dose of HMG/FSH with and without luteal phase support in intrauterine insemination cycles. Human Reproduction1998;13:199. ">Bekuretsion 1998</a>; <a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>; <a href="./references#CD012396-bbs2-0008" title="BiberogluEH , TanrikuluF , ErdemM , ErdemA , BiberogluKO . Luteal phase support in intrauterine insemination cycles: a prospective randomised study of 300 mg versus 600 mg intravaginal progesterone tablet. Gynecological Endocrinology2016;32(1):55-7. ">Biberoglu 2016</a>; <a href="./references#CD012396-bbs2-0009" title="BussoC , LabartaE , MeloMAB , NavarroC , VidalC , RemohiJ , et al. Effect of a single dose of a GnRH agonist in the luteal phase of intrauterine insemination cycles: a randomised study. Interim analysis. Human Reproduction2006;21(Suppl 1):i116. ">Busso 2006</a>; <a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0014" title="KeskinM , AytaçR . Does luteal phase support effect pregnancy rates in intrauterine insemination cycles? A prospective randomised controlled study in a tertiary center. Obstetrics and Gynecology International2020:1-5. [DOI: 10.1155/2022/6234070]">Keskin 2020</a>; <a href="./references#CD012396-bbs2-0016" title="KhosraviD , TaheripanahR , KhosraviR , Taheri PanahA , Tarighat MonfaredV , DefaeeS , et al. Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial (RCT). Iranian Journal of Obstetrics, Gynecology and Infertility2015;13:433-8. KhosraviD , TaheripanahR , TaheripanahA , MonfaredV , Hosseini-ZijoudSM . Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial. Iranian Journal of Obstetrics, Gynecology and Infertility2015;13(7):433-8. ">Khosravi 2015</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0018" title="PakrashiT , BaydounH , BoccaS , OehningerS , StadtmauerL . Luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome and ovulatory dysfunction undergoing ovulation induction with letrozole: a randomised controlled trial. Fertility and Sterility2014;102 Suppl(3):e237. ">Pakrashi 2014</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>; <a href="./references#CD012396-bbs2-0024" title="VenturellaR , MocciaroR , LicoD , RoccaM , Di CelloA , PiccioneF , et al. Subcutaneous aqueous versus vaginal progesterone gel for luteal phase support in intrauterine insemination cycles: a pilot randomised, controlled trial. Human Reproduction2016;31 Suppl 1:i304-5. ">Venturella 2016</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>). However, one RCT reported adverse events such that blinding status could have potentially affected findings (<a href="./references#CD012396-bbs2-0015" title="KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. ">Khadem 2011</a>), therefore we assessed this RCT as at high risk of bias.  </p> <p>One RCT did not report the blinding method and was thus assessed as at unclear risk of performance bias (<a href="./references#CD012396-bbs2-0013" title="KaradagB , DilbazB , KarcaaltincabaD , SahinEG , ErcanF , KarasuY , et al. The effect of luteal-phase support with vaginal progesterone on pregnancy rates in gonadotropin and clomiphene citrate/intra-uterine insemination cycles in unexplained infertility: a prospective randomised study. Journal of Obstetrics and Gynaecology2016;36:794-9. ">Karadag 2016</a>). </p> </section> <section id="CD012396-sec-0074"> <h4 class="title">Incomplete outcome data</h4> <p>Twenty‐two RCTs had less than 10% dropout and were assessed as at low risk of bias (<a href="./references#CD012396-bbs2-0001" title="AaliBS , EbrahimipourS , MedhdizadehS . The effectiveness of luteal phase support with Cyclogest in ovarian stimulated intra uterine insemination cycles: a randomised controlled trial. Iranian Journal of Reproductive Medicine2013;11(4):309-14. ">Aali 2013</a>; <a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>; <a href="./references#CD012396-bbs2-0004" title="AnSJ , JungJY , KwonHC , KimHM , HanJH , LeeSJ . Effect of luteal phase support in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2010;94 Suppl 1(4):S176-7. ">An 2010</a>; <a href="./references#CD012396-bbs2-0005" title="AzmoodehA , MohamadpoorJ , AsbaghFA , GhaseminezhadA , LorzadehN , ForghaniF . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Medicine and Health Research2016;2(9):84-8. MohamadpoorJ . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Fertility and Sterility2013;7:112. ">Azmoodeh 2016</a>; <a href="./references#CD012396-bbs2-0006" title="BekuretsionM , LundkvistO , KarlstromPO . A randomised study comparing low and high dose of HMG/FSH with and without luteal phase support in intrauterine insemination cycles. Human Reproduction1998;13:199. ">Bekuretsion 1998</a>; <a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>; <a href="./references#CD012396-bbs2-0008" title="BiberogluEH , TanrikuluF , ErdemM , ErdemA , BiberogluKO . Luteal phase support in intrauterine insemination cycles: a prospective randomised study of 300 mg versus 600 mg intravaginal progesterone tablet. Gynecological Endocrinology2016;32(1):55-7. ">Biberoglu 2016</a>; <a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0013" title="KaradagB , DilbazB , KarcaaltincabaD , SahinEG , ErcanF , KarasuY , et al. The effect of luteal-phase support with vaginal progesterone on pregnancy rates in gonadotropin and clomiphene citrate/intra-uterine insemination cycles in unexplained infertility: a prospective randomised study. Journal of Obstetrics and Gynaecology2016;36:794-9. ">Karadag 2016</a>; <a href="./references#CD012396-bbs2-0014" title="KeskinM , AytaçR . Does luteal phase support effect pregnancy rates in intrauterine insemination cycles? A prospective randomised controlled study in a tertiary center. Obstetrics and Gynecology International2020:1-5. [DOI: 10.1155/2022/6234070]">Keskin 2020</a>; <a href="./references#CD012396-bbs2-0015" title="KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. ">Khadem 2011</a>; <a href="./references#CD012396-bbs2-0016" title="KhosraviD , TaheripanahR , KhosraviR , Taheri PanahA , Tarighat MonfaredV , DefaeeS , et al. Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial (RCT). Iranian Journal of Obstetrics, Gynecology and Infertility2015;13:433-8. KhosraviD , TaheripanahR , TaheripanahA , MonfaredV , Hosseini-ZijoudSM . Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial. Iranian Journal of Obstetrics, Gynecology and Infertility2015;13(7):433-8. ">Khosravi 2015</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0024" title="VenturellaR , MocciaroR , LicoD , RoccaM , Di CelloA , PiccioneF , et al. Subcutaneous aqueous versus vaginal progesterone gel for luteal phase support in intrauterine insemination cycles: a pilot randomised, controlled trial. Human Reproduction2016;31 Suppl 1:i304-5. ">Venturella 2016</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>). Three RCTs were interim analyses (<a href="./references#CD012396-bbs2-0009" title="BussoC , LabartaE , MeloMAB , NavarroC , VidalC , RemohiJ , et al. Effect of a single dose of a GnRH agonist in the luteal phase of intrauterine insemination cycles: a randomised study. Interim analysis. Human Reproduction2006;21(Suppl 1):i116. ">Busso 2006</a>; <a href="./references#CD012396-bbs2-0018" title="PakrashiT , BaydounH , BoccaS , OehningerS , StadtmauerL . Luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome and ovulatory dysfunction undergoing ovulation induction with letrozole: a randomised controlled trial. Fertility and Sterility2014;102 Suppl(3):e237. ">Pakrashi 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>); we classified these RCTs as at high risk of attrition bias. </p> </section> <section id="CD012396-sec-0075"> <h4 class="title">Selective reporting</h4> <p>Five RCTs reported all outcomes listed in the protocol, including live birth and ongoing pregnancy rates (the primary outcomes of this review), and were therefore assessed as at low risk of reporting bias (<a href="./references#CD012396-bbs2-0001" title="AaliBS , EbrahimipourS , MedhdizadehS . The effectiveness of luteal phase support with Cyclogest in ovarian stimulated intra uterine insemination cycles: a randomised controlled trial. Iranian Journal of Reproductive Medicine2013;11(4):309-14. ">Aali 2013</a>; <a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>; <a href="./references#CD012396-bbs2-0024" title="VenturellaR , MocciaroR , LicoD , RoccaM , Di CelloA , PiccioneF , et al. Subcutaneous aqueous versus vaginal progesterone gel for luteal phase support in intrauterine insemination cycles: a pilot randomised, controlled trial. Human Reproduction2016;31 Suppl 1:i304-5. ">Venturella 2016</a>). </p> <p>We judged 19 RCTs to be at unclear risk of reporting bias because they did not have protocol registration (<a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>; <a href="./references#CD012396-bbs2-0004" title="AnSJ , JungJY , KwonHC , KimHM , HanJH , LeeSJ . Effect of luteal phase support in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2010;94 Suppl 1(4):S176-7. ">An 2010</a>; <a href="./references#CD012396-bbs2-0005" title="AzmoodehA , MohamadpoorJ , AsbaghFA , GhaseminezhadA , LorzadehN , ForghaniF . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Medicine and Health Research2016;2(9):84-8. MohamadpoorJ . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Fertility and Sterility2013;7:112. ">Azmoodeh 2016</a>; <a href="./references#CD012396-bbs2-0006" title="BekuretsionM , LundkvistO , KarlstromPO . A randomised study comparing low and high dose of HMG/FSH with and without luteal phase support in intrauterine insemination cycles. Human Reproduction1998;13:199. ">Bekuretsion 1998</a>; <a href="./references#CD012396-bbs2-0008" title="BiberogluEH , TanrikuluF , ErdemM , ErdemA , BiberogluKO . Luteal phase support in intrauterine insemination cycles: a prospective randomised study of 300 mg versus 600 mg intravaginal progesterone tablet. Gynecological Endocrinology2016;32(1):55-7. ">Biberoglu 2016</a>; <a href="./references#CD012396-bbs2-0009" title="BussoC , LabartaE , MeloMAB , NavarroC , VidalC , RemohiJ , et al. Effect of a single dose of a GnRH agonist in the luteal phase of intrauterine insemination cycles: a randomised study. Interim analysis. Human Reproduction2006;21(Suppl 1):i116. ">Busso 2006</a>; <a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0013" title="KaradagB , DilbazB , KarcaaltincabaD , SahinEG , ErcanF , KarasuY , et al. The effect of luteal-phase support with vaginal progesterone on pregnancy rates in gonadotropin and clomiphene citrate/intra-uterine insemination cycles in unexplained infertility: a prospective randomised study. Journal of Obstetrics and Gynaecology2016;36:794-9. ">Karadag 2016</a>; <a href="./references#CD012396-bbs2-0014" title="KeskinM , AytaçR . Does luteal phase support effect pregnancy rates in intrauterine insemination cycles? A prospective randomised controlled study in a tertiary center. Obstetrics and Gynecology International2020:1-5. [DOI: 10.1155/2022/6234070]">Keskin 2020</a>; <a href="./references#CD012396-bbs2-0015" title="KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. ">Khadem 2011</a>; <a href="./references#CD012396-bbs2-0016" title="KhosraviD , TaheripanahR , KhosraviR , Taheri PanahA , Tarighat MonfaredV , DefaeeS , et al. Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial (RCT). Iranian Journal of Obstetrics, Gynecology and Infertility2015;13:433-8. KhosraviD , TaheripanahR , TaheripanahA , MonfaredV , Hosseini-ZijoudSM . Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial. Iranian Journal of Obstetrics, Gynecology and Infertility2015;13(7):433-8. ">Khosravi 2015</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0018" title="PakrashiT , BaydounH , BoccaS , OehningerS , StadtmauerL . Luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome and ovulatory dysfunction undergoing ovulation induction with letrozole: a randomised controlled trial. Fertility and Sterility2014;102 Suppl(3):e237. ">Pakrashi 2014</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>). </p> <p>We assessed only one RCT as at high risk of bias due to financial connections between review authors and drug firms (<a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>). </p> </section> <section id="CD012396-sec-0076"> <h4 class="title">Other potential sources of bias</h4> <p>Thirteen RCTs reported similar causes of infertility and other baseline characteristics and were thus deemed as at low risk of other bias (<a href="./references#CD012396-bbs2-0001" title="AaliBS , EbrahimipourS , MedhdizadehS . The effectiveness of luteal phase support with Cyclogest in ovarian stimulated intra uterine insemination cycles: a randomised controlled trial. Iranian Journal of Reproductive Medicine2013;11(4):309-14. ">Aali 2013</a>; <a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>; <a href="./references#CD012396-bbs2-0008" title="BiberogluEH , TanrikuluF , ErdemM , ErdemA , BiberogluKO . Luteal phase support in intrauterine insemination cycles: a prospective randomised study of 300 mg versus 600 mg intravaginal progesterone tablet. Gynecological Endocrinology2016;32(1):55-7. ">Biberoglu 2016</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0013" title="KaradagB , DilbazB , KarcaaltincabaD , SahinEG , ErcanF , KarasuY , et al. The effect of luteal-phase support with vaginal progesterone on pregnancy rates in gonadotropin and clomiphene citrate/intra-uterine insemination cycles in unexplained infertility: a prospective randomised study. Journal of Obstetrics and Gynaecology2016;36:794-9. ">Karadag 2016</a>; <a href="./references#CD012396-bbs2-0014" title="KeskinM , AytaçR . Does luteal phase support effect pregnancy rates in intrauterine insemination cycles? A prospective randomised controlled study in a tertiary center. Obstetrics and Gynecology International2020:1-5. [DOI: 10.1155/2022/6234070]">Keskin 2020</a>; <a href="./references#CD012396-bbs2-0015" title="KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. ">Khadem 2011</a>; <a href="./references#CD012396-bbs2-0016" title="KhosraviD , TaheripanahR , KhosraviR , Taheri PanahA , Tarighat MonfaredV , DefaeeS , et al. Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial (RCT). Iranian Journal of Obstetrics, Gynecology and Infertility2015;13:433-8. KhosraviD , TaheripanahR , TaheripanahA , MonfaredV , Hosseini-ZijoudSM . Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial. Iranian Journal of Obstetrics, Gynecology and Infertility2015;13(7):433-8. ">Khosravi 2015</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>). </p> <p>We rated 12 RCTs as at high risk of bias for this domain as only abstracts were available (<a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>; <a href="./references#CD012396-bbs2-0004" title="AnSJ , JungJY , KwonHC , KimHM , HanJH , LeeSJ . Effect of luteal phase support in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2010;94 Suppl 1(4):S176-7. ">An 2010</a>; <a href="./references#CD012396-bbs2-0005" title="AzmoodehA , MohamadpoorJ , AsbaghFA , GhaseminezhadA , LorzadehN , ForghaniF . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Medicine and Health Research2016;2(9):84-8. MohamadpoorJ . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Fertility and Sterility2013;7:112. ">Azmoodeh 2016</a>; <a href="./references#CD012396-bbs2-0006" title="BekuretsionM , LundkvistO , KarlstromPO . A randomised study comparing low and high dose of HMG/FSH with and without luteal phase support in intrauterine insemination cycles. Human Reproduction1998;13:199. ">Bekuretsion 1998</a>; <a href="./references#CD012396-bbs2-0009" title="BussoC , LabartaE , MeloMAB , NavarroC , VidalC , RemohiJ , et al. Effect of a single dose of a GnRH agonist in the luteal phase of intrauterine insemination cycles: a randomised study. Interim analysis. Human Reproduction2006;21(Suppl 1):i116. ">Busso 2006</a>; <a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0018" title="PakrashiT , BaydounH , BoccaS , OehningerS , StadtmauerL . Luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome and ovulatory dysfunction undergoing ovulation induction with letrozole: a randomised controlled trial. Fertility and Sterility2014;102 Suppl(3):e237. ">Pakrashi 2014</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>; <a href="./references#CD012396-bbs2-0024" title="VenturellaR , MocciaroR , LicoD , RoccaM , Di CelloA , PiccioneF , et al. Subcutaneous aqueous versus vaginal progesterone gel for luteal phase support in intrauterine insemination cycles: a pilot randomised, controlled trial. Human Reproduction2016;31 Suppl 1:i304-5. ">Venturella 2016</a>). We attempted to contact the authors for additional information, without success. </p> </section> </section> <section id="CD012396-sec-0077"> <h3 class="title" id="CD012396-sec-0077">Effects of interventions</h3> <p>See: <a href="./full#CD012396-tbl-0001"><b>Summary of findings 1</b> Progesterone compared to no treatment or placebo (route of progesterone administration) for women trying to conceive by intrauterine insemination</a>; <a href="./full#CD012396-tbl-0002"><b>Summary of findings 2</b> Progesterone compared to placebo/no treatment for gonadotropin stimulation for women trying to conceive by intrauterine insemination</a>; <a href="./full#CD012396-tbl-0003"><b>Summary of findings 3</b> Progesterone compared to placebo/no treatment for gonadotropin plus oral (clomiphene citrate/letrozole) stimulation for women trying to conceive by intrauterine insemination</a>; <a href="./full#CD012396-tbl-0004"><b>Summary of findings 4</b> Progesterone compared to placebo/no treatment for oral (clomiphene citrate or letrozole) stimulation for women trying to conceive by intrauterine insemination</a>; <a href="./full#CD012396-tbl-0005"><b>Summary of findings 5</b> 300 mg vaginal progesterone compared to 600 mg vaginal progesterone for women trying to conceive by intrauterine insemination</a>; <a href="./full#CD012396-tbl-0006"><b>Summary of findings 6</b> Intramuscular (IM) progesterone compared to vaginal progesterone for women trying to conceive by intrauterine insemination</a>; <a href="./full#CD012396-tbl-0007"><b>Summary of findings 7</b> Oral progesterone compared to vaginal progesterone for women trying to conceive by intrauterine insemination</a>; <a href="./full#CD012396-tbl-0008"><b>Summary of findings 8</b> Aqueous subcutaneous (Sc) progesterone compared to vaginal progesterone gel for women trying to conceive by intrauterine insemination</a>; <a href="./full#CD012396-tbl-0009"><b>Summary of findings 9</b> Subcutaneous (Sc) gonadotropin‐releasing hormone (GnRH) agonist compared to placebo/no treatment for women trying to conceive by intrauterine insemination</a>; <a href="./full#CD012396-tbl-0010"><b>Summary of findings 10</b> Vaginal progesterone compared to gonadotropin‐releasing hormone (GnRH) agonist for women trying to conceive by intrauterine insemination</a>; <a href="./full#CD012396-tbl-0011"><b>Summary of findings 11</b> Human chorionic gonadotropin (hCG) injection compared to no treatment for women trying to conceive by intrauterine insemination</a> </p> <p>We included 25 RCTs (5111 participants). We could not perform any sensitivity analyses restricted to studies at low risk of selection bias and not at high risk for the other domains as no trial fulfilled the criteria. No studies reported on the outcome congenital anomalies. </p> <section id="CD012396-sec-0078"> <h4 class="title">Comparison 1. Progesterone versus no treatment or placebo (route of administration)</h4> <p>Seventeen RCTs (4101 participants) compared progesterone with placebo or no treatment (<a href="./references#CD012396-bbs2-0001" title="AaliBS , EbrahimipourS , MedhdizadehS . The effectiveness of luteal phase support with Cyclogest in ovarian stimulated intra uterine insemination cycles: a randomised controlled trial. Iranian Journal of Reproductive Medicine2013;11(4):309-14. ">Aali 2013</a>; <a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>; <a href="./references#CD012396-bbs2-0004" title="AnSJ , JungJY , KwonHC , KimHM , HanJH , LeeSJ . Effect of luteal phase support in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2010;94 Suppl 1(4):S176-7. ">An 2010</a>; <a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0013" title="KaradagB , DilbazB , KarcaaltincabaD , SahinEG , ErcanF , KarasuY , et al. The effect of luteal-phase support with vaginal progesterone on pregnancy rates in gonadotropin and clomiphene citrate/intra-uterine insemination cycles in unexplained infertility: a prospective randomised study. Journal of Obstetrics and Gynaecology2016;36:794-9. ">Karadag 2016</a>; <a href="./references#CD012396-bbs2-0014" title="KeskinM , AytaçR . Does luteal phase support effect pregnancy rates in intrauterine insemination cycles? A prospective randomised controlled study in a tertiary center. Obstetrics and Gynecology International2020:1-5. [DOI: 10.1155/2022/6234070]">Keskin 2020</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0018" title="PakrashiT , BaydounH , BoccaS , OehningerS , StadtmauerL . Luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome and ovulatory dysfunction undergoing ovulation induction with letrozole: a randomised controlled trial. Fertility and Sterility2014;102 Suppl(3):e237. ">Pakrashi 2014</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>). Only one study used an oral route (<a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>), with the remaining studies using a vaginal route. See <a href="./full#CD012396-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD012396-sec-0079"> <h5 class="title">Primary outcomes</h5> <section id="CD012396-sec-0080"> <h6 class="title">1.1 Live birth rate/ongoing pregnancy rate (per woman)</h6> <p>Seven RCTs reported live birth rate (LBR)/ongoing pregnancy rate (OPR) per woman with data that could be included in a meta‐analysis (<a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>). We are uncertain if vaginal progesterone increases LBR/OPR compared to placebo or no treatment (risk ratio (RR) 1.10, 95% confidence interval (CI) 0.81 to 1.48; 7 RCTs; 1792 participants; I<sup>2</sup> = 35% low‐certainty evidence) (<a href="./references#CD012396-fig-0004" title="">Analysis 1.1</a>). We estimated that for a woman with 12.6% chance of achieving a live birth/ongoing pregnancy with placebo or no treatment, the chance with vaginal progesterone would be between 10.2% and 18.7%. </p> <p><a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a> reported LBR per cycle, therefore we did not combine data from this trial in meta‐analysis. The study authors reported no difference between progesterone supplementation and no‐treatment group (n/N = 46/449) 10.7% and (n/N = 37/444) 8.3%, respectively; P = 0.87. </p> <p><a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a> reported LBR per cycle, therefore we did not combine data from this trial in meta‐analysis. The study authors reported no difference between progesterone supplementation and no‐treatment group (n/N = 20/122) 16.8% and (n/N = 13/123) 10.7%, respectively; P = 0.19. </p> </section> <section id="CD012396-sec-0081"> <h6 class="title">1.2 ‐ 1.3 Miscarriage rate (per clinical pregnancy/per woman)</h6> <p>Five RCTs reported miscarriage rate per clinical pregnancy with data that could be combined in a meta‐analysis (<a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>). We are uncertain about the effect of vaginal progesterone on miscarriage rate per clinical pregnancy compared to placebo or no treatment (RR 0.70, 95% CI 0.40 to 1.25; 5 RCTs; 261 participants; I<sup>2</sup> = 0%, low‐certainty evidence) (<a href="./references#CD012396-fig-0005" title="">Analysis 1.2</a>). This suggests that if the rate of miscarriage per clinical pregnancy with placebo or no treatment is 18.3%, the rate with vaginal progesterone would be between 7.3% and 22.8%. The evidence for miscarriage rate per woman compared to placebo or no treatment was also uncertain (RR 0.90, 95% CI 0.48 to 1.69; 5 RCTs; 1634 participants ; I<sup>2</sup> = 0%; low‐certainty evidence) (<a href="./references#CD012396-fig-0006" title="">Analysis 1.3</a>). </p> <p><a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a> reported miscarriage rate per cycle, therefore we did not combine data from this trial in meta‐analysis. There was no difference between progesterone supplementation and no‐treatment group (n/N = 16/449) 3.6% and (n/N = 12/444) 2.7%, respectively; P = 0.87. </p> <p><a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a> reported miscarriage rate per cycle, therefore we did not combine data from this trial in meta‐analysis. There was no difference between progesterone supplementation and no‐treatment group (n/N = 19/91) 21.1% and (n/N = 9/89) 10.3%, respectively; P &gt; 0.05. </p> <p><a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a> reported miscarriage rate per cycle, therefore we did not combine data from this trial in meta‐analysis. There was no difference between progesterone supplementation and no‐treatment group (n/N = 3/122) 2.4% and (n/N = 2/123) 1.6%, respectively; P &gt; 0.05. </p> <p><a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a> reported miscarriage rate per cycle, therefore we did not combine data from this trial in meta‐analysis. There was no difference between progesterone supplementation and no‐treatment group (n/N = 2/83) 2.4% and (n/N = 0/83) 0%, respectively. </p> </section> </section> <section id="CD012396-sec-0082"> <h5 class="title">Secondary outcomes</h5> <section id="CD012396-sec-0083"> <h6 class="title">1.4 Clinical pregnancy rate (per woman)</h6> <p>Fourteen RCTs reported clinical pregnancy rate per woman (<a href="./references#CD012396-bbs2-0001" title="AaliBS , EbrahimipourS , MedhdizadehS . The effectiveness of luteal phase support with Cyclogest in ovarian stimulated intra uterine insemination cycles: a randomised controlled trial. Iranian Journal of Reproductive Medicine2013;11(4):309-14. ">Aali 2013</a>; <a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>; <a href="./references#CD012396-bbs2-0004" title="AnSJ , JungJY , KwonHC , KimHM , HanJH , LeeSJ . Effect of luteal phase support in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2010;94 Suppl 1(4):S176-7. ">An 2010</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0013" title="KaradagB , DilbazB , KarcaaltincabaD , SahinEG , ErcanF , KarasuY , et al. The effect of luteal-phase support with vaginal progesterone on pregnancy rates in gonadotropin and clomiphene citrate/intra-uterine insemination cycles in unexplained infertility: a prospective randomised study. Journal of Obstetrics and Gynaecology2016;36:794-9. ">Karadag 2016</a>; <a href="./references#CD012396-bbs2-0014" title="KeskinM , AytaçR . Does luteal phase support effect pregnancy rates in intrauterine insemination cycles? A prospective randomised controlled study in a tertiary center. Obstetrics and Gynecology International2020:1-5. [DOI: 10.1155/2022/6234070]">Keskin 2020</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0018" title="PakrashiT , BaydounH , BoccaS , OehningerS , StadtmauerL . Luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome and ovulatory dysfunction undergoing ovulation induction with letrozole: a randomised controlled trial. Fertility and Sterility2014;102 Suppl(3):e237. ">Pakrashi 2014</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>). </p> <p>Vaginal progesterone may increase clinical pregnancy rate compared to placebo or no treatment (RR 1.35, 95% CI 1.14 to 1.61; 13 RCTs; 2794 participants; I<sup>2</sup> = 0%); low‐certainty evidence) (<a href="./references#CD012396-fig-0007" title="">Analysis 1.4</a>) (<a href="./references#CD012396-bbs2-0001" title="AaliBS , EbrahimipourS , MedhdizadehS . The effectiveness of luteal phase support with Cyclogest in ovarian stimulated intra uterine insemination cycles: a randomised controlled trial. Iranian Journal of Reproductive Medicine2013;11(4):309-14. ">Aali 2013</a>; <a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>; <a href="./references#CD012396-bbs2-0004" title="AnSJ , JungJY , KwonHC , KimHM , HanJH , LeeSJ . Effect of luteal phase support in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2010;94 Suppl 1(4):S176-7. ">An 2010</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0013" title="KaradagB , DilbazB , KarcaaltincabaD , SahinEG , ErcanF , KarasuY , et al. The effect of luteal-phase support with vaginal progesterone on pregnancy rates in gonadotropin and clomiphene citrate/intra-uterine insemination cycles in unexplained infertility: a prospective randomised study. Journal of Obstetrics and Gynaecology2016;36:794-9. ">Karadag 2016</a>; <a href="./references#CD012396-bbs2-0014" title="KeskinM , AytaçR . Does luteal phase support effect pregnancy rates in intrauterine insemination cycles? A prospective randomised controlled study in a tertiary center. Obstetrics and Gynecology International2020:1-5. [DOI: 10.1155/2022/6234070]">Keskin 2020</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0018" title="PakrashiT , BaydounH , BoccaS , OehningerS , StadtmauerL . Luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome and ovulatory dysfunction undergoing ovulation induction with letrozole: a randomised controlled trial. Fertility and Sterility2014;102 Suppl(3):e237. ">Pakrashi 2014</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>). This suggests that if the chance of clinical pregnancy following placebo or no treatment is 13.4%, the chance following vaginal progesterone would be between 15.3% and 21.6%. We conducted subgroup analysis comparing vaginal progesterone and placebo or no treatment as planned. </p> <p>In contrast, the evidence is very uncertain about the effect of oral progesterone on clinical pregnancy rate compared to placebo or no treatment (RR 0.67, 95% CI 0.40 to 1.13; 1 RCT; 99 participants; very low‐certainty evidence) (<a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>). </p> <p><a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a> reported clinical pregnancy rate per cycle, therefore we did not combine data from this trial in meta‐analysis. There was no difference between progesterone supplementation and no‐treatment group (n/N = 62/449) 13.8% and (n/N = 49/444) 11.0%, respectively; P = 0.25. </p> <p><a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a> reported clinical pregnancy rate per cycle, therefore we did not combine data from this trial in meta‐analysis. There was no difference between progesterone supplementation and no‐treatment group (n/N = 19/91) 20.9% and (n/N = 13/89) 14.6%, respectively; P &gt; 0.05. </p> <p><a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a> reported clinical pregnancy rate per cycle, therefore we did not combine data from this trial in meta‐analysis. There was no difference between progesterone supplementation and no‐treatment group (n/N = 23/122) 18.9% and (n/N = 15/123) 12.2%, respectively; P = 0.16. </p> </section> <section id="CD012396-sec-0084"> <h6 class="title">1.5 Multiple pregnancy rate (per woman)</h6> <p>Three RCTs evaluated multiple pregnancy rate per woman (<a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>). The evidence is very uncertain about the effect of vaginal progesterone on multiple pregnancy rate compared to placebo or no treatment (RR 0.84, 95% CI 0.30 to 2.34; 3 RCTs; 956 participants; I<sup>2</sup> = 0%; low‐certainty evidence) (<a href="./references#CD012396-fig-0008" title="">Analysis 1.5</a>). This suggests that if the rate of multiple pregnancy with placebo or no treatment is 1.7%, the rate with vaginal progesterone would be between 0.5% and 4.0%. </p> <p><a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a> reported multiple pregnancy rate per cycle, therefore we did not combine data from this trial in meta‐analysis. There was no difference between progesterone supplementation and no‐treatment group (n/N = 5/62) 1.1% and (n/N = 1/49) 0.2%, respectively; P = 0.33. </p> <p><a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a> reported multiple pregnancy rate per cycle, therefore we did not combine data from this trial in meta‐analysis. There was no difference between progesterone supplementation and no‐treatment group (n/N = 2/122) 1.16% and (n/N = 2/123) 1.6%, respectively; P = 0.33. </p> </section> </section> </section> <section id="CD012396-sec-0085"> <h4 class="title">Comparison 2. Progesterone versus no treatment or placebo (type of ovarian stimulation)</h4> <p>Seventeen RCTs (4101 participants) compared progesterone with placebo or no treatment (<a href="./references#CD012396-bbs2-0001" title="AaliBS , EbrahimipourS , MedhdizadehS . The effectiveness of luteal phase support with Cyclogest in ovarian stimulated intra uterine insemination cycles: a randomised controlled trial. Iranian Journal of Reproductive Medicine2013;11(4):309-14. ">Aali 2013</a>; <a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>; <a href="./references#CD012396-bbs2-0004" title="AnSJ , JungJY , KwonHC , KimHM , HanJH , LeeSJ . Effect of luteal phase support in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2010;94 Suppl 1(4):S176-7. ">An 2010</a>; <a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0013" title="KaradagB , DilbazB , KarcaaltincabaD , SahinEG , ErcanF , KarasuY , et al. The effect of luteal-phase support with vaginal progesterone on pregnancy rates in gonadotropin and clomiphene citrate/intra-uterine insemination cycles in unexplained infertility: a prospective randomised study. Journal of Obstetrics and Gynaecology2016;36:794-9. ">Karadag 2016</a>; <a href="./references#CD012396-bbs2-0014" title="KeskinM , AytaçR . Does luteal phase support effect pregnancy rates in intrauterine insemination cycles? A prospective randomised controlled study in a tertiary center. Obstetrics and Gynecology International2020:1-5. [DOI: 10.1155/2022/6234070]">Keskin 2020</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0018" title="PakrashiT , BaydounH , BoccaS , OehningerS , StadtmauerL . Luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome and ovulatory dysfunction undergoing ovulation induction with letrozole: a randomised controlled trial. Fertility and Sterility2014;102 Suppl(3):e237. ">Pakrashi 2014</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>). </p> <section id="CD012396-sec-0086"> <h5 class="title">Primary outcomes</h5> <section id="CD012396-sec-0087"> <h6 class="title">2.1 Live birth rate/ongoing pregnancy rate (per woman)</h6> <p>Seven RCTs reported LBR/OPR per woman (<a href="./references#CD012396-fig-0009" title="">Analysis 2.1</a>) (<a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>). </p> <section id="CD012396-sec-0088"> <p><b>2.1.1 In gonadotropin stimulation cycle </b></p> <p>Four RCTs evaluated LBR/OPR per woman in gonadotropin stimulation cycle (<a href="./full#CD012396-tbl-0002">summary of findings Table 2</a>) (<a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>). We are uncertain if vaginal progesterone increases LBR/OPR compared to placebo or no treatment in gonadotropin stimulation cycle (RR 1.24, 95% CI 0.80 to 1.92; 4 RCTs; 1054 participants; I<sup>2</sup> = 53%; low‐certainty evidence). (<a href="./references#CD012396-fig-0009" title="">Analysis 2.1</a>). </p> <p>We estimated that for a woman with 13.2% chance of achieving a live birth/ongoing pregnancy with placebo or no treatment, the chance with vaginal progesterone in gonadotropin stimulation cycle would be between 10.6% and 25.4%. </p> <p><a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a> reported LBR per cycle, therefore we did not combine data from this trial in meta‐analysis. There was no difference between progesterone supplementation and no‐treatment group (n/N = 46/449) 10.7% and (n/N = 37/444) 8.3%, respectively; P = 0.87. </p> <p><a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a> reported LBR per cycle, therefore we did not combine data from this trial in meta‐analysis. The study authors reported no difference between progesterone supplementation and no‐treatment group (n/N = 20/122) 16.8% and (n/N = 13/123) 10.7%, respectively; P = 0.19. </p> </section> <section id="CD012396-sec-0089"> <p><b>2.1.2 In gonadotropin plus oral (clomiphene citrate) stimulation cycle </b></p> <p>No RCTs reported on LBR. <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a> reported ongoing pregnancy (<a href="./full#CD012396-tbl-0003">summary of findings Table 3</a>). It is unclear if there was a difference between progesterone supplementation and placebo or no treatment in ongoing pregnancy (RR 0.73, 95% CI 0.37 to 1.42; 1 RCT; 253 participants; low‐certainty evidence). We estimated that for a woman with 14.2% chance of achieving an ongoing pregnancy using placebo or no treatment, the chance with vaginal progesterone would be between 5.2% and 20.1%. </p> </section> <section id="CD012396-sec-0090"> <p><b>2.1.3 In oral (clomiphene citrate or letrozole) stimulation cycle</b></p> <p><a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a> and <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a> reported LBR/OPR (<a href="./full#CD012396-tbl-0004">summary of findings Table 4</a>). It is unclear if there was a difference between progesterone supplementation and placebo or no treatment in LBR/OPR (RR 0.97, 95% CI 0.58 to 1.64; 2 RCTs; 485 participants; I<sup>2</sup> = 0%; low‐certainty evidence) (<a href="./references#CD012396-fig-0009" title="">Analysis 2.1</a>). </p> <p>We estimated that for a woman with 10.5% chance of achieving a live birth/ongoing pregnancy using placebo or no treatment, the chance with vaginal progesterone in oral stimulation cycle would be between 6.1% and 17.2%. </p> </section> </section> <section id="CD012396-sec-0091"> <h6 class="title">2.2 ‐ 2.3 Miscarriage rate (per clinical pregnancy/per woman)</h6> <p>Nine RCTs reported miscarriage rate (<a href="./references#CD012396-fig-0010" title="">Analysis 2.2</a>; <a href="./references#CD012396-fig-0011" title="">Analysis 2.3</a>) (<a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>). </p> <section id="CD012396-sec-0092"> <p><b>2.2.1 ‐ 2.3.1 In gonadotropin stimulation cycle </b></p> <p>Two RCTs reported miscarriage rate per clinical pregnancy (<a href="./full#CD012396-tbl-0002">summary of findings Table 2</a>) (<a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>). It is unclear if there was a difference between progesterone supplementation and placebo or no treatment in miscarriage rate (RR 0.68, 95% CI 0.24 to 1.91; 2 RCTs; 102 participants; I<sup>2</sup> = 0%; low‐certainty evidence) (<a href="./references#CD012396-fig-0010" title="">Analysis 2.2</a>). This suggests that if the risk of miscarriage per clinical pregnancy with placebo or no treatment is 16.7%, the risk with vaginal progesterone would be between 4.0% and 31.8%. </p> <p>The evidence for miscarriage rate per woman when comparing progesterone supplementation to placebo or no treatment was also uncertain (RR 0.74, 95% CI 0.23 to 2.32; 2 RCTs; 691 participants; I<sup>2</sup> = 9%; low‐certainty evidence) (<a href="./references#CD012396-fig-0011" title="">Analysis 2.3</a>). </p> <p><a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a> reported miscarriage rate per cycle. There was no difference between progesterone supplementation and no‐treatment group (n/N = 16/449) 3.6% and (n/N = 12/444) 2.7%, respectively; P = 0.87. </p> <p><a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a> reported miscarriage rate per cycle, therefore we did not combine data from this trial in meta‐analysis. There was no difference between progesterone supplementation and no‐treatment group (n/N = 19/91) 21.1% and (n/N = 9/89) 10.3%, respectively; P &gt; 0.05. </p> <p><a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a> reported miscarriage rate per cycle, therefore we did not combine data from this trial in meta‐analysis. There was no difference between progesterone supplementation and no‐treatment group (n/N = 3/122) 2.4% and (n/N = 2/123) 1.6%, respectively; P &gt; 0.05. </p> <p><a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a> reported miscarriage rate per cycle, therefore we did not combine data from this trial in meta‐analysis. There was no difference between progesterone supplementation and no‐treatment group (n/N = 2/83) 2.4% and (n/N = 0/83) 0%, respectively; P &gt; 0.05. </p> </section> <section id="CD012396-sec-0093"> <p><b>2.2.2 ‐ 2.3.2 In gonadotropin plus oral (clomiphene citrate or letrozole) stimulation cycle </b></p> <p>Based on pooled analysis from two RCTs, it is unclear if there is a difference between progesterone supplementation and placebo or no treatment (RR 0.67, 95% CI 0.30 to 1.50; 2 RCTs; 123 participants; I<sup>2</sup> = 0%; low‐certainty evidence) (<a href="./full#CD012396-tbl-0003">summary of findings Table 3</a>) (<a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>). This suggests that if the rate of miscarriage with placebo or no treatment is 18.8%, the rate with vaginal progesterone would be between 5.6% and 28.1%. It was also unclear if there was a difference between groups in miscarriage when data were analysed per woman (RR 1.08, 95% CI 0.44 to 2.64; 2 RCTs; 543 participants; I<sup>2</sup> = 0%). </p> </section> <section id="CD012396-sec-0094"> <p><b>2.2.3 ‐ 2.3.3 In oral (clomiphene citrate or letrozole) stimulation cycle </b></p> <p><a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a> and <a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a> evaluated miscarriage rate (<a href="./full#CD012396-tbl-0004">summary of findings Table 4</a>). It is unclear if there was a difference between progesterone supplementation and placebo or no treatment (RR 0.53, 95% CI 0.25 to 1.14; 2 RCTs; 119 participants; I<sup>2</sup> = 0%; low‐certainty evidence). This suggests that if the rate of miscarriage with placebo or no treatment is 25.6%, the rate with vaginal progesterone would be between 6.4% and 29.2%. It is unclear if there was a difference between groups when data were analysed per woman (RR 1.09, 95% CI 0.47 to 2.54; 2 RCTs; 690 participants; I<sup>2</sup> = 0%). </p> </section> </section> </section> <section id="CD012396-sec-0095"> <h5 class="title">Secondary outcomes</h5> <section id="CD012396-sec-0096"> <h6 class="title">2.4 Clinical pregnancy rate (per woman)</h6> <p>Thirteen RCTs reported clinical pregnancy rate per woman (<a href="./references#CD012396-fig-0012" title="">Analysis 2.4</a>) (<a href="./references#CD012396-bbs2-0001" title="AaliBS , EbrahimipourS , MedhdizadehS . The effectiveness of luteal phase support with Cyclogest in ovarian stimulated intra uterine insemination cycles: a randomised controlled trial. Iranian Journal of Reproductive Medicine2013;11(4):309-14. ">Aali 2013</a>; <a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>; <a href="./references#CD012396-bbs2-0004" title="AnSJ , JungJY , KwonHC , KimHM , HanJH , LeeSJ . Effect of luteal phase support in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2010;94 Suppl 1(4):S176-7. ">An 2010</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0013" title="KaradagB , DilbazB , KarcaaltincabaD , SahinEG , ErcanF , KarasuY , et al. The effect of luteal-phase support with vaginal progesterone on pregnancy rates in gonadotropin and clomiphene citrate/intra-uterine insemination cycles in unexplained infertility: a prospective randomised study. Journal of Obstetrics and Gynaecology2016;36:794-9. ">Karadag 2016</a>; <a href="./references#CD012396-bbs2-0014" title="KeskinM , AytaçR . Does luteal phase support effect pregnancy rates in intrauterine insemination cycles? A prospective randomised controlled study in a tertiary center. Obstetrics and Gynecology International2020:1-5. [DOI: 10.1155/2022/6234070]">Keskin 2020</a>; <a href="./references#CD012396-bbs2-0018" title="PakrashiT , BaydounH , BoccaS , OehningerS , StadtmauerL . Luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome and ovulatory dysfunction undergoing ovulation induction with letrozole: a randomised controlled trial. Fertility and Sterility2014;102 Suppl(3):e237. ">Pakrashi 2014</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>). </p> <section id="CD012396-sec-0097"> <p><b>2.4.1 In gonadotropin stimulation cycle</b></p> <p>Seven RCTs reported the effect of progesterone on clinical pregnancy rate (<a href="./full#CD012396-tbl-0002">summary of findings Table 2</a>) (<a href="./references#CD012396-bbs2-0001" title="AaliBS , EbrahimipourS , MedhdizadehS . The effectiveness of luteal phase support with Cyclogest in ovarian stimulated intra uterine insemination cycles: a randomised controlled trial. Iranian Journal of Reproductive Medicine2013;11(4):309-14. ">Aali 2013</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0012" title="HanJ , MotanT . The effect of luteal phase support on pregnancy rates in intrauterine insemination cycles following ovarian stimulation with gonadotropins - a randomised controlled trial. Fertility and Sterility2016;106(3):e57. ">Han 2016</a>; <a href="./references#CD012396-bbs2-0013" title="KaradagB , DilbazB , KarcaaltincabaD , SahinEG , ErcanF , KarasuY , et al. The effect of luteal-phase support with vaginal progesterone on pregnancy rates in gonadotropin and clomiphene citrate/intra-uterine insemination cycles in unexplained infertility: a prospective randomised study. Journal of Obstetrics and Gynaecology2016;36:794-9. ">Karadag 2016</a>; <a href="./references#CD012396-bbs2-0014" title="KeskinM , AytaçR . Does luteal phase support effect pregnancy rates in intrauterine insemination cycles? A prospective randomised controlled study in a tertiary center. Obstetrics and Gynecology International2020:1-5. [DOI: 10.1155/2022/6234070]">Keskin 2020</a>; <a href="./references#CD012396-bbs2-0019" title="PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomised multicenter study. Fertility and Sterility2016;106(6):1490-5. PeeraerK , D'HoogheT , LaurentP , PelckmansS , DelvigneA , LaenenA , et al. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomised multicentre study. Fertility and Sterility2016;106(6):1490-5. ">Peeraer 2016</a>; <a href="./references#CD012396-bbs2-0022" title="SeckinB , TurkcaparF , YildizY , SenturkB , YilmazN , GulermanC . Effect of luteal phase support with vaginal progesterone in intrauterine insemination cycles with regard to follicular response: a prospective randomised study. Journal of Reproductive Medicine2014;59(5):260-6. ">Seckin 2014</a>). Progesterone supplementation may result in an increase in the clinical pregnancy rate compared to placebo or no treatment (RR 1.38, 95% CI 1.10 to 1.74; 7 RCTs; 1437 participants; I<sup>2</sup> = 0%; low‐certainty evidence). This suggests that if the chance of clinical pregnancy with placebo or no treatment is 14.2%, the chance with vaginal progesterone would be between 15.6% and 24.7%. </p> <p><a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a> reported clinical pregnancy rate per cycle, therefore we did not combine data from this trial in meta‐analysis. There was no difference between progesterone supplementation and no‐treatment group (n/N = 62/449) 13.8% and (n/N = 49/444) 11.0%, respectively; P = 0.25. </p> <p><a href="./references#CD012396-bbs2-0010" title="Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27:ii226. [Abstract number: P320]Eguiluz Gutierrez-BarquinI , Sanchez SanchezV , Torres AfonsoA , Alvarez SanchezM , De Leon SocorroS , Molina CabrillanaJ , et al. Should luteal phase support be introduced in ovarian stimulation/IUI programme?Human Reproduction2012;27 Suppl 2(12):ii226-47. ">Eguiluz 2012</a> reported clinical pregnancy rate per cycle, therefore we did not combine data from this trial in meta‐analysis. There was no difference between progesterone supplementation and no‐treatment group (n/N = 19/91) 20.9% and (n/N = 13/89) 14.6%, respectively; P≥ 0.05. </p> <p><a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a> reported clinical pregnancy rate per cycle, therefore we did not combine data from this trial in meta‐analysis. There was no difference between progesterone supplementation and no‐treatment group (n/N = 23/122) 18.9% and (n/N = 15/123) 12.2%, respectively; P = 0.16. </p> </section> <section id="CD012396-sec-0098"> <p><b>2.4.2 In gonadotropin plus oral (clomiphene citrate or letrozole) stimulation cycle</b></p> <p>Four RCTs reported the clinical pregnancy rate (<a href="./full#CD012396-tbl-0003">summary of findings Table 3</a>) (<a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>; <a href="./references#CD012396-bbs2-0004" title="AnSJ , JungJY , KwonHC , KimHM , HanJH , LeeSJ . Effect of luteal phase support in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2010;94 Suppl 1(4):S176-7. ">An 2010</a>; <a href="./references#CD012396-bbs2-0020" title="RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study [The effect of luteal phase support with vaginal progesterone on pregnancy rates in intrauterine insemination (IUI) cycles]. Fertility and Sterility2014;8:149-53. RashidiBH , TanhaFD , RahmanpourH , GhazizadehM . Luteal phase support in the intrauterine insemination (IUI) cycles: a randomised double blind, placebo controlled study. Journal of Family and Reproductive Health2014;8(4):149-53. ">Rashidi 2014</a>). Progesterone supplementation may result in an increase in the clinical pregnancy rate compared to placebo or no treatment (RR 1.40, 95% CI 1.03 to 1.90; 4 RCTs; 733 participants; I<sup>2</sup> = 0%; low‐certainty evidence). This suggests that if the chance of clinical pregnancy with placebo or no treatment is 15.7%, the chance with vaginal progesterone would be between 16.1% and 29.8%. </p> </section> <section id="CD012396-sec-0099"> <p><b>2.4.3 In oral (clomiphene citrate or letrozole) stimulation cycle </b></p> <p>Six RCTs demonstrated an effect of progesterone supplementation on clinical pregnancy rate (<a href="./full#CD012396-tbl-0004">summary of findings Table 4</a>) (<a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0003" title="AlizziFJ . Pregnancy rate following luteal phase support in polycystic ovary women using letrozole with or without gonadotropin as ovulation induction. Asian Journal of Pharmacuetical and Clinical Research2018;11(9):321-4. ">Alizzi 2018</a>; <a href="./references#CD012396-bbs2-0013" title="KaradagB , DilbazB , KarcaaltincabaD , SahinEG , ErcanF , KarasuY , et al. The effect of luteal-phase support with vaginal progesterone on pregnancy rates in gonadotropin and clomiphene citrate/intra-uterine insemination cycles in unexplained infertility: a prospective randomised study. Journal of Obstetrics and Gynaecology2016;36:794-9. ">Karadag 2016</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0018" title="PakrashiT , BaydounH , BoccaS , OehningerS , StadtmauerL . Luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome and ovulatory dysfunction undergoing ovulation induction with letrozole: a randomised controlled trial. Fertility and Sterility2014;102 Suppl(3):e237. ">Pakrashi 2014</a>; <a href="./references#CD012396-bbs2-0023" title="StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. [Abstract no: P-718]StadtmauerL , PakrashiT , BeydounH , BoccaS , OehningerS . A randomised controlled trial of luteal phase supplementation with vaginal progesterone in women with polycystic ovary syndrome undergoing ovulation induction with letrozole. Human Reproduction2015;30 Suppl 1(P-718):i429. ">Stadtmauer 2015</a>). Progesterone supplement may result in an increase in clinical pregnancy rate compared to placebo or no treatment (RR 1.44, 95% CI 1.04 to 1.98; 6 RCTs; 1073 participants; I<sup>2</sup> = 22%; low‐certainty evidence). This suggests that if the chance of clinical pregnancy with placebo or no treatment is 13.1%, the chance with vaginal progesterone would be between 13.6% and 25.9%. </p> </section> </section> <section id="CD012396-sec-0100"> <h6 class="title">2.5 Multiple pregnancy rate (per woman)</h6> <p>Five RCTs evaluated multiple pregnancy rate (<a href="./references#CD012396-fig-0013" title="">Analysis 2.5</a>) (<a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>; <a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>; <a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a>; <a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a>; <a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a>). </p> <section id="CD012396-sec-0101"> <p><b>2.5.1 In gonadotropin stimulation cycle</b></p> <p>One RCT assessed multiple pregnancy rate (<a href="./full#CD012396-tbl-0002">summary of findings Table 2</a>) (<a href="./references#CD012396-bbs2-0011" title="ErdemA , ErdemM , AtmacaS , GulerI . Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomised study. Fertility and Sterility2009;91:2508-13. ">Erdem 2009</a>). It is unclear whether there was a difference between progesterone supplementation and placebo or no treatment in multiple pregnancy rate (RR 0.72, 95% CI 0.17 to 3.15; 1 RCT; 214 participants; I<sup>2</sup> = 0%; low‐certainty evidence). This suggests that if the rate of multiple pregnancy with placebo or no treatment is 3.8%, the rate with vaginal progesterone would be between 0.6% and 12.0%. </p> <p><a href="./references#CD012396-bbs2-0021" title="Romero NietoMI , Lorente GonzalezJ , Arjona-BerralJE , Del Munoz-VillanuevaM , Castelo-BrancoC . Luteal phase support with progesterone in intrauterine insemination: a prospective randomised study. Gynecological Endocrinology2014;30(3):197-201. ">Romero Nieto 2014</a> reported miscarriage rate per cycle, therefore we did not combine data from this trial in meta‐analysis. There was no difference between progesterone supplementation and no‐treatment group (n/N = 5/62) 3.6% and (n/N = 1/49) 2.7%, respectively; P = 0.87. </p> <p><a href="./references#CD012396-bbs2-0025" title="YaziciG , SavasA , TasdelenB , DilekS . Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. Journal of Reproductive Medicine2014;59(1-2):25-30. ">Yazici 2014</a> reported multiple pregnancy rate per cycle, therefore we did not combine data from this trial in meta‐analysis. There was no difference between progesterone supplementation and no‐treatment group (n/N = 2/122) 1.16% and (n/N = 2/123) 1.6%, respectively; P = 0.33. </p> </section> <section id="CD012396-sec-0102"> <p><b>2.5.2 In gonadotropin plus oral (clomiphene citrate or letrozole) stimulation cycle </b></p> <p>Evidence from one RCT is very uncertain about the effect of progesterone supplementation on multiple pregnancy rate compared to placebo or no treatment (RR 1.44, 95% CI 0.24 to 8.49; 1 RCT; 290 participants; low‐certainty evidence) (<a href="./full#CD012396-tbl-0003">summary of findings Table 3</a>) (<a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a>). This suggests that if the risk of multiple pregnancy with placebo or no treatment is 1.4%, the risk with vaginal progesterone would be between 0.3% and 12.0%. </p> </section> <section id="CD012396-sec-0103"> <p><b>2.5.3 In oral (clomiphene citrate or letrozole stimulation) cycle </b></p> <p><a href="./references#CD012396-bbs2-0017" title="KyrouD , FatemiHM , DevroeyP . The effect of luteal support on pregnancy rates in normo-ovulatory patients stimulated with clomiphene citrate for IUI: a prospective randomised study. Human Reproduction2010;25 Suppl 1(6):i44-5. [Abstract no. O]KyrouD , FatemiHM , TournayeH , DevroeyP . Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit?Human Reproduction2010;25:2501-6. ">Kyrou 2010</a> and <a href="./references#CD012396-bbs2-0002" title="Agha-HosseiniM , RahmaniM , AlleyassinA , SafdarianL , SarviF . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomised prospective trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(2):249-53. AlleyassinA , Agha HosseiniM , SarviF , SafdarianL , RahmanpourH , KokabAA . The effect of progesterone supplementation on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial. Fertility and Sterility2012;98(3 Suppl 1):S197. ">Agha‐Hosseini 2012</a> reported multiple pregnancy rate (<a href="./full#CD012396-tbl-0004">summary of findings Table 4</a>). It is unclear whether there was a difference between progesterone supplementation and placebo or no treatment in multiple pregnancy rate (RR 0.58, 95% CI 0.10 to 3.55; 2 RCTs; 586 participants; I<sup>2</sup> = 0%; low‐certainty evidence). This suggests that if the rate of multiple pregnancy with placebo or no treatment is 0.7%, the rate with vaginal progesterone would be between 0.1% and 2.6%. </p> </section> </section> </section> </section> <section id="CD012396-sec-0104"> <h4 class="title">Comparison 3. Different dosages of vaginal progesterone</h4> <p>One RCT (200 participants) compared the effects of 300 mg versus 600 mg vaginal progesterone on ongoing pregnancy and multiple pregnancy rates (<a href="./full#CD012396-tbl-0005">summary of findings Table 5</a><b>)</b> (<a href="./references#CD012396-bbs2-0008" title="BiberogluEH , TanrikuluF , ErdemM , ErdemA , BiberogluKO . Luteal phase support in intrauterine insemination cycles: a prospective randomised study of 300 mg versus 600 mg intravaginal progesterone tablet. Gynecological Endocrinology2016;32(1):55-7. ">Biberoglu 2016</a>). The certainty of the evidence for all outcomes in this comparison is very low. </p> <section id="CD012396-sec-0105"> <h5 class="title">Primary outcomes</h5> <p><a href="./references#CD012396-bbs2-0008" title="BiberogluEH , TanrikuluF , ErdemM , ErdemA , BiberogluKO . Luteal phase support in intrauterine insemination cycles: a prospective randomised study of 300 mg versus 600 mg intravaginal progesterone tablet. Gynecological Endocrinology2016;32(1):55-7. ">Biberoglu 2016</a> did not report on live birth. </p> <section id="CD012396-sec-0106"> <h6 class="title">3.1 Ongoing pregnancy rate (per woman)</h6> <p>The evidence suggests that 300 mg vaginal progesterone does not increase ongoing pregnancy compared to 600 mg vaginal progesterone (RR 1.58, 95% CI 0.81 to 3.09; 1 RCT; 200 participants; very low‐certainty evidence) (<a href="./references#CD012396-fig-0014" title="">Analysis 3.1</a>). We estimated that for a woman with 12.0% chance of achieving an ongoing pregnancy with 600 mg of vaginal progesterone, the chance with 300 mg of vaginal progesterone would be between 9.7% and 37.1%. </p> </section> </section> <section id="CD012396-sec-0107"> <h5 class="title">Secondary outcomes</h5> <section id="CD012396-sec-0108"> <h6 class="title">3.2 Multiple pregnancy rate (per woman)</h6> <p>The evidence suggests that 300 mg vaginal progesterone does not increase multiple pregnancy rate compared to 600 mg vaginal progesterone (RR 0.50, 95% CI 0.05 to 5.43; 1 RCT; 200 participants; very low‐certainty evidence) (<a href="./references#CD012396-fig-0015" title="">Analysis 3.2</a>). This suggests that if the rate of multiple pregnancy with 600 mg of vaginal progesterone is 2.0%, the rate with 300 mg of vaginal progesterone would be between 1.0% and 10.9%. </p> <p>No other outcomes were reported for this comparison.</p> </section> </section> </section> <section id="CD012396-sec-0109"> <h4 class="title">Comparison 4. Intramuscular (IM) progesterone versus vaginal progesterone</h4> <p>One RCT (225 participants) compared IM progesterone with vaginal progesterone on ongoing pregnancy, miscarriage, and clinical pregnancy rates and adverse effects (<a href="./full#CD012396-tbl-0006">summary of findings Table 6</a>) (<a href="./references#CD012396-bbs2-0015" title="KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. ">Khadem 2011</a>). The certainty of the evidence for all outcomes in this comparison is very low. </p> <section id="CD012396-sec-0110"> <h5 class="title">Primary outcomes</h5> <p><a href="./references#CD012396-bbs2-0015" title="KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. KhademN , MousavifarN , BonakdarF , RafieNB . A comparative study of intramuscular oil progesterone injection and suppository progesterone for luteal phase support in patients undergoing IUI cycles. Iranian Journal of Obstetrics, Gynecology and Infertility2011;13(6):1-5. ">Khadem 2011</a> did not report on live birth. </p> <section id="CD012396-sec-0111"> <h6 class="title">4.1 Ongoing pregnancy rate (per woman)</h6> <p>The evidence is very uncertain about the effect of IM progesterone on ongoing pregnancy rate compared to vaginal progesterone (RR 0.59, 95% CI 0.34 to 1.02; 1 RCT; 225 participants; very low‐certainty evidence) (<a href="./references#CD012396-fig-0016" title="">Analysis 4.1</a>). This suggests that if the chance of an ongoing pregnancy with vaginal progesterone is 25.2%, the chance with IM progesterone would be between 8.6% and 25.7%. </p> </section> <section id="CD012396-sec-0112"> <h6 class="title">4.2 ‐ 4.3 Miscarriage rate (per clinical pregnancy/per woman)</h6> <p>The evidence is very uncertain about the effect of IM progesterone on miscarriage rate per clinical pregnancy compared to vaginal progesterone (RR 0.75, 95% CI 0.43 to 1.32; 1 RCT; 81 participants; very low‐certainty evidence) (<a href="./references#CD012396-fig-0017" title="">Analysis 4.2</a>). This suggests that if the risk of miscarriage per clinical pregnancy with vaginal progesterone is 44.4%, the risk with IM progesterone would be between 19.1% and 58.7%. The evidence on miscarriage rate per woman was also very uncertain (RR 0.58, 95% CI 0.30 to 1.14; 1 RCT; 225 participants; very low‐certainty evidence) (<a href="./references#CD012396-fig-0018" title="">Analysis 4.3</a>). </p> </section> </section> <section id="CD012396-sec-0113"> <h5 class="title">Secondary outcomes</h5> <section id="CD012396-sec-0114"> <h6 class="title">4.4 Clinical pregnancy rate (per woman)</h6> <p>The evidence is very uncertain about the effect of IM progesterone on clinical pregnancy rate compared to vaginal progesterone (RR 0.78, 95% CI 0.55 to 1.11; 1 RCT; 225 participants; very low‐certainty evidence) (<a href="./references#CD012396-fig-0019" title="">Analysis 4.4</a>). This suggests that if the chance of clinical pregnancy with vaginal progesterone is 40.5%, the chance with IM progesterone would be between 22.3% and 45.0%. </p> </section> <section id="CD012396-sec-0115"> <h6 class="title">4.5 Adverse effects</h6> <p>Intramuscular progesterone may result in a large increase in adverse effects compared to vaginal progesterone, but the certainty of the evidence is very low (RR 9.25, 95% CI 2.21 to 38.78; 1 RCT; 225 participants; very low‐certainty evidence) (<a href="./references#CD012396-fig-0020" title="">Analysis 4.5</a>). This suggests that for a woman with 1.8% risk of adverse effects with vaginal progesterone, the corresponding risk with IM progesterone would be between 4.0% and 69.9%. </p> <p>No other outcomes were reported for this comparison.</p> </section> </section> </section> <section id="CD012396-sec-0116"> <h4 class="title">Comparison 5. Oral progesterone versus vaginal progesterone</h4> <p>One RCT (150 participants) compared oral progesterone with vaginal progesterone on ongoing pregnancy, miscarriage, and clinical pregnancy rates (<a href="./full#CD012396-tbl-0007">summary of findings Table 7</a>) (<a href="./references#CD012396-bbs2-0016" title="KhosraviD , TaheripanahR , KhosraviR , Taheri PanahA , Tarighat MonfaredV , DefaeeS , et al. Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial (RCT). Iranian Journal of Obstetrics, Gynecology and Infertility2015;13:433-8. KhosraviD , TaheripanahR , TaheripanahA , MonfaredV , Hosseini-ZijoudSM . Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial. Iranian Journal of Obstetrics, Gynecology and Infertility2015;13(7):433-8. ">Khosravi 2015</a>). </p> <section id="CD012396-sec-0117"> <h5 class="title">Primary outcomes</h5> <p><a href="./references#CD012396-bbs2-0016" title="KhosraviD , TaheripanahR , KhosraviR , Taheri PanahA , Tarighat MonfaredV , DefaeeS , et al. Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial (RCT). Iranian Journal of Obstetrics, Gynecology and Infertility2015;13:433-8. KhosraviD , TaheripanahR , TaheripanahA , MonfaredV , Hosseini-ZijoudSM . Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomised clinical trial. Iranian Journal of Obstetrics, Gynecology and Infertility2015;13(7):433-8. ">Khosravi 2015</a> did not report on live birth. </p> <section id="CD012396-sec-0118"> <h6 class="title">5.1 Ongoing pregnancy rate (per woman)</h6> <p>The evidence is very uncertain about the effect of oral progesterone on ongoing pregnancy rate compared to vaginal progesterone (RR 1.25, 95% CI 0.70 to 2.22; 1 RCT; 150 participants; very low‐certainty evidence) (<a href="./references#CD012396-fig-0021" title="">Analysis 5.1</a>). This suggests that if the chance of an ongoing pregnancy with vaginal progesterone is 21.3%, the chance with oral progesterone would be between 14.9% and 47.4%. </p> </section> <section id="CD012396-sec-0119"> <h6 class="title">5.2 ‐ 5.3 Miscarriage rate (per clinical pregnancy/per woman)</h6> <p>The evidence is very uncertain about the effect of oral progesterone on miscarriage rate per clinical pregnancy compared to vaginal progesterone (RR 0.58, 95% CI 0.11 to 3.09; 1 RCT; 41 participants; very low‐certainty evidence) (<a href="./references#CD012396-fig-0022" title="">Analysis 5.2</a>). This suggests that if the risk of miscarriage per clinical pregnancy with vaginal progesterone is 15.8%, the risk with oral progesterone would be between 1.7% and 48.8%. </p> <p>The evidence is also very uncertain about the effect of oral progesterone on miscarriage rate per woman (odds ratio 0.66, 95% CI 0.11 to 4.05; 1 RCT; 150 participants; very low‐certainty evidence) (<a href="./references#CD012396-fig-0023" title="">Analysis 5.3</a>). </p> </section> </section> <section id="CD012396-sec-0120"> <h5 class="title">Secondary outcomes</h5> <section id="CD012396-sec-0121"> <h6 class="title">5.4 Clinical pregnancy rate (per woman)</h6> <p>The evidence is very uncertain about the effect of oral progesterone on miscarriage rate compared to vaginal progesterone (RR 1.16, 95% CI 0.69 to 1.96; 1 RCT; 150 participants; very low‐certainty evidence) (<a href="./references#CD012396-fig-0024" title="">Analysis 5.4</a>). This suggests that if the chance of clinical pregnancy with vaginal progesterone is 25.3%, the chance with oral progesterone would be between 17.5% and 49.7%. </p> <p>No other outcomes were reported for this comparison.</p> </section> </section> </section> <section id="CD012396-sec-0122"> <h4 class="title">Comparison 6. Aqueous subcutaneous (Sc) progesterone versus vaginal progesterone gel</h4> <p>One RCT (246 participants) compared Sc progesterone with vaginal progesterone on ongoing pregnancy and clinical pregnancy rates (<a href="./full#CD012396-tbl-0008">summary of findings Table 8</a>) (<a href="./references#CD012396-bbs2-0024" title="VenturellaR , MocciaroR , LicoD , RoccaM , Di CelloA , PiccioneF , et al. Subcutaneous aqueous versus vaginal progesterone gel for luteal phase support in intrauterine insemination cycles: a pilot randomised, controlled trial. Human Reproduction2016;31 Suppl 1:i304-5. ">Venturella 2016</a>). </p> <section id="CD012396-sec-0123"> <h5 class="title">Primary outcomes</h5> <p><a href="./references#CD012396-bbs2-0024" title="VenturellaR , MocciaroR , LicoD , RoccaM , Di CelloA , PiccioneF , et al. Subcutaneous aqueous versus vaginal progesterone gel for luteal phase support in intrauterine insemination cycles: a pilot randomised, controlled trial. Human Reproduction2016;31 Suppl 1:i304-5. ">Venturella 2016</a> did not report on live birth. </p> <section id="CD012396-sec-0124"> <h6 class="title">6.1 Ongoing pregnancy rate (per woman)</h6> <p>The evidence is very uncertain about the effect of Sc progesterone on ongoing pregnancy rate compared to vaginal progesterone (RR 1.05, 95% CI 0.54 to 2.05; 1 RCT; 246 participants; very low‐certainty evidence) (<a href="./references#CD012396-fig-0025" title="">Analysis 6.1</a>). This suggests that if the chance of an ongoing pregnancy with vaginal progesterone is 11.9%, the chance with Sc progesterone would be between 6.4% and 24.4%. </p> </section> </section> <section id="CD012396-sec-0125"> <h5 class="title">Secondary outcomes</h5> <section id="CD012396-sec-0126"> <h6 class="title">6.2 Clinical pregnancy rate (per woman)</h6> <p>The evidence is very uncertain about the effect of Sc progesterone on clinical pregnancy rate compared to vaginal progesterone (RR 1.12, 95% CI 0.59 to 2.11; 1 RCT; 246 participants; very low‐certainty evidence) (<a href="./references#CD012396-fig-0026" title="">Analysis 6.2</a>). This suggests that if the chance of clinical pregnancy with vaginal progesterone is 12.7%, the chance with Sc progesterone would be between 7.5% and 26.8%. </p> <p>No other outcomes were reported for this comparison.</p> </section> </section> </section> <section id="CD012396-sec-0127"> <h4 class="title">Comparison 7. Gonadotropin‐releasing hormone (GnRH) agonist plus progesterone versus vaginal progesterone plus placebo </h4> <p>No RCT reported on this comparison.</p> </section> <section id="CD012396-sec-0128"> <h4 class="title">Comparison 8. Sc GnRH agonist versus placebo or no treatment</h4> <p>One RCT (291 participants) compared Sc GnRH agonist with no treatment on ongoing pregnancy rate (<a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>). Two RCTs (340 participants) compared Sc GnRH agonist with no treatment on miscarriage, clinical pregnancy, and multiple pregnancy rates (<a href="./full#CD012396-tbl-0009">summary of findings Table 9</a>) (<a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>; <a href="./references#CD012396-bbs2-0009" title="BussoC , LabartaE , MeloMAB , NavarroC , VidalC , RemohiJ , et al. Effect of a single dose of a GnRH agonist in the luteal phase of intrauterine insemination cycles: a randomised study. Interim analysis. Human Reproduction2006;21(Suppl 1):i116. ">Busso 2006</a>).<b> </b> </p> <section id="CD012396-sec-0129"> <h5 class="title">Primary outcomes</h5> <p>The studies did not report on live birth.</p> <section id="CD012396-sec-0130"> <h6 class="title">8.1 Ongoing pregnancy rate (per woman)</h6> <p>One RCT evaluated ongoing pregnancy rate (<a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>). The evidence is very uncertain about the effect of Sc GnRH agonist on ongoing pregnancy rate compared to no treatment (RR 1.10, 95% CI 0.70 to 1.74; 1 RCT; 291 participants; very low‐certainty evidence) (<a href="./references#CD012396-fig-0027" title="">Analysis 7.1</a>). This suggests that if the chance of an ongoing pregnancy with placebo or no treatment is 19.3%, the chance with GnRH agonist would be between 13.5% and 33.6%. </p> </section> <section id="CD012396-sec-0131"> <h6 class="title">8.2 ‐ 8.3 Miscarriage rate (per clinical pregnancy/per woman)</h6> <p>Two RCTs reported miscarriage rate (<a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>; <a href="./references#CD012396-bbs2-0009" title="BussoC , LabartaE , MeloMAB , NavarroC , VidalC , RemohiJ , et al. Effect of a single dose of a GnRH agonist in the luteal phase of intrauterine insemination cycles: a randomised study. Interim analysis. Human Reproduction2006;21(Suppl 1):i116. ">Busso 2006</a>). <a href="./references#CD012396-bbs2-0009" title="BussoC , LabartaE , MeloMAB , NavarroC , VidalC , RemohiJ , et al. Effect of a single dose of a GnRH agonist in the luteal phase of intrauterine insemination cycles: a randomised study. Interim analysis. Human Reproduction2006;21(Suppl 1):i116. ">Busso 2006</a> reported no events in both the intervention and control groups. The evidence is very uncertain about the effect of Sc GnRH agonist on miscarriage rate per clinical pregnancy compared to no treatment (RR 0.73, 95% CI 0.26 to 2.10; 2 RCTs; 79 participants; I<sup>2</sup> = 0%; very low‐certainty evidence) (<a href="./references#CD012396-fig-0028" title="">Analysis 7.2</a>). This suggests that if the risk of miscarriage per clinical pregnancy with placebo or no treatment is 17.1%, the risk with GnRH agonist would be between 4.4% and 35.9%.  </p> <p>Miscarriage rate per woman compared to vaginal progesterone: RR 0.76, 95% CI 0.25 to 2.34; 2 RCTs; 340 participants; I<sup>2</sup> = 0%; very low‐certainty evidence; <a href="./references#CD012396-fig-0029" title="">Analysis 7.3</a>. </p> </section> </section> <section id="CD012396-sec-0132"> <h5 class="title">Secondary outcomes</h5> <section id="CD012396-sec-0133"> <h6 class="title">8.4 Clinical pregnancy rate (per woman)</h6> <p>Two RCTs assessed clinical pregnancy rate (<a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>; <a href="./references#CD012396-bbs2-0009" title="BussoC , LabartaE , MeloMAB , NavarroC , VidalC , RemohiJ , et al. Effect of a single dose of a GnRH agonist in the luteal phase of intrauterine insemination cycles: a randomised study. Interim analysis. Human Reproduction2006;21(Suppl 1):i116. ">Busso 2006</a>). The evidence suggests that Sc GnRH agonist does not increase clinical pregnancy rate compared to no treatment (RR 1.00, 95% CI 0.68 to 1.47; 2 RCTs; 340 participants; I<sup>2</sup> = 0%; very low‐certainty evidence) (<a href="./references#CD012396-fig-0030" title="">Analysis 7.4</a>). This suggests that if the chance of clinical pregnancy with placebo or no treatment is 23.3%, the chance with GnRH agonist would be between 15.8% and 34.2%. </p> </section> <section id="CD012396-sec-0134"> <h6 class="title">8.5 Multiple pregnancy rate (per woman)</h6> <p>Two RCTs assessed multiple pregnancy rate (<a href="./references#CD012396-bbs2-0007" title="BellverJ , LabartaE , BoschE , MeloMA , VidalC , RemohiJ , et al. GnRH agonist administration at the time of implantation does not improve pregnancy outcomes in intrauterine insemination cycles: a randomised controlled trial. Fertility and Sterility2010;94:1065-71. ">Bellver 2010</a>; <a href="./references#CD012396-bbs2-0009" title="BussoC , LabartaE , MeloMAB , NavarroC , VidalC , RemohiJ , et al. Effect of a single dose of a GnRH agonist in the luteal phase of intrauterine insemination cycles: a randomised study. Interim analysis. Human Reproduction2006;21(Suppl 1):i116. ">Busso 2006</a>). The evidence suggests that Sc GnRH agonist may result in a large reduction in multiple pregnancy rate compared to the no‐treatment group (RR 0.28, 95% CI 0.11 to 0.70; 2 RCTs; 126 participants; I<sup>2</sup> = 0%; very low‐certainty evidence) (<a href="./references#CD012396-fig-0031" title="">Analysis 7.5</a>). This suggests that if the rate of multiple pregnancy with placebo or no treatment is 28.1%, the rate with GnRH agonist would be between 3.1% and 19.7%. </p> <p>No other outcomes were reported for this comparison.</p> </section> </section> </section> <section id="CD012396-sec-0135"> <h4 class="title">Comparison 9. Vaginal progesterone versus Sc GnRH agonist</h4> <p>One RCT (242 participants) compared Sc GnRH agonist with vaginal progesterone on clinical pregnancy rate (<a href="./full#CD012396-tbl-0010">summary of findings Table 10</a><b>)</b> (<a href="./references#CD012396-bbs2-0005" title="AzmoodehA , MohamadpoorJ , AsbaghFA , GhaseminezhadA , LorzadehN , ForghaniF . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Medicine and Health Research2016;2(9):84-8. MohamadpoorJ . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Fertility and Sterility2013;7:112. ">Azmoodeh 2016</a>). </p> <section id="CD012396-sec-0136"> <h5 class="title">Secondary outcomes</h5> <p><a href="./references#CD012396-bbs2-0005" title="AzmoodehA , MohamadpoorJ , AsbaghFA , GhaseminezhadA , LorzadehN , ForghaniF . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Medicine and Health Research2016;2(9):84-8. MohamadpoorJ . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Fertility and Sterility2013;7:112. ">Azmoodeh 2016</a> did not report on live birth. </p> <section id="CD012396-sec-0137"> <h6 class="title">9.1 Clinical pregnancy rate (per woman)</h6> <p><a href="./references#CD012396-bbs2-0005" title="AzmoodehA , MohamadpoorJ , AsbaghFA , GhaseminezhadA , LorzadehN , ForghaniF . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Medicine and Health Research2016;2(9):84-8. MohamadpoorJ . Comparision the effect of GNRH agonist administration versus vaginal progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility. International Journal of Fertility and Sterility2013;7:112. ">Azmoodeh 2016</a> specified clinical pregnancy rate as a main outcome. The evidence is very uncertain about the effect vaginal progesterone in clinical pregnancy rate (RR 1.00, 95% CI 0.51 to 1.95; 1 RCT; 242 participants; very low‐certainty evidence) (<a href="./references#CD012396-fig-0032" title="">Analysis 8.1</a>). This suggests that if the chance of clinical pregnancy with Sc GnRH agonist is 12.4%, the chance with vaginal progesterone would be between 6.3% and 24.2%. </p> <p>No other outcomes were reported for this comparison.</p> </section> </section> </section> <section id="CD012396-sec-0138"> <h4 class="title">Comparison 10. HCG injection versus no treatment</h4> <p>One RCT (130 participants) compared hCG injection to vaginal progesterone on clinical pregnancy and multiple pregnancy rates (<a href="./full#CD012396-tbl-0011">summary of findings Table 11</a>) (<a href="./references#CD012396-bbs2-0006" title="BekuretsionM , LundkvistO , KarlstromPO . A randomised study comparing low and high dose of HMG/FSH with and without luteal phase support in intrauterine insemination cycles. Human Reproduction1998;13:199. ">Bekuretsion 1998</a>). </p> <section id="CD012396-sec-0139"> <h5 class="title">Secondary outcomes</h5> <p><a href="./references#CD012396-bbs2-0006" title="BekuretsionM , LundkvistO , KarlstromPO . A randomised study comparing low and high dose of HMG/FSH with and without luteal phase support in intrauterine insemination cycles. Human Reproduction1998;13:199. ">Bekuretsion 1998</a> did not report on live birth. </p> <section id="CD012396-sec-0140"> <h6 class="title">10.1 Clinical pregnancy rate (per woman)</h6> <p>The evidence is very uncertain about the effect hCG injection on clinical pregnancy rate compared to no treatment (RR 0.93, 95% CI 0.40 to 2.13; 1 RCT; 130 participants; very low‐certainty evidence) (<a href="./references#CD012396-fig-0033" title="">Analysis 9.1</a>). We estimated that for a woman with 15.2% chance of achieving a clinical pregnancy with placebo or no treatment, the chance with hCG injection would be between 6.1% and 32.3%. </p> </section> <section id="CD012396-sec-0141"> <h6 class="title">10.2 Multiple pregnancy rate (per woman)</h6> <p>The evidence is very uncertain about the effect of hCG injection on multiple pregnancy rate compared to no treatment (RR 1.03, 95% CI 0.22 to 4.92; 1 RCT; 130 participants; very low‐certainty evidence) (<a href="./references#CD012396-fig-0034" title="">Analysis 9.2</a>). This suggests that if the rate of multiple pregnancy with placebo or no treatment is 4.5%, the risk with hCG injection would be between 1.0% and 22.4%. </p> <p>No other outcomes were reported for this comparison.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012396-sec-0142" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012396-sec-0142"></div> <section id="CD012396-sec-0143"> <h3 class="title" id="CD012396-sec-0143">Summary of main results</h3> <p>This Cochrane Review aimed to determine the effectiveness and safety of LPS in infertile women trying to conceive by IUI or by sexual intercourse. We included 25 RCTs assessing LPS in IUI cycle. No RCT evaluated the effect of LPS in natural cycle. Seventeen RCTs compared progesterone with placebo or no treatment; one RCT compared 300 mg vaginal progesterone with 600 mg vaginal progesterone; three RCTs compared vaginal progesterone with other routes of progesterone; three RCTs compared other interventions with placebo or no treatment; and one RCT compared vaginal progesterone with another intervention.  </p> <p>Overall, we are uncertain if vaginal progesterone increases live birth/ongoing pregnancy rate when compared with placebo or no treatment. Vaginal progesterone may increase clinical pregnancy rates per woman when compared with placebo or no treatment. We are uncertain of the effect of vaginal progesterone on multiple pregnancy and miscarriage rate. Oral progesterone may result in little to no difference in clinical pregnancy compared to placebo or no treatment. Progesterone given during the luteal phase may increase clinical pregnancy rates in all types of ovarian stimulation compared to placebo or no treatment. We are uncertain of the effect of type of ovarian stimulation on live birth/ongoing pregnancy, multiple pregnancy, and miscarriage rate. </p> <p>When comparing different routes of progesterone (oral or IM or Sc), we are uncertain whether route of progesterone has an effect on our outcomes of interest. Intramuscular progesterone may increase the risk of adverse effects compared to vaginal progesterone; however, the reported event was mainly pain at the injection site. </p> <p>We found no conclusive evidence of a difference between other interventions (Sc GnRH agonist or hCG injection) and no treatment given during the luteal phase in live birth, ongoing pregnancy, clinical pregnancy, multiple pregnancy, and miscarriage rates.  </p> <p>When comparing Sc GnRH agonist with placebo or no treatment, this relatively new method of LPS may reduce multiple pregnancy rate, but the certainty of the evidence was very low. It is unclear if Sc GnRH agonist results in a difference in ongoing pregnancy, miscarriage, or clinical pregnancy rates compared to no treatment. </p> </section> <section id="CD012396-sec-0144"> <h3 class="title" id="CD012396-sec-0144">Overall completeness and applicability of evidence</h3> <p>A number of methodological considerations must be considered when interpreting the results, as clinical heterogeneity was noted in the included RCTs. The included studies were similar with regard to participant mean age. Most RCTs excluded women over 40 years of age. Most fertility research centres have a maximum age of inclusion because of lower success rates with older women, related to lower ovarian reserve and oocyte quality in women over 40 years of age (<a href="./references#CD012396-bbs2-0089" title="BukmanA , HeinemanMJ . Ovarian reserve testing and the use of prognostic models in patients with subfertility. Human Reproduction Update2001;7(6):581-90.">Bukman 2000</a>). The duration of infertility was at least one year in all included studies (where reported) and was often longer than three years. It is known that fertility treatment is less successful with longer duration of infertility. In addition, information is lacking regarding effect by types of infertility. This is perhaps a very important issue that limits the overall applicability of the evidence.  </p> <p>The method of ovarian stimulation varied amongst the included RCTs. The included studies used the following ovarian stimulation protocols: gonadotropin, gonadotropin plus oral (clomiphene citrate or letrozole), and oral (clomiphene citrate or letrozole) stimulation. More aggressive ovarian stimulation such as using gonadotropin is likely to increase the number of follicles retrieved, yet cause more disturbance in the hormonal system; this should be taken into account when study results are compared.  </p> <p>The included RCTs investigated various different interventions for luteal phase support in IUI cycle. The majority of RCTs evaluated the effect of progesterone supplementation or hCG injection or Sc GnRH agonist in woman who underwent IUI. Data were available for our primary outcomes of live birth, ongoing pregnancy, and miscarriage rates, and our secondary outcome of clinical pregnancy rate. Adverse effects were poorly reported in most of the included RCTs. </p> <p>In our protocol, we planned to include RCTs that compared GnRH agonist plus progesterone supplement to progesterone supplement only. However, we identified no RCT focusing on this comparison. In addition, we identified no RCT evaluating the effect of luteal support in natural cycle. </p> </section> <section id="CD012396-sec-0145"> <h3 class="title" id="CD012396-sec-0145">Quality of the evidence</h3> <p>This Cochrane Review used the domain‐based evaluation to assess risk of bias, as outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012396-bbs2-0101" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2021</a>), and the GRADE approach to assess the certainty of evidence across RCTs for many of the primary and secondary outcomes. The risk of bias of the studies included in this review was variable. </p> <p>The most common problem relating to the quality of the included RCTs was failure to describe an acceptable method of allocation concealment. Most RCTs described acceptable methods of sequence generation and were at low risk of attrition bias and other sources of bias. Most RCTs appeared to be unblinded, but this was considered unlikely to cause bias due to the objective nature of the outcomes. </p> <p>Using GRADE methods, we assessed the certainty of the evidence for effectiveness outcomes to be low or very low for most comparisons, denoting that further research may have an important impact on our confidence in the estimate of effect, and may change the estimate. Reasons for downgrading the certainty of evidence included risk of bias in the primary studies (e.g. lack of clearly described blinding, failure to fully describe methods of randomisation and allocation concealment, and risk of attrition bias) and imprecision due to small sample size. </p> </section> <section id="CD012396-sec-0146"> <h3 class="title" id="CD012396-sec-0146">Potential biases in the review process</h3> <p>To prevent bias in the review process, we conducted this review according to the standards recommended in the <i>Cochrane Handbook</i>, as described in the <a href="#CD012396-sec-0015">Methods</a>. None of the review authors has any connection with pharmaceutical companies that have pharmaceutical product related to this review question, or was involved in any of the included RCTs. </p> </section> <section id="CD012396-sec-0147"> <h3 class="title" id="CD012396-sec-0147">Agreements and disagreements with other studies or reviews</h3> <p>We identified three other non‐Cochrane systematic reviews evaluating the effect of progesterone supplementation during LPS in women undergoing IUI (<a href="./references#CD012396-bbs2-0092" title="CohlenBJ . Should luteal phase support be introduced in ovarian stimulation/IUI programmes? An evidence-based review. Reproductive Biomedicine Online2009;19(Suppl 4):4239-46. [PMID: 20034415]">Cohlen 2009b</a>; <a href="./references#CD012396-bbs2-0099" title="GreenKA , ZoltonJR , SchermerhornSM , LewisTD , HealyMW , TerryN , et al. Progesterone luteal support after ovulation induction and intrauterine insemination: an updated systematic review and meta-analysis. Fertility and Sterility2017;107:924-33. [DOI: 10.1016/j.fertnstert.2017.01.011] [PMID: 28238492]">Green 2017b</a>; <a href="./references#CD012396-bbs2-0107" title="MiralpeixE , Gonzalez-ComadranM , SolaI , ManauD , CarrerasR , ChecaMA . Efficacy of luteal phase support with vaginal progesterone in intrauterine insemination: a systematic review and meta-analysis. Journal of Assisted Reproduction and Genetics2014;31(1):89-100. [PMID: 24189966]">Miralpeix 2014b</a>). Our results for live birth/ongoing pregnancy rate were not consistent with their findings, and the certainty of the evidence was very low to low. <a href="./references#CD012396-bbs2-0092" title="CohlenBJ . Should luteal phase support be introduced in ovarian stimulation/IUI programmes? An evidence-based review. Reproductive Biomedicine Online2009;19(Suppl 4):4239-46. [PMID: 20034415]">Cohlen 2009b</a> included only one RCT (214 participants) that compared vaginal progesterone with placebo in IUI cycle on live birth rate. That review reported that vaginal progesterone supplementation increased live birth rate. Another systematic review and meta‐analysis of five RCTs (1271 participants<b>)</b> found that vaginal progesterone increased live birth and clinical pregnancy rate (<a href="./references#CD012396-bbs2-0107" title="MiralpeixE , Gonzalez-ComadranM , SolaI , ManauD , CarrerasR , ChecaMA . Efficacy of luteal phase support with vaginal progesterone in intrauterine insemination: a systematic review and meta-analysis. Journal of Assisted Reproduction and Genetics2014;31(1):89-100. [PMID: 24189966]">Miralpeix 2014b</a>). Subgroup analysis showed increased live birth rate and clinical pregnancy rate in women who underwent ovulation induction with gonadotropin stimulation protocol (<a href="./references#CD012396-bbs2-0107" title="MiralpeixE , Gonzalez-ComadranM , SolaI , ManauD , CarrerasR , ChecaMA . Efficacy of luteal phase support with vaginal progesterone in intrauterine insemination: a systematic review and meta-analysis. Journal of Assisted Reproduction and Genetics2014;31(1):89-100. [PMID: 24189966]">Miralpeix 2014b</a>). Finally, <a href="./references#CD012396-bbs2-0099" title="GreenKA , ZoltonJR , SchermerhornSM , LewisTD , HealyMW , TerryN , et al. Progesterone luteal support after ovulation induction and intrauterine insemination: an updated systematic review and meta-analysis. Fertility and Sterility2017;107:924-33. [DOI: 10.1016/j.fertnstert.2017.01.011] [PMID: 28238492]">Green 2017b</a>, which included 11 RCTs (2842 participants), found that live birth and clinical pregnancy rates were improved in women receiving progesterone supplementation; however, they analysed the data per cycle, whilst we analysed the data per woman. They also included one study that we excluded (<a href="./references#CD012396-bbs2-0053" title="MaherMA . Luteal phase support may improve pregnancy outcomes during intrauterine insemination cycles. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2011;157:57-62. ">Maher 2011</a>). <a href="./references#CD012396-bbs2-0107" title="MiralpeixE , Gonzalez-ComadranM , SolaI , ManauD , CarrerasR , ChecaMA . Efficacy of luteal phase support with vaginal progesterone in intrauterine insemination: a systematic review and meta-analysis. Journal of Assisted Reproduction and Genetics2014;31(1):89-100. [PMID: 24189966]">Miralpeix 2014b</a> also analysed data per cycle and included <a href="./references#CD012396-bbs2-0053" title="MaherMA . Luteal phase support may improve pregnancy outcomes during intrauterine insemination cycles. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2011;157:57-62. ">Maher 2011</a>. These reviews found a higher pregnancy rate for progesterone in gonadotropin stimulation cycle. In addition, we included seven other RCTs that compared oral or vaginal micronised progesterone supplementation to placebo or no treatment in which the pooled results did not show an increase in live birth/ongoing pregnancy rate. Moreover, we included other RCTs comparing different dosages of vaginal progesterone supplementation; different routes of progesterone administration; and comparing other interventions (e.g. hCG or GnRH agonist) with placebo or no treatment. However, there was insufficient evidence to draw any conclusions regarding optimal dosage of progesterone supplementation, route of progesterone administration, or benefit of the other interventions due to imprecision related to small sample size. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012396-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012396-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012396-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012396-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Progesterone versus no treatment or placebo (route of progesterone administration), Outcome 1: Live birth/ongoing pregnancy rate" data-id="CD012396-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Progesterone versus no treatment or placebo (route of progesterone administration), Outcome 1: Live birth/ongoing pregnancy rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Progesterone versus no treatment or placebo (route of progesterone administration), Outcome 2: Miscarriage per clinical pregnancy" data-id="CD012396-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Progesterone versus no treatment or placebo (route of progesterone administration), Outcome 2: Miscarriage per clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Progesterone versus no treatment or placebo (route of progesterone administration), Outcome 3: Miscarriage per woman" data-id="CD012396-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Progesterone versus no treatment or placebo (route of progesterone administration), Outcome 3: Miscarriage per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Progesterone versus no treatment or placebo (route of progesterone administration), Outcome 4: Clinical pregnancy per woman" data-id="CD012396-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Progesterone versus no treatment or placebo (route of progesterone administration), Outcome 4: Clinical pregnancy per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Progesterone versus no treatment or placebo (route of progesterone administration), Outcome 5: Multiple pregnancy per woman" data-id="CD012396-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Progesterone versus no treatment or placebo (route of progesterone administration), Outcome 5: Multiple pregnancy per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Progesterone versus no treatment or placebo (type of ovarian stimulation), Outcome 1: Live birth/ongoing pregnancy rate" data-id="CD012396-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Progesterone versus no treatment or placebo (type of ovarian stimulation), Outcome 1: Live birth/ongoing pregnancy rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Progesterone versus no treatment or placebo (type of ovarian stimulation), Outcome 2: Miscarriage per clinical pregnancy" data-id="CD012396-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Progesterone versus no treatment or placebo (type of ovarian stimulation), Outcome 2: Miscarriage per clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Progesterone versus no treatment or placebo (type of ovarian stimulation), Outcome 3: Miscarriage per woman" data-id="CD012396-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Progesterone versus no treatment or placebo (type of ovarian stimulation), Outcome 3: Miscarriage per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Progesterone versus no treatment or placebo (type of ovarian stimulation), Outcome 4: Clinical pregnancy per woman" data-id="CD012396-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Progesterone versus no treatment or placebo (type of ovarian stimulation), Outcome 4: Clinical pregnancy per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Progesterone versus no treatment or placebo (type of ovarian stimulation), Outcome 5: Multiple pregnancy per woman" data-id="CD012396-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Progesterone versus no treatment or placebo (type of ovarian stimulation), Outcome 5: Multiple pregnancy per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: 300 mg vaginal progesterone versus 600 mg vaginal progesterone, Outcome 1: Ongoing pregnancy per woman" data-id="CD012396-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: 300 mg vaginal progesterone versus 600 mg vaginal progesterone, Outcome 1: Ongoing pregnancy per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: 300 mg vaginal progesterone versus 600 mg vaginal progesterone, Outcome 2: Multiple pregnancy per woman" data-id="CD012396-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: 300 mg vaginal progesterone versus 600 mg vaginal progesterone, Outcome 2: Multiple pregnancy per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: IM progesterone versus vaginal progesterone, Outcome 1: Ongoing pregnancy per woman" data-id="CD012396-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: IM progesterone versus vaginal progesterone, Outcome 1: Ongoing pregnancy per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: IM progesterone versus vaginal progesterone, Outcome 2: Miscarriage per clinical pregnancy" data-id="CD012396-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: IM progesterone versus vaginal progesterone, Outcome 2: Miscarriage per clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: IM progesterone versus vaginal progesterone, Outcome 3: Miscarriage per woman" data-id="CD012396-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: IM progesterone versus vaginal progesterone, Outcome 3: Miscarriage per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: IM progesterone versus vaginal progesterone, Outcome 4: Clinical pregnancy per woman" data-id="CD012396-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: IM progesterone versus vaginal progesterone, Outcome 4: Clinical pregnancy per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: IM progesterone versus vaginal progesterone, Outcome 5: Adverse effect" data-id="CD012396-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: IM progesterone versus vaginal progesterone, Outcome 5: Adverse effect</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Oral progesterone versus vaginal progesterone, Outcome 1: Ongoing pregnancy per woman" data-id="CD012396-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Oral progesterone versus vaginal progesterone, Outcome 1: Ongoing pregnancy per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Oral progesterone versus vaginal progesterone, Outcome 2: Miscarriage per clinical pregnancy" data-id="CD012396-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Oral progesterone versus vaginal progesterone, Outcome 2: Miscarriage per clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Oral progesterone versus vaginal progesterone, Outcome 3: Miscarriage per woman" data-id="CD012396-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Oral progesterone versus vaginal progesterone, Outcome 3: Miscarriage per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Oral progesterone versus vaginal progesterone, Outcome 4: Clinical pregnancy per woman" data-id="CD012396-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Oral progesterone versus vaginal progesterone, Outcome 4: Clinical pregnancy per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Aqueous Sc progesterone versus vaginal progesterone gel, Outcome 1: Ongoing pregnancy per woman" data-id="CD012396-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Aqueous Sc progesterone versus vaginal progesterone gel, Outcome 1: Ongoing pregnancy per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Aqueous Sc progesterone versus vaginal progesterone gel, Outcome 2: Clinical pregnancy per woman" data-id="CD012396-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Aqueous Sc progesterone versus vaginal progesterone gel, Outcome 2: Clinical pregnancy per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Sc GnRH agonist versus no treatment or placebo, Outcome 1: Ongoing pregnancy per woman" data-id="CD012396-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Sc GnRH agonist versus no treatment or placebo, Outcome 1: Ongoing pregnancy per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Sc GnRH agonist versus no treatment or placebo, Outcome 2: Miscarriage per clinical pregnancy" data-id="CD012396-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Sc GnRH agonist versus no treatment or placebo, Outcome 2: Miscarriage per clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Sc GnRH agonist versus no treatment or placebo, Outcome 3: Miscarriage per woman" data-id="CD012396-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Sc GnRH agonist versus no treatment or placebo, Outcome 3: Miscarriage per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Sc GnRH agonist versus no treatment or placebo, Outcome 4: Clinical pregnancy per woman" data-id="CD012396-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Sc GnRH agonist versus no treatment or placebo, Outcome 4: Clinical pregnancy per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Sc GnRH agonist versus no treatment or placebo, Outcome 5: Multiple pregnancy per woman" data-id="CD012396-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Sc GnRH agonist versus no treatment or placebo, Outcome 5: Multiple pregnancy per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Vaginal progesterone versus GnRH agonist, Outcome 1: Clinical pregnancy per woman" data-id="CD012396-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Vaginal progesterone versus GnRH agonist, Outcome 1: Clinical pregnancy per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: HCG injection versus no treatment, Outcome 1: Clinical pregnancy per woman" data-id="CD012396-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: HCG injection versus no treatment, Outcome 1: Clinical pregnancy per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012396-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/urn:x-wiley:14651858:media:CD012396:CD012396-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: HCG injection versus no treatment, Outcome 2: Multiple pregnancy per woman" data-id="CD012396-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_t/tCD012396-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: HCG injection versus no treatment, Outcome 2: Multiple pregnancy per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/media/CDSR/CD012396/image_n/nCD012396-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012396-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Progesterone compared to no treatment or placebo (route of progesterone administration) for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Progesterone compared to no treatment or placebo (route of progesterone administration) for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women trying to conceive by intrauterine insemination<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> progesterone<br/><b>Comparison:</b> no treatment or placebo (route of progesterone administration) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes*</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects** (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no treatment or placebo (route of progesterone administration)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with progesterone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth/ongoing pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000<br/>(102 to 187) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.10<br/>(0.81 to 1.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1792<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage per clinical pregnancy</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>183 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 per 1000<br/>(73 to 228) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70<br/>(0.40 to 1.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy per woman</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>134 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>181 per 1000<br/>(153 to 216) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.35<br/>(1.14 to 1.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2794<br/>(13 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy per woman ‐ oral route</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>449 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>301 per 1000<br/>(180 to 507) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.67<br/>(0.40 to 1.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple pregnancy per woman</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000<br/>(5 to 40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.84<br/>(0.30 to 2.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>956<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events, OHSS, preterm delivery, congenital anomaly</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*All studies reporting vaginal route unless otherwise indicated.<br/>**<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>  </p> <p><b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection and reporting bias.<br/><sup>b</sup>Evidence downgraded by one level due to imprecision (small study size).<br/><sup>c</sup>Evidence downgraded by two levels due to serious imprecision; single study with low event rate. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Progesterone compared to no treatment or placebo (route of progesterone administration) for women trying to conceive by intrauterine insemination</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012396-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Progesterone compared to placebo/no treatment for gonadotropin stimulation for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Progesterone compared to placebo/no treatment for gonadotropin stimulation for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with gonadotropin stimulation<br/><b>Setting: </b> clinic<br/><b>Intervention:</b> progesterone<br/><b>Comparison:</b> placebo/no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with progesterone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth rate/ongoing pregnancy rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>132 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>164 per 1000<br/>(106 to 254) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.24<br/>(0.80 to 1.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1054<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate per clinical pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1000<br/>(40 to 318) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.68<br/>(0.24 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>142 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>196 per 1000<br/>(156 to 247) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.38<br/>(1.10 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1437<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple pregnancy rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000<br/>(6 to 120) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.72<br/>(0.17 to 3.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events, OHSS, preterm delivery, congenital anomaly</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection and reporting bias.<br/><sup>b</sup>Evidence downgraded by one level due to imprecision (low event rate). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Progesterone compared to placebo/no treatment for gonadotropin stimulation for women trying to conceive by intrauterine insemination</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012396-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Progesterone compared to placebo/no treatment for gonadotropin plus oral (clomiphene citrate/letrozole) stimulation for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Progesterone compared to placebo/no treatment for gonadotropin plus oral (clomiphene citrate/letrozole) stimulation for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with gonadotropin plus oral (clomiphene citrate or letrozole) stimulation<br/><b>Setting: </b> clinic<br/><b>Intervention:</b> progesterone<br/><b>Comparison:</b> placebo/no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with progesterone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing pregnancy rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>142 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>103 per 1000<br/>(52 to 201) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.73<br/>(0.37 to 1.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate per clinical pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>188 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000<br/>(56 to 281) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.67<br/>(0.30 to 1.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>157 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>219 per 1000<br/>(161 to 298) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.40<br/>(1.03 to 1.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>733<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup>  </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple pregnancy rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(3 to 120) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.44<br/>(0.24 to 8.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>290<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events, OHSS, preterm delivery, congenital anomaly</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection and reporting bias.<br/><sup>b</sup>Evidence downgraded by one level due to imprecision (small study size). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Progesterone compared to placebo/no treatment for gonadotropin plus oral (clomiphene citrate/letrozole) stimulation for women trying to conceive by intrauterine insemination</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012396-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Progesterone compared to placebo/no treatment for oral (clomiphene citrate or letrozole) stimulation for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Progesterone compared to placebo/no treatment for oral (clomiphene citrate or letrozole) stimulation for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with oral (clomiphene citrate or letrozole) stimulation<br/><b>Setting: </b> clinic<br/><b>Intervention:</b> progesterone<br/><b>Comparison:</b> placebo/no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with progesterone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth rate/ongoing pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1000<br/>(61 to 172) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.97<br/>(0.58 to 1.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate per clinical pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>256 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000<br/>(64 to 292) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.53<br/>(0.25 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>131 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 per 1000<br/>(136 to 259) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.44<br/>(1.04 to 1.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1073<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(1 to 26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.58<br/>(0.10 to 3.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>586<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>Low <sup>a,b</sup> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events, OHSS, preterm delivery, congenital anomaly</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection and reporting bias.<br/><sup>b</sup>Evidence downgraded by one level due to imprecision (small study size). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Progesterone compared to placebo/no treatment for oral (clomiphene citrate or letrozole) stimulation for women trying to conceive by intrauterine insemination</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012396-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">300 mg vaginal progesterone compared to 600 mg vaginal progesterone for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>300 mg vaginal progesterone compared to 600 mg vaginal progesterone for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women trying to conceive by intrauterine insemination<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> 300 mg vaginal progesterone<br/><b>Comparison:</b> 600 mg vaginal progesterone </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with 600 mg vaginal progesterone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with 300 mg vaginal progesterone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing pregnancy rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000<br/>(97 to 371) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.58<br/>(0.81 to 3.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple pregnancy rate</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/>(1 to 109) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.50<br/>(0.05 to 5.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>None of the other main outcomes were reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection and reporting bias.<br/><sup>b</sup>Evidence downgraded by two levels due to very serious imprecision (small study size). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">300 mg vaginal progesterone compared to 600 mg vaginal progesterone for women trying to conceive by intrauterine insemination</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012396-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Intramuscular (IM) progesterone compared to vaginal progesterone for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intramuscular (IM) progesterone compared to vaginal progesterone for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women trying to conceive by intrauterine insemination<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> IM progesterone<br/><b>Comparison:</b> vaginal progesterone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with vaginal progesterone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with IM progesterone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth rate</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>252 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>149 per 1000<br/>(86 to 257) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.59<br/>(0.34 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333 per 1000<br/>(191 to 587) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.75<br/>(0.43 to 1.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>405 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>316 per 1000<br/>(223 to 450) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.78<br/>(0.55 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000<br/>(40 to 699) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 9.25<br/>(2.21 to 38.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OHSS, preterm delivery, congenital anomaly</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection, performance, detection, and reporting bias.<br/><sup>b</sup>Evidence downgraded by two levels due to imprecision (small study size). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Intramuscular (IM) progesterone compared to vaginal progesterone for women trying to conceive by intrauterine insemination</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012396-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Oral progesterone compared to vaginal progesterone for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Oral progesterone compared to vaginal progesterone for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women trying to conceive by intrauterine insemination<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> oral progesterone<br/><b>Comparison:</b> vaginal progesterone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with vaginal progesterone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with oral progesterone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth rate</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>213 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>267 per 1000<br/>(149 to 474) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.25<br/>(0.70 to 2.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate per clinical pregnancy</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1000<br/>(17 to 488) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.58<br/>(0.11 to 3.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>253 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>294 per 1000<br/>(175 to 497) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.16<br/>(0.69 to 1.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events, OHSS, preterm delivery, congenital anomaly</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection and reporting bias.<br/><sup>b</sup>Evidence downgraded by two levels due to imprecision (small study size). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Oral progesterone compared to vaginal progesterone for women trying to conceive by intrauterine insemination</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012396-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Aqueous subcutaneous (Sc) progesterone compared to vaginal progesterone gel for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Aqueous subcutaneous (Sc) progesterone compared to vaginal progesterone gel for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women trying to conceive by intrauterine insemination<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> aqueous Sc progesterone<br/><b>Comparison:</b> vaginal progesterone gel </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with vaginal progesterone gel</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with aqueous Sc progesterone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>119 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>125 per 1000<br/>(64 to 244) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.05<br/>(0.54 to 2.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>246<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>127 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>142 per 1000<br/>(75 to 268) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.12<br/>(0.59 to 2.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>246<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>None of the other main outcomes were reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection bias and high risk of other bias.<br/><sup>c</sup>Evidence downgraded by two levels due to imprecision (small study size). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Aqueous subcutaneous (Sc) progesterone compared to vaginal progesterone gel for women trying to conceive by intrauterine insemination</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012396-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Subcutaneous (Sc) gonadotropin‐releasing hormone (GnRH) agonist compared to placebo/no treatment for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Subcutaneous (Sc) gonadotropin‐releasing hormone (GnRH) agonist compared to placebo/no treatment for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women trying to conceive by intrauterine insemination<br/><b>Setting: </b> clinic<br/><b>Intervention:</b> Sc GnRH agonist<br/><b>Comparison:</b> placebo/no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Sc GnRH agonist</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ongoing pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>193 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>213 per 1000<br/>(135 to 336) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.10<br/>(0.70 to 1.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>291<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17.1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>125 per 1000<br/>(44 to 359) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.73<br/>(0.26 to 2.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>233 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>233 per 1000<br/>(158 to 342) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/>(0.68 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>281 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000<br/>(31 to 197) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.28<br/>(0.11 to 0.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events, OHSS, preterm delivery, congenital anomaly</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection and reporting bias.<br/><sup>b</sup>Evidence downgraded by two levels due to imprecision (small study size and wide CIs). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Subcutaneous (Sc) gonadotropin‐releasing hormone (GnRH) agonist compared to placebo/no treatment for women trying to conceive by intrauterine insemination</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012396-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Vaginal progesterone compared to gonadotropin‐releasing hormone (GnRH) agonist for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Vaginal progesterone compared to gonadotropin‐releasing hormone (GnRH) agonist for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women trying to conceive by intrauterine insemination<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> vaginal progesterone<br/><b>Comparison:</b> GnRH agonist </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with GnRH agonist</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with vaginal progesterone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>124 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>124 per 1000<br/>(63 to 242) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/>(0.51 to 1.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>None of the other main outcomes were reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection and reporting bias.<br/><sup>b</sup>Evidence downgraded by two levels due to imprecision (small study size). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Vaginal progesterone compared to gonadotropin‐releasing hormone (GnRH) agonist for women trying to conceive by intrauterine insemination</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012396-tbl-0011"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Human chorionic gonadotropin (hCG) injection compared to no treatment for women trying to conceive by intrauterine insemination</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Human chorionic gonadotropin (hCG) injection compared to no treatment for women trying to conceive by intrauterine insemination</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> women trying to conceive by intrauterine insemination<br/><b>Setting:</b> clinic<br/><b>Intervention:</b> hCG injection<br/><b>Comparison:</b> no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with hCG injection</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>152 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>141 per 1000<br/>(61 to 323) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.93<br/>(0.40 to 2.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b,</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple pregnancy rate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000<br/>(10 to 224) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03<br/>(0.22 to 4.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>a,b,</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>None of the other main outcomes were reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded by one level due to unclear risk of selection and reporting bias and high risk of other bias.<br/><sup>b</sup>Evidence downgraded by two levels due to imprecision as small study size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Human chorionic gonadotropin (hCG) injection compared to no treatment for women trying to conceive by intrauterine insemination</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/full#CD012396-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012396-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Progesterone versus no treatment or placebo (route of progesterone administration)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Live birth/ongoing pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Vaginal route</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.81, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Miscarriage per clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Vaginal route</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.40, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Miscarriage per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Vaginal route</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.48, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Clinical pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Vaginal route</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.14, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Oral route</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.40, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Multiple pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Vaginal route</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>956</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.30, 2.34]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Progesterone versus no treatment or placebo (route of progesterone administration)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012396-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Progesterone versus no treatment or placebo (type of ovarian stimulation)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Live birth/ongoing pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 In gonadotropin stimulation cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.80, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 In gonadotropin plus oral (clomiphene citrate) stimulation (ongoing pregnancy only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.37, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 In oral (clomiphene citrate or letrozole) stimulation cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.58, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Miscarriage per clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 In gonadotropin stimulation cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.24, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 In gonadotropin plus oral (clomiphene citrate or letrozole) stimulation cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.30, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 In oral (clomiphene citrate or letrozole) stimulation cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.25, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Miscarriage per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 In gonadotropin stimulation cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>691</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.23, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 In gonadotropin plus oral (clomiphene citrate or letrozole) stimulation cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.44, 2.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 In oral (clomiphene citrate or letrozole) stimulation cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.47, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Clinical pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 In gonadotropin stimulation cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.10, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 In gonadotropin plus oral (clomiphene citrate or letrozole) stimulation cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.03, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 In oral (clomiphene citrate or letrozole) stimulation cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1073</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [1.04, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Multiple pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 In gonadotropin stimulation cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.17, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 In gonadotropin plus oral (clomiphene citrate or letrozole) stimulation cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.24, 8.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.3 In oral (clomiphene citrate or letrozole) stimulation cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.10, 3.55]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Progesterone versus no treatment or placebo (type of ovarian stimulation)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012396-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">300 mg vaginal progesterone versus 600 mg vaginal progesterone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Ongoing pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Multiple pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">300 mg vaginal progesterone versus 600 mg vaginal progesterone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012396-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">IM progesterone versus vaginal progesterone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Ongoing pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Miscarriage per clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Miscarriage per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Clinical pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">IM progesterone versus vaginal progesterone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012396-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Oral progesterone versus vaginal progesterone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Ongoing pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Miscarriage per clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Miscarriage per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Clinical pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Oral progesterone versus vaginal progesterone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012396-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Aqueous Sc progesterone versus vaginal progesterone gel</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Ongoing pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Clinical pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Aqueous Sc progesterone versus vaginal progesterone gel</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012396-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Sc GnRH agonist versus no treatment or placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Ongoing pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Miscarriage per clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.26, 2.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Miscarriage per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.25, 2.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Clinical pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.68, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Multiple pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.11, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Sc GnRH agonist versus no treatment or placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012396-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Vaginal progesterone versus GnRH agonist</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Clinical pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Vaginal progesterone versus GnRH agonist</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012396-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">HCG injection versus no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Clinical pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Multiple pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">HCG injection versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012396.pub2/references#CD012396-tbl-0020">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012396.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012396-note-0016">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012396-note-0023">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012396-note-0021">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012396-note-0022">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD012396-note-0020">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD012396-note-0019">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012396-note-0017">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012396-note-0018">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012396\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012396\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012396\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012396\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012396\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012396\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012396\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012396\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012396\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012396\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012396\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012396\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012396\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012396\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012396\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012396\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012396\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012396\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012396.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012396.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012396.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012396.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012396.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724870899"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012396.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724870903"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012396.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e6d6268acf4ca',t:'MTc0MDcyNDg3MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 